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ABSTRACT 
 Microtubule stabilizing drugs (MSD) bind and stabilize microtubules, thus inhibiting their 
normal function. MSD exhibit anti-mitotic effects which makes them attractive as cancer 
chemotherapeutics and much of existing research has focused on these effects in 
proliferating cells. In contrast, we are interested in assessing the effects of microtubule 
stabilization on non-proliferating cells, such as macrophages, to determine potential 
mitosis-independent actions of MSD on microtubule function. Thus, we investigated the 
effects of MSD on macrophage receptor-mediated endocytosis of low density lipoproteins 
(LDL) and found no significant effect on the ability of paclitaxel-treated macrophages to 
endocytose LDL.  
Alterations to macrophage phagocytic and killing efficiency due to treatment with 
paclitaxel, peloruside or docetaxel, as well as the recently discovered compounds, 
ixabepilone, mycothiazole, and zampanolide were investigated. Treatment with paclitaxel, 
peloruside or docetaxel did not significantly inhibit phagocytosis or killing of bacteria. 
Results from confocal microscopy suggest that paclitaxel alters phagocytic kinetics in 
macrophages. Respectively, zampanolide and mycothiazole significantly inhibited 
macrophage bactericidal and killing ability, while Ixabepilone enhanced bacterial killing. 
MSD treatment also altered production of tumor necrosis factor alpha (TNF-α) and nitric 
oxide (NO) during bacterial killing. Optimal activation of macrophages with IFN-γ did not 
alter the effects of MSD. Taken together, these results suggest that MSD have multiple 
immunomodulatory effects unrelated to their anti-mitotic effects. The data suggests that 
during MSD treatment, macrophage activity maybe altered or impaired, thus modifying the 
ability of patients to fight off bacterial infections. 
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CHAPTER 1: INTRODUCTION 
1.1 Microtubules and Microtubule targeting agents: 
1.1.1 Microtubule structure and dynamics 
Microtubules are extremely important in cell division and mitosis, which makes them 
an effective target for anti-cancer drugs (Jordan et al., 2004; Risinger et al., 2008). 
Compounds that target microtubules and inhibit their normal function have proven to be 
one of the best classes of cancer chemotherapeutic drugs to date (Zhou et al., 2005). One of 
the reasons for the effectiveness of these compounds is that cancer cells divide more 
frequently than normal cells, and they do not respond to cell cycle checkpoints. 
Additionally, spindle microtubules are 10 – 100 fold more dynamic than cytoplasmic 
microtubules (Jordan et al., 2004; Jordan et al., 2007). Therefore these cells are more 
vulnerable to mitotic poisons.  
Microtubules are dynamic polymers composed of αβ–tubulin dimers and along with 
actin and intermediate filaments, make up the cytoskeleton. Microtubules are found in all 
dividing and interphase eukaryotic cells (Desai et al., 1997; Jordan et al., 2004; Risinger et 
al., 2008). They have diverse roles in mitosis, cell motility, intracellular transport, secretion 
and maintenance of cell shape and polarity (Downing et al., 1998a; Conde et al., 2009). 
Microtubules form when α- and β- tubulin associate into heterodimers, which then 
associate in a head to tail fashion to form linear protofilaments. Typically thirteen 
protofilaments associate in parallel, but axially offset to form the hollow 24 nm wide 
cylindrical microtubule (Fig 1.1A) (Desai et al., 1997; Risinger et al., 2008; Conde et al., 
2009). Microtubules are polar structures, with a plus end and a minus end, due to the 
pattern in which the subunits assemble. Within eukaryotic cells, the minus ends of 
microtubules are anchored and stabilized at the centrosome or microtubule organizing 
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centre (MTOC) via γ-tubulin (Li et al., 1995; Howard et al., 2003). Interaction of the minus 
end with γ-tubulin of the MTOC occurs via α-tubulin and β-tubulin remains exposed at the 
plus end (Nogales, 2000). Thus, the microtubule plus ends extend towards the cell 
periphery and consequently all addition and loss of subunits occurs at the plus end 
(Risinger et al., 2008). Polymerization rates are also more rapid and extensive at the plus 
end (Desai et al., 1997; Downing et al., 1998a; Nogales et al., 1999).  
The tubulin heterodimer contains two GTP-binding sites, an exchangeable site (E-
site) on β-tubulin and a non-exchangeable site (N-site) on α-tubulin (Gelfand et al., 1991; 
Desai et al., 1997). Each tubulin monomer binds GTP, however GTP-binding at the N-site 
is non-exchangeable, while GTP-binding at the E-site is exchangeable (Downing et al., 
1998b; Nogales, 2000). Assembly of tubulin subunits into protofilaments is promoted by 
binding of GTP to E-sites on β-tubulin, which enables polymerization (Cassimeris et al., 
1987; Gelfand et al., 1991; Nogales, 2000). After polymerization, GTP hydrolyzes to GDP 
and becomes non-exchangeable, resulting in a microtubule body of GDP bound tubulin and 
a layer of GTP bound tubulin capping the top of the microtubule (Fig 1.1B) (Cassimeris et 
al., 1987; Gelfand et al., 1991; Downing et al., 1998b; Nogales, 2000). E-site GDP is not 
exchanged for GTP when in the microtubule polymer, but if the GTP cap is lost and 
depolymerisation occurs, the free tubulin dimers can then exchange E-site GDP for GTP 
(Cassimeris et al., 1987; Desai et al., 1997). This unique pattern of GTP binding and 
hydrolysis seen on α- and β-tubulin leads to non-equilibrium behaviour of microtubules, 
known as dynamic instability (Cassimeris et al., 1987; Desai et al., 1997; Nogales, 2000). 
During dynamic instability, the microtubules alternate stochastic switching of the plus 
end between long periods of slow lengthening and brief periods of rapid shortening (Jordan 
et al., 2004). Dynamic instability is characterized by four main variables: the rate of 
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microtubule growth, the rate of shortening, the frequency of switching between growth and 
shortening (called catastrophe) and the frequency of switching between shortening and 
growth (called rescue) (Fig. 1.1B) (Jordan et al., 2004; Risinger et al., 2008). Another 
dynamic behaviour displayed by microtubules is called “treadmilling”. This behaviour is 
characterized by a net flow of subunits from the plus end to the minus end, with no 
significant change in microtubule mass or length (Desai et al., 1997; Nogales, 2000; Jordan 
et al., 2004; Risinger et al., 2008). Dynamic instability and treadmilling are compatible 
processes (Nogales, 2000; Jordan et al., 2004), and a population of microtubules can 
exhibit primarily treadmilling behaviour, dynamic instability behaviour or a combination of 
both (Jordan et al., 2004). Tubulin isotypes, the extent of post-translational modifications 
and the presence of regulatory proteins determine the dynamic behaviour that a population 
of microtubules display (Desai et al., 1997; Jordan et al., 2004). 
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Figure 1.1 
A 
 
 
 
 
 
 
 
 
 
 
 
 
                  
Figure 1.1 Microtubule structure and polymerization. 
A: αβ tubulin heterodimers associate to form protofilaments. Typically, 13 protofilaments 
associate parallel to each other to form the microtubule. Microtubules have a plus end and a 
minus end and are 24 nm in diameter while each heterodimer layer is 8 nm in diameter. 
B: Presence of a GTP-bound tubulin cap stabilizes the microtubule, but loss of this cap 
leads to catastrophe and microtubule destabilization. 
This figure was adapted from Jordan and Wilson, 2004. Nature Reviews Cancer. 
B 
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 Dynamic instability is important for microtubule function. It allows microtubules to 
rapidly reorganize the cytoskeleton and adopt spatial arrangements in response to cellular 
need or mechanical work (Desai et al., 1997). This is especially important during transition 
between mitosis and interphase stages of the cell cycle (Cassimeris et al., 1987). Various 
cellular processes, such as the intracellular transport of proteins and other cargo across the 
cell, cell polarization, adhesion, cell migration and morphogenesis depend on microtubules 
and the maintenance of microtubule dynamics (Cassimeris et al., 1987; Kelly, 1990; Jordan 
et al., 2008). The motor proteins kinesin and dynenin depend on microtubule and actin 
scaffolding to carry out transport functions (Rogers et al., 2000; Apodaca, 2001). 
Microtubules are also involved in the organization of the cytoskeleton itself. For example, 
organization of actin filaments during cell migration is achieved by transport of the actin 
components along the microtubule network (Rogers et al., 2000). Polymerization dynamics 
of microtubules are central to their biological function and altering these dynamics has 
impacts on physiological and cellular function. 
 
1.1.2 Microtubule destabilizing drugs (MDDs) 
Microtubule targeting agents (MTA) inhibit mitosis by blocking proliferation in the 
G2/M phase, causing the damaged cells to undergo apoptosis (Jordan et al., 2004; Jordan et 
al., 2007). MTA have been isolated from natural as well as synthetic sources and include 
the clinically important drugs paclitaxel (Taxol), docetaxel (Taxotere) and the vinca 
alkaloids (vincristine and vinblastine), as well as epothilones, discodermolide, nocodazole, 
and colchicine (Sorger et al., 1997). Based upon their effects on microtubules, MTAs are 
divided into two classes of compounds – the microtubule destabilizing drugs (MDD), and 
the microtubule stabilizing drugs (MSD). Drugs from both classes are currently used 
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clinically to treat lymphomas, leukemia and solid tumors (Jordan et al., 2004; Jordan et al., 
2007).  
Microtubule destabilizing drugs or MDDs, as their name suggests, interact with 
microtubules causing destabilization of protofilaments, inhibition of polymerization and an 
overall decrease in polymer mass (Jordan et al., 2007; Risinger et al., 2008). MDDs include 
compounds such as the Vinca alkaloids (vinblastine, vincristine, vinorelbine), 
cryptophycins, halichondrins, colchicine and combretastatins (Jordan et al., 2004). Since 
these compounds bind to microtubule and alter dynamics and function, they have been 
successful as anti-cancer chemotherapeutics (Risinger et al., 2008). A large majority of 
MDDs bind microtubules in either of two domains, the vinca domain or the colchicine 
domain (Fig 1.2). The Vinca alkaloids and halichondrins bind to the vinca domain, while 
colchicine, 2-methoxyestradiol (2ME2) and combretastatins bind to the colchicine domain 
(Jordan et al., 2004; Risinger et al., 2008).  
 
1.1.2.1 Microtubule destabilizing agent – Colchicine 
Colchicine is a naturally occurring MDD isolated from the meadow saffron 
Colchicum autmnale (Zhou et al., 2005). It is one of the earliest MTAs identified and its 
mechanism of action has been extensively investigated (Zhou et al., 2005; Correia et al., 
2008). Colchicine exhibits potent anti-mitotic, anti-inflammatory and anti-fibrotic 
properties, and is used in the treatment of gout (Jordan et al., 2004; Bhattacharyya et al., 
2008). Colchicine has also been used successfully in the treatment of autoinflammatory 
diseases such as familial Mediterranean fever (FMF) (Bhattacharyya et al., 2008). Although 
colchicine is a potent microtubule depolymerizer with anti-mitotic properties, its 
development as a chemotherapeutic is hampered due to the severe toxicities that 
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accompany its use at doses required for therapeutic effects (Jordan et al., 2004; Morris et 
al., 2008; Risinger et al., 2008).  
Colchicine binds microtubules at the interface of the α/β tubulin heterodimer 
(Risinger et al., 2008). It preferentially binds to unpolymerized tubulin heterodimers in 
solution and forms a stable complex that inhibits microtubule dynamics upon addition to 
microtubule ends (Fig 1.2) (Jordan et al., 2004; Risinger et al., 2008). While high dose 
colchicine is toxic, at lower doses it displays immunomodulating properties that make it 
useful in the treatment of gout (Jordan et al., 2004; Risinger et al., 2008). Other agents that 
bind in the colchicine domain, such as combretastatin, are currently being investigated in 
clinical trials against solid tumors, to validate these agents as chemotherapeutics (Jordan et 
al., 2004; Schmidt et al., 2007; Risinger et al., 2008) .  
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Anti-mitotic drugs and their microtubule binding sites. 
A: Vinca alkaloid binding site: Vinblastine molecules bind to high-affinity sites at 
the plus-end of the microtubule. 
B: Colchicine binding site: colchicine molecules form a complex with tubulin 
dimers at the interface of α/β tubulin heterodimers and copolymerize into the 
microtubule lattice. 
C: Taxane binding site: microtubule cut away to view interior surface; paclitaxel 
binds along the inside surface of the microtubule. 
This figure was adapted from Jordan and Wilson, 2004. Nature Reviews Cancer 
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1.1.3 Microtubule stabilizing drugs (MSDs) 
Microtubule stabilizing drugs or MSDs, as the name suggests, interact with 
microtubules causing their stabilization and increasing the polymer mass. MSD include 
drugs such as paclitaxel, docetaxel, the epothilones, peloruside A, laulimalide, the 
sarcodictyins and the eleutherobins. MSDs can affect dividing cells as well as non-dividing 
or interphase cells and their effects vary depending on the stage of cell cycle (Jordan et al., 
1993; Altmann, 2001; Hood et al., 2002). MSDs such as paclitaxel, docetaxel and 
epothilones are currently used clinically as chemotherapeutics, while analogues of these 
compounds are in single or combination phase I, II or III clinical trials (Jordan et al., 2007) 
. While the classification of MTAs as “stabilizers” or “destabilizers” is simple and useful, it 
is also slightly misleading. At high concentrations, MDDs cause destabilization and a 
decrease in polymer mass, while MSDs cause stabilization and an increase in polymer mass 
(Jordan et al., 2004; Risinger et al., 2008). However at lower, clinically relevant doses, 
both groups potently suppress microtubule dynamics (Jordan et al., 2007). Since 
microtubule dynamics are extremely sensitive to regulation, at low doses both MDDs and 
MSDs can kinetically stabilize microtubules without changing the polymer mass. Thus at a 
very basic level and at low concentrations, both MSD and MDD act as mitotic inhibitors. 
Due to this, their effects on microtubule dynamics are more powerful than their effects on 
polymerization or depolymerization (Jordan et al., 2004; Jordan et al., 2007).  
While it is known that MSDs have cytotoxic effects on dividing cells, (Hood et al., 
2002; Gaitanos et al., 2004) little is known about their effects in interphase cells. MSD 
treatment in interphase cells leads to appearance of multiple micronuclei and microtubule 
bundling resulting in functional disturbance (Jordan et al., 1993; Hood et al., 2002). While 
microtubule actives have enjoyed great clinical success, there are significant difficulties 
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associated with their use. These in particular are related to toxicity and their limited 
effectiveness in some cancers due to multi-drug resistance. Consequently, new compounds 
that target microtubules in similar ways and are effective in multi-drug resistant cancers are 
continuously being sought. MSDs and their effects are discussed in more detail in the 
sections below. 
 
1.1.3.1 Microtubule stabilizing agent – paclitaxel 
 Paclitaxel, isolated from the bark of the Pacific yew tree, taxus brevifolia, belongs to 
the Taxane group of anti-mitotic agents (Wani et al., 1971; Chan et al., 2000). It was the 
first identified microtubule stabilizer and is used clinically to treat solid tumors of the breast, 
ovaries and lung, as well as in combination therapies with different agents to treat head and 
neck and gastroesophageal cancers (Rowinsky et al., 1995; Spratlin et al., 2007; Morris et 
al., 2008). At low nanomolar concentrations, paclitaxel is capable of stabilizing 
microtubules and promoting their polymerized form. However these microtubules are 
dysfunctional, leading to apoptosis and cell cycle arrest in the G2/M phase of the cell cycle 
(Panchagnula, 1998). paclitaxel is also able to induce abnormal spindle morphologies, 
causing spindles to lose organization and aggregate into ball-shaped masses with condensed 
chromosomes and multiple asters (Jordan et al., 1993). In addition to causing mitotic block, 
low doses of paclitaxel induce microtubule bundling in interphase cells (Jordan et al., 1993; 
Risinger et al., 2008). Microtubule bundling affects cellular function and processes 
dependent on dynamic microtubules. This bundling effect could also contribute to the anti-
proliferative activity of paclitaxel (Jordan et al., 1993).  
While paclitaxel is an effective chemotherapeutic, it is not without its drawbacks, 
particularly hypersensitivity and toxic side effects. The principal toxic effects associated 
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with paclitaxel treatment were neutropenia, gastro-intestinal disturbances, alopecia, cardiac 
effects and neurotoxicity (Rowinsky et al., 1995). Paclitaxel was also susceptible to 
development of resistance by multi-drug resistance transporters such as P-glycoprotein (P-
gp) (Risinger et al., 2008). A major concern with paclitaxel treatment was the development 
of type I hypersensitivity reactions in reaction to paclitaxel’s vehicle, polyoxyethylated 
castor oil (Cremophor EL) (Rowinsky et al., 1995). Due to paclitaxel’s hydrophobicity, and 
limited aqueous solubility, it is necessary to use Cremophor EL for drug delivery to cells 
(Rowinsky et al., 1995; Gelderblom et al., 2001). This solves solubility concerns, but can 
cause severe hypersensitivity reactions (Panchagnula, 1998; Gelderblom et al., 2001; 
Spratlin et al., 2007). This problem was partially overcome by pre-medicating with 
corticosteroids and histamine H1 and H2 antagonists, which caused the incidence of 
hypersensitivity to drop (Rowinsky et al., 1995). Several anti-mitotic agents and MSD with 
fewer side effects and increased efficacy are currently under development to overcome the 
above mentioned limitations. 
 
1.1.3.2 Microtubule stabilizing agent – docetaxel  
Docetaxel is a second generation taxane derived from the needles of the European 
Yew tree (Herbst et al., 2003). It is a semi-synthetic analogue of paclitaxel and is a more 
potent MSD as compared to paclitaxel (Herbst et al., 2003; Si et al., 2003). Docetaxel has 
unique properties to paclitaxel as it exhibits linear pharmacokinetics and is retained 
intracellularly for a longer period than paclitaxel due to differences in drug efflux (Herbst et 
al., 2003). Docetaxel is currently used in treating a variety of tumors, including breast, 
prostate and head and neck cancers, in combination as well as in mono-therapies (Herbst et 
al., 2003; Zhou et al., 2005). Docetaxel can be administered without Cremophor EL and 
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while side effects such as neutropenia, neuropathy and immunosuppression are common, 
these are to a much lesser extent as compared to paclitaxel. 
  
1.1.3.3 Microtubule stabilizing agent – peloruside A 
A novel MSD, peloruside A was isolated in 2000 from the New Zealand marine 
sponge Mycale hentscheli (West et al., 2000).  Similarly to paclitaxel, peloruside A binds to 
polymerized tubulin and blocks mitosis at the G2/M checkpoint (Hood et al., 2002). 
Peloruside A can also cause microtubule bundling in a manner similar to paclitaxel (Hood 
et al., 2002; Crume et al., 2007). The interest generated by peloruside A is due to the fact 
that it is cytotoxic in the paclitaxel resistant cell lines. Additionally, its tubulin binding site 
is distinct to that of the taxanes, suggesting that peloruside A and the taxanes could be used 
synergistically (Hood et al., 2002; Gaitanos et al., 2004; Wilmes et al., 2007). Peloruside A 
is currently being developed for clinical use and it has promising advantages over the 
existing taxanes and other agents, however studies involving peloruside A are restricted due 
to its limited supply.   
Docetaxel, and paclitaxel, are among some of the most effective anti-cancer drugs 
introduced in the last ten years for the treatment of breast and ovarian cancer. These drugs 
not only exhibit potent anti-cancer activity but also have the potential to be used as 
therapeutics in hyper-proliferative autoimmune diseases. Understanding the 
immunomodulatory effects of existing MSDs along with newly discovered MSDs will 
improve their use as chemotherapeutics as well as extend their potential applications 
beyond oncology.  
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1.2 Macrophage Functions and Immune Responsiveness 
1.2.1 Macrophage Function: General role in immunity 
Macrophages are cells of the innate immune system that are specialized in 
phagocytosis and pathogen killing. Macrophages are also involved in other processes such 
as antigen presentation to T-cells, activation of the adaptive immune system, tissue 
remodeling and wound repair, as well as defense against microbial invasion and recognition 
and killing of tumor cells (Klimp et al., 2002; Mukhopadhyay et al., 2004). Macrophages 
carry out their functions via phagocytosis and killing, or via the release of reactive oxygen 
species (ROS) and cytokines such as tumor necrosis factor – α (TNF-α) and interleukin 
(IL)-12, IL-6 and IL-8 (Klimp et al., 2002; Fujihara et al., 2003).  
Macrophages respond to pathogens via pattern-recognition receptors (PRRs) that 
recognize pathogen associated molecular patterns (PAMPs) (Aderem et al., 1999). 
PAMPSs are evolutionary conserved pathogen motifs, such as dsRNA, lipopolysaccharide 
(LPS), and flagellin (Taylor et al., 2005). Macrophages express a variety of cell surface 
receptors to aid in particle recognition and internalization. Some of these receptors are 
involved in transmitting signals for initiation of phagocytes, while others increase binding  
and internalization efficiency (Aderem et al., 1999; Underhill et al., 2002). Phagocytic 
receptors include Fc receptors (FcR) such as FcγRI (CD64), FcγRIII (CD16), complement 
receptors (CR) such as CR1 and CR3 (CD11b, Mac1), scavenger receptors (SR) such as 
SRA, and Toll-like receptors (TLR) such as TLR2 and TLR4 (Aderem et al., 1999; 
Underhill et al., 2002; Mukhopadhyay et al., 2004). When faced with a pathogenic 
challenge, macrophages not only carry out phagocytosis but also secrete proinflammatory 
cytokines. LPS from gram negative bacteria activates macrophages via TLR-4 and initiates 
the secretion of TNF-α, interleukin (IL)-1, IL-6, IL-8 and IL-12 (Ding et al., 1990b; 
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Dobrovolskaia et al., 2002; Fujihara et al., 2003). Macrophages also secrete other 
proinflammatory mediators such as nitric oxide (NO) and reactive oxygen species (ROS) in 
response to bacterial stimuli. 
 
1.2.1.1 Fcγ Receptors and complement receptors 
 Opsonization or coating of pathogens with complement proteins or IgG antibodies 
stimulates phagocytosis via the CRs or the FcRs respectively (Aderem et al., 1999; 
Underhill et al., 2002). IgG opsonized particles can be recognized and phagocytosed by 
FcγRs. Macrophages express a combination of low affinity receptors (FcγRIIA and 
FcγRIIIA) and high affinity receptors (FcγRI) so IgG-opsonized particles are recognized 
simultaneously, increasing internalization (Underhill et al., 2002). FcγRs contain a 
stimulatory immunoreceptor tyrosine-based activation motif (ITAM) that activates 
phosphorylation cascades, or an immunoreceptor tyrosine-based inhibition motif (ITIM) 
that inhibits signaling (Aderem et al., 1999; Underhill et al., 2002).  
In contrast, phagocytosis via CRs occurs when complement proteins in the serum 
opsonize particles via an antibody–dependent or –independent mechanism (Underhill et al., 
2002). Complement opsonized particles are internalized via specific CRs, which include 
CR1, CR3 (CD11b or Mac1), and CR4 (Aderem et al., 1999). While FcγR are 
constitutively active for phagocytosis, CRs need additional signals in order to internalize 
complement-opsonized particles (Aderem et al., 1999; Underhill et al., 2002). In vitro this 
activation can be stimulated with phorbol 12-myristate 13-acetate (PMA), inflammatory 
cytokines such as TNF-α, microbial products such as LPS as well as by granulocyte 
macrophage colony stimulating factor (GM-CSF) (Aderem et al., 1999; Underhill et al., 
2002).  
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While both FcγR- and complement-mediated phagocytosis require actin 
polymerization at the internalization site, the process by which these IgG– and 
complement–opsonized particles are internalized differ (Aderem et al., 1999). FcγR-
mediated phagocytosis is an active process where “veils” of membrane rise around the 
particle and ingest it into the macrophage, while CR-mediated phagocytosis is more passive 
and particles “sink” into the cell with little to no formation of pseudopodia (Kaplan, 1977; 
Allen et al., 1996; Aderem et al., 1999). Using these different processes of uptake, 
macrophage receptors are capable of functioning synergistically to enhance internalization. 
When particles are coated with sub-optimal levels of IgG that would normally lower 
phagocytic efficiency, CR and FcγRs are able to coordinate ligation to enhance 
phagocytosis and produce synergistic effects of internalization (Ehlenberger et al., 1977).  
 
1.2.1.2 Scavenger receptors 
Scavenger receptors (SR) were first identified by Brown and Goldstein during their 
studies of low density lipoprotein (LDL) accumulation in atherosclerotic plaques (Goldstein 
et al., 1979). SR are involved in a wide range of functions, from receptor mediated 
endocytosis (discussed below), to host defense against bacteria, apoptotic cell phagocytosis, 
as well as cell adhesion (Peiser et al., 2000; Peiser et al., 2002). SR bind a range of ligands 
such as LDL, polyribonucleotides and silica particles and are classified into six different 
classes (A–F) according to their multi-domain structure (Mukhopadhyay et al., 2004).  
SR-A has three spliced variants, SR-AI/II and SR-AIII, where SR-AIII is non-
functional (Peiser et al., 2002; Mukhopadhyay et al., 2004). SR-A recognizes the lipid A 
moiety of LPS, the lipoteichoic acid (LTA) of gram positive bacteria, as well as bacterial 
CpG DNA. In studies characterizing the role of SR-A in bacterial phagocytosis, SR-A 
–/–
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BMDM (bone-marrow-derived macrophages) from mice ingested fewer E.coli compared to 
wild-type cells (Peiser et al., 2000). The SR-A 
–/–
 mice also showed increased susceptibility 
to endotoxic shock and bacterial infections, due to impaired clearance of LPS and 
microorganisms (Peiser et al., 2000), thus confirming the role of SR-A in binding and 
ingestion of microbes. 
 
1.2.2 Macrophage function: endocytosis 
Endocytosis collectively refers to the processes by which cells internalize small 
molecules, macromolecules, and particles (Mukherjee et al., 1997). Phagocytosis, 
pinocytosis, clathrin-dependent receptor-mediated endocytosis and clathrin-independent 
receptor-mediated endocytosis all fall under the endocytosis umbrella. Endocytosis is 
important in processes such as regulation of cell surface receptor expression, cholesterol 
homeostasis and maintenance of cell polarity (Mukherjee et al., 1997). Clathrin-dependent 
receptor-mediated endocytosis and phagocytosis are the two main endocytic processes used 
by macrophages to endocytose pathogens and particles (Aderem et al., 1999). Receptor 
mediated endocytosis (RME) is the uptake of macromolecules and small particles (< 0.2 
µm) and occurs via a clathrin based, actin-independent mechanism, while phagocytosis is 
the uptake of large particles (>0.5µm) and is actin-dependent and clathrin-independent 
(Brown et al., 1979b; Mellman, 1996; Mukherjee et al., 1997; Aderem et al., 1999).   
 
1.2.2.1 Macrophage function: Receptor mediated endocytosis 
The receptor mediated endocytic pathway was first studied using the lipoprotein 
receptor system and since then has come to be regarded as the prototype for receptor 
mediated studies (Brown et al., 1979b; Goldstein et al., 1979). Lipoprotein particles are 
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cholesterol carriers that can be transported in the plasma and carried to target tissues. In 
humans the major cholesterol carrier is low density lipoprotein (LDL), which is taken up 
into macrophages via receptor mediated endocytosis (Brown et al., 1979b; Brown et al., 
1983). Normal tissue macrophages from mice or other species, express few if any receptors 
for native LDL (Brown et al., 1979a; Brown et al., 1979b; Goldstein et al., 1979; Brown et 
al., 1983). Macrophages in vitro only take up minimal amounts of LDL and the cellular 
cholesterol content does not increase (Brown et al., 1983). However chemically modified 
LDL, such as acetylated LDL (ac-LDL) is taken up with high efficiency and results in 
massive cholesterol accumulation (Brown et al., 1979a; Goldstein et al., 1979).  
Receptors that function in the uptake of native LDL are the LDL receptor, CD36 and 
SR-B1, while SR-A and -BI are involved in acetylated-LDL uptake (Brown et al., 1979a; 
Goldstein et al., 1979; Plüddemann et al., 2007).  Receptor mediated endocytosis occurs 
via clathrin coated pits, where LDL binds to its receptor and the plasma membrane 
invaginates to form a coated vesicle which is trafficked to the lysosome. After fusing with 
the lysosome, the receptors are recycled to the plasma membrane and LDL is degraded (Fig 
1.3) (Anderson et al., 1977; Anderson et al., 1982).  
 
1.2.2.2 Macrophage function: phagocytosis 
In contrast to receptor mediated endocytosis, phagocytosis is a largely actin-
dependent process. However, only initial phagocytic events are actin-dependent. Once actin 
polymerizes at the phagocytic cup and the phagosome forms, actin is shed and phagosome 
maturation occurs along the endocytic pathway which is microtubule-dependent 
(Desjardins et al., 1994a; Aderem et al., 1999; Peachman et al., 2004). Phagocytosis 
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involves a higher level of antigen processing and presentation than RME and depends on a 
functional and coordinated actin and microtubule cytoskeleton (Peachman et al., 2004). 
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Figure 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Macrophage receptor mediated endocytosis 
Receptor mediated endocytosis of Low density lipoprotein (LDL) via clathrin coated pits, 
where the endosome fuses with the lysosome to degrade LDL in the presence of hydrolytic 
enzymes. LDL receptors are recycled to the plasma membrane via recycling endosomes. 
This figure was adapted from Molecular biology of the cell, 2007. Albert and Johnson. 
 
Clathrin coated pit 
Figure 1.3: Figure Legend 
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1.2.3 Immunomodulatory effects of anti-mitotic agents 
As mentioned above, secretion of cytokines and phagocytosis both require functional 
cytoskeletal machinery and membrane trafficking processes. Microtubules are involved in 
the production and release of cytokines such as IL-1β and TNF-α (Tsavaris et al., 2002). 
Additionally, the requirement of microtubules in bacterial uptake and antigen processing 
has long been established (von Figura et al., 1978; Harrison et al., 2002; Peachman et al., 
2004; Murray et al., 2005). Anti-mitotic agents could potentially impede the above 
mentioned processes, leading to major implications in cancer therapy. MTA, which include 
both MSD and MDD, could potentially affect phagocytosis or endocytosis as well as 
exocytosis or cytokine secretion, as these processes are microtubule dependent (Peachman 
et al., 2004). 
There are multiple studies investigating the effects of MSD on endocytosis as well as 
cytokine production. In murine macrophages, treatment with paclitaxel stabilizes 
microtubules and inhibits the uptake of liposomal antigen, a result also seen in colchicine-
treated murine BMDM (Peachman et al., 2004). Docetaxel causes anti-proliferative effects 
in lymphocytes and promotes activation-induced apoptosis (Si et al., 2003). In a study 
involving breast cancer patients, paclitaxel and docetaxel caused a pronounced effect on 
enhancing interferon-γ (IFN-γ), IL-2, IL-6 and GM-CSF (granulocyte macrophage – colony 
stimulating factor), while reducing IL-1 and TNF-α levels (Tsavaris et al., 2002). In the 
same study, when compared to paclitaxel, docetaxel displayed a greater efficiency in 
modifying cytokine levels. The cytokines IFN-γ, IL-2 and GM-CSF, which were elevated 
are pre-dominantly T-helper-1 (Th1) cytokines, which activate macrophages and promote 
cell-mediated responses (Opal et al., 2000). They are also involved in expansion of 
cytotoxic T lymphocytes (CTL) in autoimmune diseases (Dinarello, 2007). An interesting 
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proposition is that due to their cytotoxic effects on tumor cells, the two taxanes may induce 
production of cytokines via secondary recognition of tumor-derived antigens by tumor-
infiltrating monocytes and B-cells (Tsavaris et al., 2002). However, these 
immunomodulatory events are currently poorly defined and require in-depth studies. A 
study in our lab also showed peloruside A treated macrophages produce decreased levels of 
TNF-α, IL-12p40 and nitric oxide (NO) (Crume et al., 2007). 
In addition to anti-cancer activity, taxanes are also currently being investigated as 
autoimmune therapeutics. Paclitaxel has been effective in inhibiting induction of 
experimental allergic encephalomyelitis (EAE), which is a murine model of multiple 
sclerosis (Cao et al., 2000). Paclitaxel has also been effective in other autoimmune diseases 
such as systemic lupus erythematosus (SLE) and collagen-induced arthritis (CIA) (Brahn et 
al., 1994; Song et al., 1998). Peloruside A and paclitaxel treatment also lead to a reduced 
incidence and significant delay in the development of EAE (Crume et al., 2009). This data 
combined with continuing studies, suggests that in addition to being valuable cancer 
chemotherapeutics, microtubule actives have a significant potential as immunomodulatory 
agents in autoimmune and inflammatory diseases. 
 
1.2.3.1 Tumor Necrosis Factor-α 
TNF-α is an important cytokine, with roles in inflammation, immunity and induction 
of apoptosis (Scheringa et al., 1990; Tracey et al., 1994; van Horssen et al., 2006). TNF-α 
is one of the earliest, most potent cytokines secreted by macrophages in response to LPS 
stimulation (Carswell et al., 1975; Ding et al., 1990b; Scheringa et al., 1990). Studies have 
found TNF-α in culture as early as 2 hours and while there is conflicting evidence as to how 
long TNF-α can be detected in prolonged cultures, these differences can be explained by 
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differing assay protocols (Vassalli, 1992; Tracey et al., 1993; Crume et al., 2007). TNF-α 
secretion occurs via recycling endosomes, where it is transported from the golgi to the cell 
membrane at the phagocytic cup for secretion (Murray et al., 2005; Manderson et al., 
2007). Blocking of this recycling membrane prevents TNF-α secretion, and causes 
accumulation of TNF-α in the Golgi.  
TNF-α acts via TNF receptor 1 (TNFR-1) and TNFR-2, both of which are found on 
almost all nucleated cells. Although TNF-α affinity for TNFR-2 is 5 times higher than that 
for TNFR-1, majority of the activity occurs via TNFR-1 (Mocellin et al., 2005; van 
Horssen et al., 2006).  The main difference between the two receptors is the presence of the 
death domain (DD) on TNFR-1 and its absence on TNFR-2 (Mocellin et al., 2005; van 
Horssen et al., 2006). TNFR-1 is a dual receptor, with roles in the induction of apoptosis as 
well as in transduction of survival signals. These signaling pathways occur via the 
activation of transcription factors such as nuclear factor–κB (NFκB) and the mitogen-
activated protein kinase (MAPK)/cJun N-terminal kinase (JNK) (Dempsey et al., 2003; 
Mocellin et al., 2005; van Horssen et al., 2006). TNFR-2 lacks a death domain and is 
involved in immune signaling (Aggarwal, 2003; van Horssen et al., 2006). The binding of 
TNF-α to TNFR-1 leads to activation of NFκB. NFκB works together with MAPK and 
cJNK to induce transcription of anti-apoptotic, proliferative, and inflammatory genes 
(Vandenabeele et al., 1995; Mocellin et al., 2005; van Horssen et al., 2006). The murine 
TNF-α promoter and the expression of TNF-α inducing genes are partially controlled by 
NFκB (Baeuerle et al., 1994). Additionally, as mentioned, TNF-α is a potent activator of 
NFκB. Together this suggests that TNF-α once produced, is capable of stimulating its own 
secretion. 
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1.2.3.2 Nitric Oxide  
Nitric oxide (NO) results from L-arginine metabolism and plays a major role in 
vascular and immune systems (Knowles et al., 1994; Bruckdorfer, 2005). NO is 
synthesized by three isoforms of nitric oxide synthase (NOS), one of which is inducible 
NOS (iNOS or NOS2) that induces large amounts of NO particularly from macrophage-
monocyte cell lineages (Forstermann et al., 1994; Karpuzoglu et al., 2006). Production of 
inducible NO is notable in that it is produced only upon activation of 
macrophages/monocytes, in response to IFN-γ, LPS or TNF-α (Ding et al., 1988; Geller et 
al., 1993; Bogdan et al., 2000). iNOS also has an ability to induce higher levels of NO than 
those induced by the other two isoforms (Karpuzoglu et al., 2006).  
Nitric oxide is a major mediator of macrophage tumoricidal activity (Stuehr et al., 
1989). While macrophages produce elevated levels of NO in inflammatory disorders and 
microbial infections as well as in autoimmune processes, this production occurs at a later 
timepoint as compared to TNF-a production (Bogdan et al., 2000; Feng et al., 2002). NO is 
also involved in cytokine regulation, for instance, IFN-γ stimulus produces high levels of 
NO that in turn down-regulates IFN-γ to prevent dangerous levels of pro-inflammatory 
IFN-γ production (Karpuzoglu et al., 2006). NO also regulates IL-12 production in 
RAW264.7 macrophages (Rothe et al., 1996). Treatment of tumor bearing hosts (TBH) 
with paclitaxel leads to NO production, which regulates paclitaxel-mediated IL-12 
production and restores immunocompetence in these hosts (Mullins et al., 1999). This 
interesting finding shows that MSD can alter cytokine production, which in turn can affect 
macrophage immune responses.  
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1.2.3.3 Interferon-γ (IFN-γ) 
IFN-γ is among the most important cytokines that is involved in activating 
macrophages for anti-microbial and -tumour responses, as well as causing an up-regulation 
of antigen-processing and presentation (Young et al., 1995; Schroder et al., 2004). 
Interferons are classified as type I or II depending on receptor specificity and sequence 
homology (Schroder et al., 2004; Platanias, 2005). There are several type I IFNs, which 
bind to a common type I IFN receptor, but there is only one type II IFN, IFN-γ, which 
binds to a distinct type II IFN receptor (Bach et al., 1997; Platanias, 2005) Macrophages 
secrete IL-12, IL-18 and chemokines such as macrophage inflammatory protein (MIP), the 
combined stimulus of which acts on T-cells and natural killer cells, leading to increased 
production of IFN-γ (Munder et al., 1998; Schroder et al., 2004).  
Traditional views suggested that pre-treatment with IFN-γ activated macrophages to 
respond to tumour cells or TLR-agonists such as LPS; however recent studies indicate that 
irrespective of the time-course, or sequence of IFN-γ stimulation and TLR-agonist 
challenge, macrophages are still able to respond to LPS and promote the production of NO 
and IL-12 (Lorsbach et al., 1993; Ma et al., 1996; Schroder et al., 2006). The production of 
IL-12 and NO irrespective of the sequence of IFN-γ priming and LPS stimuli suggests 
synergy between IFN-γ and LPS signalling pathways. Since macrophages still mediate 
priming if an IFN-γ stimulus is presented after LPS or TLR stimulation, it is likely that 
signals distinct from the early TLR activation signals are involved in synergy of the two 
pathways (Schroder et al., 2006). Mechanisms such as activation of the transcription factors 
STAT-1 in the IFN pathway and NF-κB in the TLR/LPS pathway, and crosstalk between 
the two signalling pathways, may be responsible for an amplification of the priming effect 
of IFN-γ (Schroder et al., 2006).  The ability of IFN-γ to synergise with other cytokines and 
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activate macrophages widen the possible activities that IFN-γ has over macrophage 
activation (Munder et al., 1998; Schroder et al., 2004; Schroder et al., 2006)  
Stimulation of macrophages with IFN-γ results in the up-regulation of FcRγ, 
complement proteins that aid in opsonization of pathogens, and complement receptors such 
as Mac-1 that enable responses to microbial and intracellular pathogens (Schroder et al., 
2004). In the presence of LPS, macrophages increase secretion of NO, IL-12 and 
chemokines, as mentioned above. These mediators act on NK cells to increase production 
of IFN-γ. IL-12 along with IFN-γ then coordinates the link between pathogen recognition 
by the innate immune system, and induction of specific adaptive immune responses by 
promoting Th1 responses (Schroder et al., 2004). During the course of the experiments 
carried out in this thesis, within various assays, macrophages were primed with 100 U/ml 
IFN-γ to investigate the effects of priming or absence of priming on phagocytic responses 
in the presence of MSDs. 
 
1.2.4 Shared actions of LPS and Paclitaxel on TNF-α production 
While paclitaxel has no structural similarity to LPS, it induces normal murine 
macrophage responses similar to those generated by LPS, including increased production of 
TNF-α, NO, and IL-1β (Ding et al., 1990b; Kirikae et al., 1996). Murine macrophages also 
respond to LPS and paclitaxel by reducing cell surface expression of TNFR and increasing 
production of TNF-α (Ding et al., 1989; Ding et al., 1990b). The LPS mimetic activities of 
paclitaxel also include activation of NF-κB, tyrosine phosphorylation of MAPK and 
induction of LPS-inducible gene expression (Manthey et al., 1992; Ding et al., 1993; Perera 
et al., 1996; Byrd-Leifer C.A. et al., 2001). Interestingly paclitaxel’s ability to produce 
inflammatory mediators and mimic LPS is observed only in macrophages from LPS 
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responsive mice, while macrophages from LPS-hyporesponsive mice are incapable of 
producing these mediators in response to LPS or paclitaxel (Ding et al., 1990b; Bogdan et 
al., 1992; Kirikae et al., 1996), suggesting that LPS and paclitaxel share a common 
signaling pathway (Ding et al., 1990b; Burkhart et al., 1994). Additionally, the LPS 
mimetic property of paclitaxel is species specific and paclitaxel does not induce LPS 
specific responses in human cells, including human macrophages (Kawasaki et al., 2000; 
Kawasaki et al., 2001a; Kawasaki et al., 2001b). TLR-4 confers responsiveness to LPS; 
however presence of TLR-4 alone is insufficient in conferring LPS responsiveness in 
human cells (Kawasaki et al., 2001a). MD-2 an accessory protein, associates with TLR-4 
on the cell surface and can confer LPS responsiveness in a normally unresponsive murine 
cell line (Kawasaki et al., 2000; Kawasaki et al., 2001a). The presence of TLR-4/MD-2 
complex mediates the LPS mimicry signal by paclitaxel (Kawasaki et al., 2000). 
Furthermore murine MD-2 is responsible for the species specificity of paclitaxel’s LPS 
mimicry, as demonstrated using combinations of human TLR-4, human MD-2, murine 
TLR-4 and murine MD-2 (Kawasaki et al., 2001a; Zimmer et al., 2008).  Recent studies by 
Kawasaki, K. et al., 2001. further demonstrated that a glutamine 22 (Gln
22
) point mutation 
in the murine MD-2 molecule led to a significant decrease in paclitaxel signaling, while 
LPS signaling was unaffected, suggesting that Gln
22
 was essential for paclitaxel but not 
LPS signaling (Kawasaki et al., 2001b). The mimetic activity of paclitaxel is not observed 
in other MSD, including peloruside A or docetaxel (Manthey et al., 1993; Crume et al., 
2007). 
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1.3 Summary of known immunological effects  
Taxanes exert multiple effects on the immune system as discussed. They act as anti-
cancer agents by directly inhibiting cellular division through microtubule stabilization. 
However, taxanes can also stimulate antitumor activity indirectly, by activating 
macrophages and cytokine production (Chan et al., 2000). Further to this, taxanes also 
exhibit immunosuppressive activity and may be valuable as therapeutics in autoimmune 
diseases (Fitzpatrick et al., 2003; Javeed et al., 2009).  As mentioned above, peloruside A 
does not mimic LPS effects. Recent studies indicate that in limiting LPS conditions, both 
paclitaxel and peloruside A are capable of inhibiting LPS-induced TNF-α production 
(Crume et al., 2007). As mentioned, microtubules are involved in almost all cellular 
functions and alteration of the microtubule network due to MSD treatment could have far-
reaching effects with regards to immune responses. It is essential to understand the 
pathways and interactions within immune responses to bacterial infections, particularly due 
to the above-mentioned interactions of paclitaxel with LPS, TNF-α and NFκB. 
Furthermore, cytokine production could be impaired due to the ability of MSD to alter 
cytokine profiles (Chan et al., 2000). Paclitaxel, docetaxel and peloruside could affect 
macrophage function in different methods in vitro and in vivo. Understanding how MSD 
alter macrophage function will provide insights into the primary effects of MSDs during 
anti-cancer therapies. 
 
1.4 Research Aims and Hypothesis 
Based on the above information and the current knowledge of the immunomodulatory 
effects of MSD, we had three main research aims. We wanted to study the effects of MSD 
on macrophage endocytic processes, as there is limited knowledge regarding the effects of 
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MSD on non-proliferating cells such as the macrophage. The first aim we had was to 
investigate the effect of MSD on the macrophage’s ability to maintain receptor mediated 
endocytosis. We hypothesized that paclitaxel would not cause major alterations to this 
process as endocytosis is, for the most part independent of microtubules. The second aim 
we had was to study the effects of MSD on macrophage processes of bacterial phagocytosis 
and killing ability. We assumed that if there were alterations to the phagocytic process, they 
would mainly involve inhibition of phagocytosis, rather than killing ability being affected. 
This was based on the rationale that phagocytosis requires functional microtubules. Our 
third aim was closely related to the second aim, as we were interested in investigating the 
effects of MSD on cytokine production. In particular we asked if MSD affected cytokine 
production, which in turn would affect macrophage ability to phagocytose and kill bacteria. 
We also investigated the possibility of IFN-γ activation in macrophages altering the effects 
of MSD. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Reagents 
Paclitaxel, purified from Taxus yannanensis, colchicine and LPS (from Escherichia 
coli) were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). 
Docetaxel was purchased from LC Laboratories (Woburn, MA, USA). Ixabepilone 
(Ixempra) was purchased from Bristol Myers Squibb (Noble Park, Victoria, Australia). 
Zampanolide and mycothiazole were isolated and purified from a Tongan marine sponge 
Cacospongia mycofijiensis. Peloruside A was isolated and purified from New Zealand 
marine sponge Mycale hentscheli, and latrunculin A was isolated and purified from the Red 
Sea sponge Latrunculia magnifica. All sponge material was generously provided by Dr 
Peter Northcote (School of Chemical and Physical Sciences, Victoria University of 
Wellington). All drugs were dissolved in absolute ethanol, with the exception of 
mycothiazole, which was dissolved in dimethyl sulfoxide (DMSO). All drugs were stored 
at -80°C, with the exception of latrunculin A which was stored at -20°C and colchicine 
which was stored at room temperature, protected from light. Stock concentrations were: 
paclitaxel at 2 mM, peloruside A, docetaxel, zampanolide and ixabepilone at 1mM, and 
colchicine and latrunculin A at 10mM.  
Low density lipoprotein (LDL) and acetylated low density lipoprotein (ac-LDL), both 
from human plasma, and complexed to DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethyl-
indocarbocyanineperchlorate), were purchased from Invitrogen, Molecular Probes (Eugene, 
Oregon, USA). LDL-DiI and ac-LDL-DiI were stored at 4°C, protected from light. 
pHrodo
TM
 E.coli bioparticles
®
 for phagcytosis and Cell Tracker Orange (CMTMR) 
(Invitrogen, Molecular Probes) were purchased and stored at -20°C protected from light. If 
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re-suspension was carried out, pHrodo bioparticles were stored as 50 µl aliquots to avoid 
multiple freeze-thaw cycles.  
 
2.2 Cell culture 
2.2.1 Macrophage cell lines 
All cell culture work was carried out in a sterile class II biological safety fume hood. 
The murine RAW264.7 and J774.2 macrophage-like cell lines were generously provided by 
The Malaghan Institue of Medical Research (MIMR). Cells lines were maintained at 37°C, 
5% CO2 atmosphere, in complete T-cell medium (CTCM; See Appendix A (Gibco, 
Invitrogen, Grand Island, NY, USA)). Cell lines were passaged twice weekly in T-75 tissue 
culture flasks (BD Biosciences, Franklin Lakes, NJ, USA) according to ATCC passage 
protocol (Hsueh et al., 2008) by scraping of adherent cells with cells scrapers (Greiner Bio-
one, Frickenhausen, Germany) and diluting to a obtain a final cell count of 1x10
6
/ml in 
complete media. For experimental use, cells were freshly thawed and passaged to two 
passages. Following this initial passage, cells were used between 2 to 10 passages to 
prevent activation (Berghaus et al., 2009). Frozen cell stocks were maintained in liquid 
nitrogen at 1x10
6
/ml in freezing medium (See Appendix A) 
 
2.2.2 The HL-60 cell line 
The human promyelocytic leukemic blood leukocyte cell line, HL-60 was generously 
donated by Dr John H. Miller (School of Biological Sciences, Victoria University of 
Wellington). HL-60 cells were maintained in RPMI-1640 medium (Roswell Park Memorial 
Institute, RPMI; Gibco, Life Technologies) supplemented with 10% FCS, 100 U/ml 
penicillin (Invitrogen) and 100 µg/ml streptomycin (Invitrogen). Hl-60 cells were 
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maintained at 37°C, 5% CO2 atmosphere and passaged once weekly in T-25 tissue culture 
flasks (BD Biosciences, Franklin Lakes, NJ, USA) by diluting cells in a 1:10 ratio in 
RPMI-1640 media. Cells were used for 25-30 passages. 
 
2.2.3 The Escherichia coli DH5α strain 
Two Escherichia coli, (E.coli) DH5α lab strains; pOT11 GFP-labelled E.coli and 
PMMB207 control strain E.coli without GFP label was generously provided by Dr Ronan 
O’Toole (School of Biological Sciences, Victoria University of Wellington). Bacterial 
strains were stored in 80% glycerol at -80°C and used within 4-5 freeze/thaw cycles. E.coli 
was grown in a 37°C shaking incubator, in Luria Bertani media (LB media; See Appendix 
A (BD Biosciences, Franklin Lakes, NJ, USA). The GFP-label was isopropyl β-D-1-
thiogalactopyranoside (IPTG; Bioline, Randolph, MA, USA) dependent and not 
constitutively expressed. When GFP label expression was required, bacterial cultures were 
set up with IPTG at 100 µg/ml added into growth media. E.coli culture was carried out in 
the presence of 34 µg/ml chloramphenicol antibiotic (Duchefa Biochemie, Bioline, 
Randolph, MA, USA). 
 
2.3 Receptor-mediated Endocytosis (RME) 
This assay was set up to investigate the endocytosis of DiI-labeled LDL and ac-LDL 
(Invitrogen, Molecular Probes) by RAW264.7 cells. The basic methodology followed for 
this assay was as per described in (Cao et al., 2001; Yao et al., 2009). Briefly, RAW264.7 
cells at a concentration of 2x10
6
/ml in CTCM were seeded on the day of the experiment at 
50 µL/well in 96-well round bottom plates (Falcon). Unless otherwise stated, the cells were 
pre-treated for 2 hours with drug or equivalent concentration of ethanol as vehicle control 
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or left untreated with equal volume of media as controls. Final concentrations and drugs are 
stated in figures. At the end of the drug pre-treatment period, 20 µg/ml of LDL-DiI or ac-
LDL-DiI was added to the cells and a further incubation for 2 hours was carried out. Plates 
were removed onto ice and adherent cell populations were detached by thorough pipetting. 
Cells were washed once with 1x Phosphate Buffered Saline (PBS; See Appendix A (Merck, 
Darmstadt, Germany)) and then stained for F4/80 and CD11b markers in FACS buffer (See 
Appendix A; Appendix B for sources of all antibodies) and subjected to flow cytometry. 
Live gates were set using forward and side scatter parameters. Background fluorescence 
was set using isotype controls and single antibody stained cells were used to set 
compensations. Uptake of LDL or ac-LDL by RAW264.7 macrophages was measured by 
increases in DiI fluorescence intensity in the FL-2 channel. Data presented is mean from 
two experiments each with duplicate wells ± SEM. Data is representative of three 
individual experiments. 
 
2.4 Phagocytosis assay – GFP-labelled E.coli phagocytosis 
2.4.1 Seeding of RAW 264.7 or J774.2 cells 
On the day previous to the experiment, RAW264.7 or J774.2 cells at a concentration 
of 2x10
6
/ml were serum-starved and seeded at 50 µL/well in DMEM supplemented with 
5% FCS (experimental media) in 96 well flat bottom plates (BD Biosciences, Falcon, 
Franklin Lakes, NJ, USA).  If cell staining with Cell Tracker Orange (CMTMR) was 
required, it was carried out before cell seeding. Staining was carried out as previously 
described (Hermans et al., 2004). Briefly, cells were washed once in CTCM and incubated 
at 2x10
7
/ml in CTCM at 37°C for 15 minutes with 10 µM CMTMR. This was followed by 
incubation in fresh CTCM for 15 minutes at 37°C. Cells were then washed twice with 
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Wash buffer (See Appendix A) before plating at the required concentration. If cell 
stimulation was required for the experiment (explained in the relevant sections and stated in 
figure legends), cells were either stimulated with 100 units/ml (U/ml) IFN-γ overnight or 
left unstimulated with equal volume of experimental media added. On the day of the 
experiment, media was carefully replaced to prevent detachment of cells. Cells were pre-
treated for 45 minutes at 37°C with drug, ethanol (as vehicle control) or left untreated with 
equal volumes of media added in. Final drug concentrations and drugs used are stated in 
figures.  
 
2.4.2 Preparation of E.coli 
E.coli cultures were set up on the day previous to the experiment in LB media 
supplemented with 34 µg/ml chloramphenicol and 100 µg/ml IPTG as required for GFP 
induction. Following previously described protocols, along with some optimization 
adjustments as described below, on the day of the experiment, 20 ml of overnight cultured 
bacteria were spun down in a 50 ml polystyrene tube (BD Biosciences, Falcon) at 1850xg 
(3102 rpm) for 15 minutes (Sukumaran et al., 2003; Laroux et al., 2005). Bacteria were 
washed thrice in 1xPBS and bacterial opsonization was carried out with BALB/c mouse 
serum at 10 µl/ml for 15 minutes at 37°C. The optical density (OD) of the bacterial solution 
was measured and using OD600 of 1 = 1.92x10
9
 CFU/ml, bacteria were suspended in 
experimental media at required concentrations. 
 
2.4.3 Macrophage infection with E.coli 
At the end of the drug pre-treatment, bacteria were added to the cells at a multiplicity 
of infection (MOI) of 25:1 bacteria: macrophage. Concentration of drugs was maintained 
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after addition of bacteria. Plates were incubated at 37°C for 1 hour to allow phagocytosis to 
occur, following which cells were placed on ice and transferred to FACS buffer. At this 
stage, 50 µl of sample was removed for cytospin analysis (see section 2.8 for explanation 
on cytospin techniques) as required, to confirm bacterial internalization. As noted in 
figures, cells were stained for CD11b and F4/80 markers or left unstained in FACS buffer, 
followed by data collection on the flow cytometer. 
 
2.5 Phagocytosis assay - pHrodo phagocytosis 
2.5.1 Preparation and seeding of RAW264.7cells 
On the day previous to the experiment, cells were washed in 0.1% FCS/PBS. 
Approximately 2 – 3 mL of cells at 2x107/ml was incubated with 625 nM 5,6-
carboxyfluorescein succinimidyl ester (CFSE, Sigma) for 8 minutes at room temperature. 
CFSE labelling was quenched with 100% FCS, at a volume equivalent to that of the initial 
cell volume (i.e. 2 – 3 mL as relevant) for 2-4 minutes at room temperature. This was 
followed by a 10 minute incubation at 37°C, to enable excess intracellular CFSE dye 
efflux. Cells were washed thrice in 2% FCS/PBS and resuspended to a concentration of 
2x10
6
/ml. The cells were then seeded in 96 well flat bottom plates at 50 µL/well. If 
required, (explained in the relevant sections and stated in figure legends), 100 U/ml INF-γ 
overnight treatment was also carried out. On the experimental day, media was carefully 
replaced and cells were pre-treated for 45 minutes at 37°C with drug, ethanol (as vehicle 
control) or left untreated with equal volumes of media added in. Final drug concentrations 
and drugs used are stated in figures.  
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2.5.2 Preparation of pHrodo E.coli bioparticles 
pHrodo bioparticles are particles labelled with a novel flurogenic dye that increases in 
fluorescence as the pH of its surroundings becomes more acidic (Molecular Probes, 
Invitrogen). These particles are excellent for use in phagocytic assays as phagocytosis is 
measured based on acidification of the particles as they change from being non-fluorescent 
to exhibiting a bright red fluorescence as they are taken up. According to the 
manufacturer’s recommendations, pHrodo E.coli bioparticles were resuspended to 1 mg/ml 
in Uptake buffer (Hank’s Buffered Saline Solution (HBSS; Sigma Chemicals) buffered 
with 20 mM HEPES (Gibco, Life Technologies), adjusted to pH 7.4 with NaOH). The 
particles were briefly vortexed, transferred to a sterile glass tube and sonicated at room 
temperature in a water-bath sonicator, (Soniclean 80T, Thebarton, SA, Australia) at power 
8 for 5 minutes or until particles were homogenized (as visualized by the dark pink pellet at 
the bottom of the tube being resuspended to a uniform pink solution). 
 
2.5.3 Macrophage infection with pHrodo E.coli bioparticles 
At the end of the drug treatment, pHrodo particles were added to the cells at a final 
concentration of 0.5 mg/ml. Concentration of drugs was maintained after addition of 
pHrodo. To enable optimal phagocytosis, plates were spun at 500xg for 3 minutes to allow 
contact between adhered cells and particles and incubated for 2 hours at 37°C in a CO2-free 
atmosphere. Incubation was carried out in a CO2 free environment, based on manufacturer’s 
instructions, as elevated levels of CO2 causes artificial acidification of the Uptake buffer, 
leading to elevated background fluorescence. Following 2 hour infection, plates were 
placed on ice and supernatant was collected and stored at -20°C for cytokine analysis via 
ELISA. The samples were then resuspend in 1xPBS was and subjected to flow cytometry 
  Chapter 2: Materials and methods 
 
36 
collection. Live gates were set using forward and side scatter parameters. Background 
fluorescence and compensations were set using single samples of pHrodo alone and CFSE 
stained cells alone. Uptake of pHrodo was measured by an increase in pHrodo fluorescence 
intensity in the FL-2 channel. Unless otherwise described, data is presented as mean ± SEM 
from two duplicate wells, and representative of one experiment.  
 
2.6 Gentamicin survival E.coli phagocytosis assay 
2.6.1 Seeding of RAW 264.7 or J774.2 cells 
Cells were left unstained and seeded exactly as described in section 2.4.1. IFN-γ 
stimulation if required, and drug and ethanol vehicle controls were also carried out exactly 
as described in section 2.4.1 Presence or absence of IFN-γ, final drug concentrations and 
drugs used are stated in figures.  
 
2.6.2 Preparation of E.coli 
Bacteria were prepared as described in section 2.4.2, with the exception that GFP 
labelling was not induced. If required, bacterial opsonization was carried out as described 
in section 2.4.2. The optical density (OD) of the bacterial solution was measured and using 
OD600 of 1 = 1.92x10
9
 CFU/ml, bacteria were suspended in experimental media at required 
concentrations. 
 
2.6.3 Macrophage infection with E.coli 
At the end of the drug pre-treatment, bacteria were added to the cells at a multiplicity 
of infection (MOI) of 25:1 bacteria: macrophage. Concentration of drugs was maintained 
after addition of bacteria. Plates were spun at 500xg for 3 minutes to allow contact between 
adhered cells and bacteria and then incubated at 37°C for 1 hour to allow phagocytosis. 
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Following 1 hour invasion, cells were placed on ice and supernatant was collected and 
stored at -20°C for cytokine analysis via ELISA. At this stage, 50 µl of sample was 
removed for cytospin analysis as required, to confirm bacterial internalization. 
Following removal of supernatant, working quickly, samples that were controls for 
total bacterial counts or cells alone were resuspended by thorough pipetting in 100 µl LB 
broth and removed for plating on LB agar plates. The remaining samples were washed in 
1xPBS and resuspended in experimental media with 100 µg/ml gentamicin (Gibco, 
Invitrogen, Grand Island, NY, USA) for 2 hours at 37°C in to allow killing of extracellular 
bacteria. Supernatant was collected again and cells were washed with 1xPBS, followed 
with lysis of cells by 1% TritonX-100 (Sigma Chemicals) for 5 minutes at room 
temperature. Cells were then pelleted by spinning at 1017xg (2300 rpm) for 5 minutes and 
resuspended in 100 μL LB broth. All samples were cultured overnight at 37°C on LB agar 
plates and E.coli colonies were counted the following day. Figures show bacterial survival 
as CFU/ml adjusted for dilutions while plating on LB agar plates. Unless otherwise 
described, data is presented as mean ± SEM of two dilutions each from two duplicate wells 
and is representative of one experiment. 
 
2.7 General flow cytometry 
Staining for RME and GFP-E.coli assays were carried out in FACS buffer (See 
Appendix A) in 96-well round bottom plates. Cells were stained with F4/80-fitc and 
CD11b-bio, with a secondary stain Streptavidin-cyc (SA-cyc). IgG-fitc and IgG-bio/SA-cyc 
isotype controls were included in staining. An Fc receptor (FcR) blocking antibody, 24G2, 
was also used in the control mix to prevent non-specific Fc receptor ligation. Samples were 
incubated with antibody mix or control mix at room temperature for 10 minutes, followed 
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by 1x wash in FACS buffer and resuspension in FACS buffer for flow cytometry. When 
secondary staining was done, samples were washed to remove the primary stain and 
incubated with the secondary stain for 10 minutes at room temperature.  
Samples were collected using a BD FACSScan analytical flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA), and analyzed using BD Cell Quest Pro Software 
(Becton Dickinson, Franklin Lakes, NJ, USA). Samples from RME assays were collected 
using F4/80-FITC in the FL-1, CD11b-bio/SA-cyc in the FL-3 and LDL-DiI or ac-LDL-DiI 
in the FL-2 photomultiplier channels. For GFP-E.coli phagocytosis assays, samples were 
collected using CMTMR in the FL-1 and GFP in the FL-2 photomultiplier channels. While 
for pHrodo E.coli bioparticle phagocytosis, samples were collected using CFDA-SE in the 
FL-1 and pHrodo-SE in the FL-2 photomultiplier channels. Unless mean fluorescence 
levels for unloaded control cells was negligible, it was subtracted from the mean 
fluorescence levels of each assay condition. With experiments, background fluorescence 
was set using isotype controls and compensation was set using single stained cells or 
bacteria. All data, including dot plots and histogram generation was analyzed using Cell 
Quest Pro Software and graphed using GraphpadPrism version 4.0. 
 
2.8 Cytospin and light microscopy 
Presence of bacteria within the macrophages during infection assays were confirmed 
by carrying out cytospins. Cytospins are a type of centrifugation where cells are spun onto 
glass slides. Drying and staining of these slides then renders them suitable for microscopic 
analysis. After infection with bacteria, as mentioned in the sections above, 50 µL of select 
samples were removed for confirmation of infection. Glass slides were pre-labelled with 
sample number and dates, and then loaded into the metal cytospin holders along with 
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cardboard filters attached to cuvettes. 50 µL of the samples were added to each cuvette 
loaded into the Cytospin 3 (ThermoShandon, Cheshire, WAT, UK). Samples were run at 
1250 rpm for 5 minutes. On completion of spin, the cuvette and the filter were carefully 
detached, ensuring no disarrangement to the fresh cytospin. Slides were air-dried overnight, 
followed by methanol fixation, and staining in 100% Giemsa’s stain (Gurr Microscopy 
Materials, BDH Chemicals LTD, Poole, England). (Staining protocol: See Appendix A). 
Slides were then viewed under a light microscope using 100x oil immersion objective. 
 
2.9 ELISA: Enzyme linked Immunosorbant assay 
The presence of cytokines TNF-α, and IL-12 was detected using Enzyme-linked 
Immunosorbant Assay (ELISA) run according to manufacturer’s instructions. All 
antibodies and reagents were from BD Bioscience. ELISAs were set up using cytokine 
specific Rat-anti-mouse TNF-α or IL-12 capture antibodies in 96 well ELISA plates (BD 
Bioscience). The capture antibody was diluted to 2 µg/ml in sodium phosphate buffer at pH 
6.0 for TNF-α and 1 µg/ml in sodium phosphate buffer at pH 9.0 for IL-12. Plates were 
blocked with 100 L of 5% FCS in 1xPBS for 2 hours at room temperature, followed by 4 
washes in 0.05% Tween in 1xPBS. TNF-α or IL-12 standards at 4 ng/ml (serial diluted for 
12 dilutions) and samples (either neat or diluted in 5% FCS/1xPBS) were loaded into the 
plates for 2 hours at room temperature. Plates were washed 4 more times, and detected with 
cytokine specific biotinylated rat anti-mouse-TNF or IL-12 for 1 hour at room 
temperature, followed by 6 more washes, after which plates were incubated with 
Streptavadin-Horse-Radish-Peroxidase (SA-HRP) for 1 hour at room temperature. Plates 
were washed another 8 times, followed with addition of 100 µl TMB Substrate Reagents A 
& B (BD Biosciences) mixed in equal volumes. After sufficient color development, the 
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reaction was quenched with 100 µl Stop Buffer (0.18M H2SO4, pH 6.0). Plates were read 
on a Versamax microplate reader (Molecular devices, Sunnyvale, CA, USA) at 450 nm 
within 10 minutes of quenching and cytokine levels were quantified against the standards 
using Softmax Pro Version 3.0, Molecular Devices Corporation.  
 
2.10 Greiss Reaction 
The Greiss reaction is normally used to measure nitric oxide production. Measuring 
NO  production is difficult due to its production normally being in nanomolar ranges and its 
instability in the presence of oxygen (Archer, 1993). NO production can be indirectly 
measured via measuring production of its stable forms, nitrite (NO2
–
)
 
and nitrate (Schmidt, 
1995). A reliable, simple way of measuring NO is via the Greiss reaction as described 
previously (Sun et al., 2003; Crume et al., 2007). Fifty µl of culture supernatants from 
pHrodo or bacterial phagocytosis assays were added to 96-well flat bottom ELISA plates. 
Sodium nitrite (NaNO2) standards with a concentration range of 500 – 0 µM, and media 
blanks were also included for each plate. Greiss A and B reagents were then combined in 
equal volumes and 50 µl was added to each well. Plates were read at 570 nm on a 
Versamax microplate reader (Molecular devices, Sunnyvale, CA, USA) and NO production 
was quantified using the standard curve. 
 
2.11 Metabolism and proliferation assays (MTT Assays) 
3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) is a 
tetrazolium salt that is reduced to purple formazan crystals in the presence of reducing 
agents such as NADH and NADPH (Berridge et al., 1996). The MTT assays were used to 
obtain dose response curves to establish the cytotoxicity of drugs to the RAW264.7, J774.2 
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and HL-60 cells following 72 hour incubations. Similarly, the cytotoxic effect of paclitaxel 
on RAW264.7 cells and the metabolic activity of lipopolysaccharide (LPS) and paclitaxel 
stimulated RAW264.7 cells were tested following 2 and 8 hour incubations. Each of the 
MTT experiments consisted of three replicate wells, and the IC50 values ± SEM in table 3.1 
are based on three independent experiments, unless otherwise stated. Data is presented as 
percentage of control using the formula: 
(absorbance – blank / average control – blank) x 100.  
 
2.11.1 MTT assay to determine cytotoxicity of drugs 
The MTT assay was used to determine minimum inhibitory concentrations (MIC) and 
cytotoxicity of drugs over 72 hours in RAW264.7, J774.2 and HL-60 cells. Final 
concentrations and drugs are stated in figures. When setting up 72 hour MTT assays in 96 
well flat bottom plates, drug stocks were made up to twice the final required concentration, 
followed by serial or half-log dilutions. Cells were seeded at 2x10
5
/ml into the same wells, 
resulting in required concentration of drug. A cell-free media blank and a drug-free positive 
control were also set up on the same plate. Plates were incubated for 72 hours at 37°C, 5% 
CO2, at the end of which 20µL of sterile filtered 5mg/ml MTT (Sigma) in 1xPBS was 
added to each well, including cell blank and control wells, to allow crystal formation. The 
reaction was stopped with 10% w/v sodium dodecyl sulphate (SDS; Sigma) in 0.01N HCl 
(MTT solubilizer solution) and the plates were incubated overnight at 37°C to allow 
dissolving of all crystals. Plates were read on a Versamax microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) at 570nm and data was analyzed using the software Sigma 
Plot (Sigma Plot, Version 8.02 for Windows, SPSS Inc. Chicago, IL, USA). 
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2.11.2 MTT assays to determine changes in metabolic activity or cytokine 
production due to LPS and drug treatment 
The MTT assay was also used to determine changes in metabolic activity of 
RAW264.7 cells treated with LPS and paclitaxel. Final concentrations and drugs used are 
stated in figures. These MTT assays were run on culture experiments that were previously 
set up as follows. Cells were stimulated with 5 ng/ml (high) or 0.3 ng/ml (low) doses of 
LPS and simultaneously either treated with a range of concentrations of paclitaxel or left 
untreated. Following a 2 or 8 hour incubation, the supernatant was removed, either leaving 
100µL in all wells, or replacing wells with CTCM to a final volume of 100µL. The 
supernatants collected were stored at -20°C for TNF-α analysis. As described above, 20µL 
of sterile filtered 5mg/ml MTT was added then to each well; plates were incubated at 37°C 
for 2 hours, followed by addition of MTT solubilizer solution to stop the reaction. Plates 
were incubated overnight at 37°C to allow dissolving of all crystals, and were read on a 
Versamax microplate reader (Molecular Devices) at 570nm and data was analyzed using 
the Sigma Plot software. 
 
2.12 Confocal Microscopy 
2.12.1 Cell staining and preparation 
RAW264.7 cells were plated onto 35 mm glass bottomed confocal dishes (MatTek, 
Ashland, MA) in 1 ml of CTCM 2 days prior to the experiment and allowed to grow to 
80% confluency (as visually determined). On the day of the experiment, cells were gently 
washed with fresh CTCM and 600 µl Uptake buffer (see section 2.5.2) was used as 
experimental media.  
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If cells were being stained as noted in figure legends, staining was carried out on the 
adherent cells on the day of the experiment. Cells were stained with CFSE as previously 
described in section 2.5.1. One change was increasing the number of wash steps as cells 
were adherent and dye efflux was harder to achieve. Cells were also stained using the blue 
fluorescent, cell permeant nucleic acid stain Hoechst 33342 component of the Image-it™ 
kit (Invitrogen, Molecular Probes). For Hoechst staining, cells were washed once in Krebs 
buffer (See Appendix A) followed by incubation with 1 µM Hoechst dye for 10 minutes at 
room temperature. Cells were then washed 5 – 6 times in Krebs buffer and 2 -3 times in 
Uptake buffer after which they were incubated for experiments in 600 µl Uptake buffer. 
When staining cells with CFSE and Hoechst, CFSE staining was carried out before Hoechst 
staining.  
 
2.12.2 Fluorescent microscopy and Image acquisition 
Following a 45 minute drug or ethanol vehicle control treatment, pHrodo particles 
were added to the dishes at a final concentration of 25 µg/ml. Plates were incubated at 37°C 
in a CO2 free incubator, for 30 minutes following pHrodo addition before data collection. 
Cells were left untreated or were treated with 1 µM paclitaxel, 1 µM latrunculin A, 10 µM 
colchicine or equivalent concentration of ethanol as vehicle control. Drug concentration 
was maintained following addition of pHrodo. Cells were observed using an Olympus 
FluoView FV1000 confocal laser scanning biological microscope (inverted model IX81) 
under 60x oil immersion objective lens. Images were taken every 30 minutes after pHrodo 
addition for 4 hours, with the exception of vehicle treated cells, where images were taken at 
30, 150, 240, 330 and 420 minutes after pHrodo addition. This was to done to ensure all 
drug and control treatments were able to be carried out on the same day for the same time 
intervals.  
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During imaging, dishes were enclosed in a heat plate insulated, humidified double 
layer chamber (INU-ZILCS-F1 model, Tokai Hit Co., LTD, Japan) at 37°C. Images were 
obtained using XYZ scanning series to obtain a XY confocal image through the thickness 
of the sample. At each timepoint, at least 3 fields of view were randomly selected and 
images were acquired using lasers and standard filters as described in Table 2.1. Phase 
contrast images were acquired using Differential Interference Contrast (DIC) with confocal 
pHrodo overlay. XY confocal images were also taken using CFDA-SE, Hoechst, pHrodo-
SE and phase contrast along with and Hoechst, pHrodo-SE and phase contrast alone. 
 
2.12.3 Analysis 
Images were collected and analyzed using Olympus FV10-ASW software. There was 
one plate set up per drug; each plate was imaged in at least 3 randomly chosen fields of 
view, at every 30 minute time point. For analysis, at least 350 cells in total were manually 
counted from the images at each 30 minute timepoint. The pHrodo positive cells were 
visually identified and expressed as a percentage of the total number of cells counted in the 
field of view. 
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Table 2.1 List of filters, lasers and excitation-emission ranges for dyes used during 
confocal imaging.  
  
Excitation – Emission 
Wavelength 
 
Filter Laser 
CFDA-SE 
 
492 – 517 nm 
 
488 473 
pHrodo-SE 
 
560* – 585 nm 
 
554 559 
Hoechst 33342 
 
350 – 461 nm 
 
DAPI 405 
Phase contrast 
 
N/A 
 
N/A 473 
 
Table 2.1 Range of imaging parameters for confocal imaging with 3 colour dyes 
and non-confocal differential phase contrast imaging. * indicating pHrodo-SE is 
comparably excited using the 488 argon-ion laser as specified by manufacturer. 
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2.13 Statistics 
Data from MSD cytotoxicity and MTT assays of paclitaxel/LPS interations over 2 
and 8 hours was analyzed using SigmaPlot software version 8 (Systat Software Inc., Point 
Richmond, CA, USA) using the four parameter logistic curve to generate IC50 curves. 
Phagocytic assay data was analyzed with GraphpadPrism 4.0 (Graphpad Software Inc., San 
Diego, CA, USA), using one-way ANOVA tests with Bonferroni or Newman-Keuls post 
hoc test. Standard curves for ELISA and Greiss reaction data were generated by using 
Softmax Pro Version 3.0 (Molecular Devices Corporation, Sunnyvale, CA, USA), and the 
data was analyzed in GraphpadPrism using one-way ANOVA with Bonferroni post hoc 
test. ELISA data from paclitaxel and LPS interaction over 2 and 8 hours were analyzed 
using two-way ANOVA with Bonferroni post hoc test in GraphpadPrism. Confocal 
experiments were analyzed using Olympus FV10-ASW software and two-way ANOVA 
with Bonferroni post hoc test in GraphpadPrism. 
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CHAPTER 3: CYTOTOXIC EFFECTS OF MSD ON RAW264.7 AND J774.2 MURINE 
MACROPHAGES. 
3.1 Introduction  
Previous studies involving MSD have focussed on their anti-mitotic effects in 
proliferating cells. However, because of the diverse role of microtubules in cellular function 
(Peachman et al., 2004), it is possible that MSD also alter microtubule mediated cellular 
function in non-proliferating cells. Studies in our lab looking at MSD and macrophages 
have focussed on primary macrophages; in particular, bone marrow derived macrophages 
(BMDM) (Crume et al., 2007) , and the effects of MSD on these macrophages are distinct 
to cytotoxic effects (Crume et al., 2007; Crume et al., 2009). In this thesis, we investigate 
the effects of MSD on macrophages, which are non-proliferating cells. The cells used 
within our studies were the murine macrophage cell lines RAW264.7 and J774.2 
macrophages. Using murine macrophage cell lines offer advantages of immortalized, 
relatively stable cells with an adherent macrophage like phenotype.  Both these cell lines 
exhibit the macrophage maturity markers F4/80 and CD11b and have been used in 
numerous studies as models for macrophages (Maurya et al., 2007). RAW264.7 cells 
predominantly display Th1 properties, while J774.2 cells predominantly display Th2 
properties (Su et al., 2001). However, there are conflicting views on the origin of 
RAW264.7 macrophages. The RAW264.7 cells display an inflammatory phenotype when 
stimulated with LPS and produce high levels of TNF-α and NO (Fitzgerald et al., 2000; 
Sosroseno et al., 2002; Berghaus et al., 2009). This is similar to responses exhibited by 
macrophages from C57BL/6 mice (Santos et al., 2006), however RAW264.7 were derived 
from a BALB/c mouse (Raschke et al., 1978). Additionally, BALB/c mice are unable to 
Chapter 3: Cytotoxic effects of MSD  
on RAW264.7 and J774.2 macrophages 
 
48 
produce Th1 lymphocytes, and macrophages from these mice are not as sensitive to IFN-γ 
and LPS stimulation as C57BL/6 macrophages (Santos et al., 2006). Another study 
comparing RAW264.7 macrophages and C57BL/6 BMMO found the cells to closely 
resemble each other (Berghaus et al., 2009).  
However, both in vitro and in vivo RAW264.7 and J774.2 macrophages display 
phenotypes similar to those of primary macrophages. RAW264.7 macrophages are also 
considered similar to murine peritoneal macrophages (Ralph et al., 1977a; Sakagami et al., 
2009).  Both cell lines are good models for macrophage studies and although there are 
differences in cell signalling pathways, cell surface receptor expression and cytokines 
produced, for the most part these cell lines are similar to using primary macrophages 
(Maurya et al., 2007). In addition, both cell lines have been used extensively to study 
phagocytosis (Walter et al., 1980; Renwick et al., 2001; Suzuki et al., 2006; Anand et al., 
2007).  
The RAW264.7 and J774.2 cell lines are both proliferative, however when studied 
over shorter time frames, such as 2 to 4 hours, the cells are non-proliferative. Thus within 
the context of our assays, the cells are non-proliferative macrophages. To demonstrate this, 
we tested the cytotoxic effects of the MSDs on these cell lines using MTT assays. MTT 
assays are simple colorimetric assays that are used to measure cytotoxicity of a compound 
or cell viability (Kasugai et al., 1990; Pozzolini et al., 2003). MTT is a yellow, water-
soluble tetrazolium salt, and metabolically active cells are able to reduce this to blue water-
insoluble formazan crystals. MTT assays work on the premise that if metabolism is un-
affected, an increase in the amount of blue crystals correlates to cell proliferation. Thus if a 
low absorbance value is obtained after drug treatment, it would indicate that toxic effects of 
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the drug lead to cellular death. MTT assays provide minimum inhibitory concentration 
(MIC) or IC50 values, which indicate the efficacy of the drug in the particular cell line. We 
tested the efficacy and cytotoxicity of paclitaxel, peloruside A and docetaxel on RAW264.7 
(Fig 3.1.1) and J774.2 macrophages (Fig 3.1.2) over 72 hours. These assays were done to 
ensure that both cell lines were susceptible to the MSDs but also to rule out the possibility 
of mistaking cytotoxic effects for alterations in functionality of macrophages due to MSD 
treatment. We expected the cells to be sensitive to the drugs and compared the IC50 values 
obtained to those of HL-60 cells (Fig 3.1.3), which have been previously described (Hood 
et al., 2002; Sahin et al., 2008) . The effects of high dose (10 μM) paclitaxel on RAW264.7 
cells over 2 and 8 hours were also studied to ensure there were no cytotoxic effects over the 
duration of the experiments (Fig 3.1.4). Further to this, since all assays were seeded at the 
same cell concentration, we looked at the proliferation of untreated cells within each of the 
MTT assays to ensure that cytotoxicity results were not due to absence of cell proliferation 
(Fig 3.1.5) Drugs and final concentrations are stated in the figures. We expected 
RAW264.7 and J774.2 macrophages to react similarly to all 3 MSD. Further, we also 
expected these cell lines to be sensitive to the compounds as they proliferate in-vitro. IC50 
figures are representative dose response curves for the drug with its corresponding IC50 
value. 
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3.2 Results 
Figure 3.1.1 
          
 
         
 
Figure 3.1.1 Representative IC50 curves for (A) paclitaxel, (B) docetaxel and (C) 
peloruside A in RAW264.7 macrophages. Cells were seeded at 2x10
5
/ml for all assays 
and incubated with (A) paclitaxel (B) docetaxel or (C) peloruside A for 72 hours. Results 
are shown as a percentage of control, where controls are non-drug treated cells. Curves are 
a representative curve out of 3 individual experiments, except peloruside A which is out of 
2 individual experiments. Data presented as mean ± SEM. 
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Figure 3.1.2  
           
 
     
 
Figure 3.1.2 Representative IC50 curves for (A) paclitaxel, (B) docetaxel and (C) 
peloruside A in J774.2 macrophages. Cells were seeded at 2x10
5
/ml for all assays and 
incubated with (A) paclitaxel (B) docetaxel or (C) peloruside A for 72 hours. Results are 
shown as a percentage of control, where controls are non-drug treated cells. Curves are a 
representative curve out of 3 individual experiments, except peloruside A which is out of 2 
individual experiments. Data presented as mean ± SEM. 
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Figure 3.1.3  
           
           
     
 
Figure 3.1.3 IC50 curves for (A) paclitaxel, (B) docetaxel and (C) peloruside A in HL-
60 cells. Cells were seeded at 2x10
5
/ml for all assays and incubated with (A) paclitaxel (B) 
docetaxel or (C) peloruside A for 72 hours. Results are shown as a percentage of control, 
where controls are non-drug treated cells. Curves are a representative curve out of 3 
individual experiments, except peloruside A which is out of 2 individual experiments. Data 
presented as mean ± SEM. 
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Table 3.1 IC50 values for paclitaxel, docetaxel and peloruside A in RAW264.7, J774.2 
and HL-60 cell lines. 
 
 MSD 
 
 paclitaxel docetaxel peloruside A 
Cell 
Lines 
RAW264.7 75.54 nM ± 8.64 48.31 nM ± 3.71 155.93 ± 2.13 nM 
J774.2 19.81 nM ± 4.42 2.93 nM ± 0.50 11.31 nM ± 7.93 
HL-60 1.2 nM ± 0.83 0.84 nM ± 0.26 6.98 nM ± 1.59 
 
Table 3.1 IC50 values obtained from 72 hour incubations of each specified drug 
with three cell lines. Data presented as mean of three IC50 values ± SEM, 
except peloruside A in RAW264.7 cells which is a mean of two IC50 values. 
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Figure 3.1.4 
 
 
Figure 3.1.4 MTT curves for 
paclitaxel at 2 and 8 hours in 
RAW264.7 cells. Cells were 
seeded at 2x10
5
/ml for both 
assays and incubated with 
paclitaxel for 2 ( ) hours or 8 
( ) hours. Results are shown 
as a percentage of control, where controls are non-drug treated cells. Curves are presented 
as mean ± SEM of two replicates. **p<0.01 8 hours vs 2 hours at 0.1 µM dose, ***p<0.001 
overall trend 8 hours vs 2 hours, two-way ANOVA with Bonferroni post test. 
 
Figure 3.1.5 
 
Figure 3.1.5 OD570 values from a 72 
hour MTT assay on RAW264.7, 
J774.2 and HL-60 cells. All the 3 cell 
lines were seeded at 50 µL/well at an 
inital concentration of 2x10
5
/ml, and 
incubated in media alone for 72 hours. 
OD570 absorbance values due to MTT 
reduction, indicate level of cell 
proliferation or level of viable cells after 72 hours. RAW264.7 and J774.2 cells have 
proliferated to a greater extent as compared to HL-60 cells, in 72 hours. Results are 
presented as mean ± SEM of absorbance values. ***p<0.001; One-way ANOVA with 
Bonferroni Correction, RAW264.7 vs HL-60 cells and J774.2 vs HL-60 cells. 
  
]*** 
** 
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3.3 Discussion 
The first set of experiments was aimed at understanding the cytotoxic effects of the 3 
MSD on the proliferative macrophage cell lines. As these cell lines were proliferative, we 
expected the MSD to have cytotoxic effects on the cells; however we were interested in 
establishing the efficacy of the drugs in each cell line. Also, since we were interested in 
examining the effects of MSD on macrophage function, it was necessary to establish if the 
cell lines were resistant or susceptible to the 3 MSD.  Although RAW264.7 and J774.2 are 
both macrophage cell lines, the effect of MSD could vary in both these cell lines. We also 
expected the efficacy of the 3 MSD to vary in the macrophage cell lines as compared to 
HL-60 cells. 
 
We found that J774.2 cells were more susceptible to all the 3 MSD when compared to 
RAW264.7 cells, while HL-60 cells were the most susceptible to all the 3 drugs. Compared 
to J774.2 cells, paclitaxel was 4-fold more resistant, docetaxel was 17-fold more resistant, 
and peloruside A was 14-fold more resistant in RAW264.7 cells. There was also a much 
higher fold of resistance when comparing RAW264.7 to HL-60 cells for all the 3 drugs. 
Paclitaxel was 63-fold, docetaxel was 58-fold and peloruside A was 22-fold more resistant 
in RAW264.7 cells when compared to HL-60 cells. Interestingly, comparatively higher IC50 
values for peloruside A was seen in all the 3 cell lines, although resistance to paclitaxel in 
J774.2 cells was marginally higher than resistance to peloruside A. This increase in fold 
resistance could be due to microtubule-mediated resistance mechanisms (discussed below). 
Another possibility for peloruside A being relatively more resistant in all three cell lines 
could be related to its tubulin binding, in particular the isoform of tubulin to which it binds, 
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and the location of the binding site, which is still un-known (Jimenez-Barbero et al., 2006; 
Huzil et al., 2008). If peloruside A was unable to bind onto its tubulin site, cell lines would 
presumably exhibit resistance towards the drug, as it would be unable to exert mitotic or 
immune-mediated effects in these cells. 
 Resistance to anti-mitotic drugs often results from over-expression of membrane 
transporter proteins called ATP-binding cassette (ABC) transporters (Geney et al., 2002; 
Jordan et al., 2004). Resistance to paclitaxel is also well established and occurs via over-
expression of P-glycoprotein (P-gp) (Geney et al., 2002; Risinger et al., 2008). P-gp is a 
small transmembrane glycoprotein encoded by a family of multi-drug resistance (MDR) 
genes. There are two MDR genes in humans, MDR1 and MDR2, while mice and rodents 
express three MDR genes, mdr1a, mdr1b and mdr2 (Gupta, 2003) While P-gp is expressed 
in humans and mice, it is not clear if P-gp is expressed on murine hematopoietic cells 
(Gupta, 2003). Furthermore, if murine macrophages expressed P-gp it does not confirm the 
presence of P-gp in RAW264.7 murine macrophages.  
Currently there are no reports of RAW264.7 cells expressing P-gp and it would be 
interesting to investigate the possible presence of P-gp or other ABC-transporters on 
RAW264.7 cells, which could be responsible for increased resistance to not just paclitaxel 
but also docetaxel and possibly other MSDs. In addition, what makes the fold resistance 
seen in RAW264.7 cells towards peloruside A remarkable, is that peloruside A is not a 
good substrate for the P-gp drug pump (Gaitanos et al., 2004). The presence of alternative 
MDR pumps, with peloruside A as a substrate would be worth investigating, especially 
with the aim of developing peloruside A as a chemotherapeutic in paclitaxel resistant 
cancers. However, it would be more beneficial to investigate microtubule mediated 
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resistance, especially due to the fact that peloruside A has an un-identified tubulin binding 
site, novel to that of the taxanes.   
Resistance to MSD could also arise from microtubule-related mechanisms, such as 
expression of regulatory proteins, post-translational modifications, differences in levels of 
tubulin content, alterations in microtubule associated protein (MAP) content and presence 
of tubulin isotypes (Burkhart et al., 2001; Orr et al., 2003; Jordan et al., 2004). 
Microtubules have multiple α- and β-tubulin isotypes that are encoded by different genes, 
located on different chromosomes. While the structure of tubulin is conserved, tubulin 
isotypes differ in their carboxy-terminal tails (the last 20-27 amino acids) (Kavallaris, 
2010). Further to this, each isotype can undergo post-translational modifications, which can 
lead to alterations in microtubule interactions with microtubule associated proteins (MAPs) 
(Jordan et al., 2004; Kavallaris, 2010). The difference in tubulin isotypes and its differing 
expression in tissues and cell lines contribute towards explaining the development of 
resistance to various MSD in different cell lines.  
Two point mutations in β-tubulin near the taxane binding site, β274ThrIle and 
β282ArgGln have resulted in resistance to epothilones and taxanes via impaired tubulin 
binding (Giannakakou et al., 2000). Studies have shown that increased expression of Mβ2, 
a class II β-tubulin isotype, contributed to development of high resistance to paclitaxel and 
altered expression of Mβ2 lead to paclitaxel and docetaxel resistance in J774.2 cells (Haber 
et al., 1995). Given the difference in fold-resistance seen with paclitaxel and docetaxel in 
RAW264.7 compared to J774.2 cells, it is possible that RAW264.7 macrophages express a 
β-tubulin isotype different to that of J774.2 macrophages. Further, the level of expression 
of the tubulin isotype could also differ, and this could contribute to increased resistance. If 
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RAW264.7 cells had an acquired point mutation in β-tubulin near the taxane binding site, 
this would also lead to an increase in resistance to paclitaxel and docetaxel.  
Alternate explanations for the increased fold resistance to MSD seen with the two 
macrophage cell lines could be related to increased microtubule dynamics. Paclitaxel and 
other such MSDs are capable of altering microtubule dynamics even at low concentrations 
(Kelling et al., 2003; Jordan et al., 2008), indicating that their effects on dynamics are more 
potent. Paclitaxel resistant A549-T12 and –T24 lung cancer cells were also seen to have 
increased microtubule dynamics, indicating that microtubule dynamics were a significant 
factor in MSD resistance (Goncalves et al., 2001). Many of the factors mentioned above, 
such as tubulin isotypes, MAP expression and alteration and tubulin mutations could 
probably affect microtubule dynamics. All these factors in combination could account for 
the higher fold-resistance seen in the RAW264.7 cells to not only paclitaxel but also 
docetaxel and peloruside A.  
 
The MTT assays were also carried out to ensure that there were no cytotoxic effects 
of the MSD on the cells over the time-course of the experiment. Both macrophage cell lines 
have doubling times of between 12 to 18 hours (Rebres et al., 2004; American Type 
Culture Collection, 2007; Sakagami et al., 2009). While MSD are toxic to proliferating 
cells, within the time period of our assays we expected there to be no proliferation and thus 
no cytotoxic effects. Any alterations in the response of treated cells as compared to un-
treated cells could therefore be attributed to effects other than cytotoxic effects of MSD. 
This was demonstrated by carrying out a 2 and 8 hour MTT with paclitaxel treatment 
on RAW264.7 cells. We used a two-way ANOVA test with Bonferroni post test to analyse 
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the results. We tested if proliferation was affected by varying concentrations of paclitaxel 
over the 2 or 8 hour incubation time and varying incubation time alone, independent of 
concentrations. We found that cell viability was not affected after 2 hours of paclitaxel 
treatment, indicating that there was no proliferation over 2 hours. Additionally, there was 
no effect of varying concentration over the 2 hour incubation. At 8 hours however; analysis 
indicated that there was a significant decrease in cell viability after incubation with 
paclitaxel as compared to viability at 2 hours. Using the Bonferroni post test, comparing 2 
and 8 hours, at the concentration of 0.1 µM, there was a decrease in cell viability. However 
at higher concentrations, there was no significant difference between 2 and 8 hours 
suggesting that the significance could be due to assay variability. The 0.1 µM concentration 
was the only dose at which there was a significant change in cell viability. Despite this, 
using the Bonferroni post test to analyze the interactions between time and concentration at 
2 and 8 hours, we found a highly significant difference between the two incubation times, 
indicating that overall there was a decrease in viability at 8 hours as compared to 2 hours.   
Interestingly, there was no significant difference in treatment with increasing 
concentrations of paclitaxel over 8 hours. We found that the higher range of paclitaxel 
concentrations did not affect the viability of cells at 2 or 8 hours as compared to the lower 
range of concentrations. Furthermore, cells were able to survive at doses of 10 µM 
paclitaxel for both 2 and 8 hours, although survival was lower at 8 hours. Ten µM is a high 
dose as compared to the IC50 value of paclitaxel in RAW264.7 cells. However, previous 
studies carried out in non-proliferative primary macrophages, have used these high doses to 
study effects of MSD (Khandani et al., 2007; Robinson, 2009). Therefore we tested the 
survival and viability of RAW264.7 cells at these high doses of paclitaxel over short 
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periods of time to rule out cytotoxic effects of MSD on cells.  Overall, the results enabled 
us to affirm that for the assays carried out further along the study, since the maximum 
incubation time in the presence of drug was 4 hours or less, any effects seen were not due 
to cytotoxic effects on cell viability. A reason for cytotoxic effects at 8 hours would most 
likely be the increased exposure to high doses of drug. It is likely that this cytotoxic effect 
would not be present if paclitaxel doses were lower and incubation was still carried out 
over 8 hours.  
An interesting observation was that there was no increase in the metabolic activity of 
RAW264.7 cells stimulated with paclitaxel. Bone marrow derived macrophages have been 
seen to increase their metabolic activity when stimulated with paclitaxel (Crume et al., 
2007), however this increase was after a 72 hour incubation with paclitaxel. Given the LPS 
mimicry of paclitaxel, this increase in metabolism over 72 hours is not surprising. 
Macrophages respond to LPS or paclitaxel by increasing production of inflammatory 
mediators (Raetz, 1990; Tracey et al., 1994), and this would lead to increase in cell 
metabolism. While our results show a slight increase in cell metabolism after 8 hours of 
paclitaxel stimulation, this is not seen at 2 hours of paclitaxel stimulation. Since paclitaxel 
has LPS mimicry, the increase in metabolism at 8 hours could be due to an increase in 
production of inflammatory mediators, or due to an increase in proliferation due to LPS-
like signal (Crume et al., 2007). It is possible that increasing incubation periods with 
paclitaxel could lead to increased metabolism in RAW264.7 cells; however the timing of 
this incubation would be limited due to the proliferative nature of RAW264.7 cells, where 
incubation with paclitaxel over extended time periods, would lead to cell cycle arrest and 
cellular death. 
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The MTT assays allowed us to investigate another aspect of cell proliferation. We 
looked at proliferation of cells in relation to presence or absence of MSDs. Since we set up 
controls of non-drug treated cells for each of the MTT assays, it seemed obvious to ensure 
that the cytotoxic effects we observed on the cell lines were not due to a lack of cell 
proliferation over 72 hours. We compared the 72 hour OD570 values for wells with un-
treated cells after addition of MTT, which indicates proliferation of cells and cell viability. 
Since all 3 cell lines were seeded at the same concentration, we initially expected that HL-
60 cells would have higher proliferation and in comparison the macrophage cell lines 
would have lower rates of proliferation over 72 hours. If this held true, we hypothesized 
that the remarkably high IC50 values, especially for paclitaxel and peloruside A in 
RAW264.7 cells could be a result of lack of proliferation over 72 hours. Surprisingly, when 
looking at OD570 values, we found that the RAW264.7 and J774.2 cells had similar levels of 
cell proliferation and in contrast the HL-60 cells had significantly lower proliferation rates.  
The decreased proliferation of the HL-60 is explained by the doubling time of the 
cells, which is between 36 to 48 hours (Gallagher et al., 1979). As mentioned earlier, the 
macrophage cells have a doubling time of 12 to 18 hours. With the increased macrophage 
proliferation, the MSDs should have had a greater cytotoxic effect, resulting in lower IC50 
values. However, the IC50 values were higher indicating that the cells were resistant despite 
their higher proliferation rates. Contrary to our expectations, the HL-60 cells proliferated 
less over 72 hours and thus the MSDs had less of a cytotoxic effect, leading to 
comparatively lower IC50 values as compared to the macrophage cell lines. An 
improvement to the HL-60 MTT assays would be to run them over 48 hours, or alter initial 
seeding of cells to compensate for differences in proliferation speeds. The difference in 
Chapter 3: Cytotoxic effects of MSD  
on RAW264.7 and J774.2 macrophages 
 
62 
MTT incubation protocol for HL-60 cells could also explain the differences in the IC50 
values we found as compared to the data previously published. Previous IC50 values of 7 ± 
4 nM (Hood et al., 2002) published for peloruside A in HL-60 cells, have been comparable 
to our results of 6.98 ± 1.59 nM.  However, HL-60s were seen to have 48 hour IC50 values 
of 22 ± 8 nM for paclitaxel (Hood et al., 2002) and 20 nM and 5 nM for respectively for 
paclitaxel and docetaxel (Sahin et al., 2008). In contrast, our data gave 72 hour IC50 values 
of 1.2 ± 0.83 and 0.84 ± 0.26 nM for paclitaxel and docetaxel, respectively. It is likely that 
cell death was higher due to incubation times being 72 hours, thus resulting in lower IC50 
values. However we wanted to compare MSD effects on the macrophages and the HL-60s 
and so maintained constant conditions for all the assays.  
 
We investigated the cytotoxic effects of 3 MSD, namely paclitaxel, docetaxel and 
peloruside A, on 2 proliferating macrophage cell lines RAW264.7 and J774.2. We also 
compared these effects to effects on a proliferating promyelocytic blood leukaemia cell 
line, HL-60. Our results indicated that while all 3 proliferating cell lines were susceptible to 
the MSD, there was a varying degree of susceptibility with HL-60 cells being most 
affected, followed by J774.2 cell and lastly RAW264.7 cells. We also found that there was 
a 14-fold and 22-fold increase in resistance to peloruside A in RAW264.7 cells as 
compared to J774.2 and HL-60 cells respectively. This was noteworthy for two reasons; 
firstly, peloruside A is normally active in MDR cell lines (Gaitanos et al., 2004), and 
secondly, peloruside A is also known to bind to a tubulin site different from that of 
paclitaxel (Gaitanos et al., 2004); both of which suggest that peloruside A should be active 
in paclitaxel resistant cell lines. Further to this, we were able to show that over short 
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incubations of 2 to 8 hours, MSD did not have cytotoxic effects on proliferating cells. 
Taken together, our findings suggest that the use of the macrophage cell lines was a valid 
choice for the endocytic studies we were interested in carrying out. It also showed that cell 
lines from similar lineages could exhibit vastly different responses to MSD treatment. This 
is an important consideration when investigating reasons for the development of MDR 
strains or when exploring potential new anti-cancer therapeutics.  
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CHAPTER 4: EFFECT OF MSD ON RECEPTOR MEDIATED ENDOCYTOSIS 
4.1 Introduction 
Endocytosis is the process by which cells internalize small molecules and particles 
and target them to specific organelles within the cytoplasm (Smythe et al., 1991; Aderem et 
al., 1999). Endocytosis includes phagocytosis, pinocytosis, clathrin-dependent receptor-
mediated endocytosis (receptor mediated endocytosis; RME), and clathrin-independent 
endocytosis (Mellman, 1996). The RME pathway was first studied using uptake of 
lipoprotein, and since then this mechanism has been well characterized (Goldstein et al., 
1979; Gaffney et al., 1985). When ligand binding occurs, the receptor complex is 
internalized and fuses with an endosome. Receptor and ligand dissociate and the receptor is 
recycled, while the ligand-containing vesicles fuse with a lysosome (Mellman, 1996). This 
trafficking along the endocytic pathway mainly depends on functional microtubules and 
actin (Aderem et al., 1999). While trafficking of the receptor-ligand bound vesicle is more 
microtubule-dependent compared to the initial events of receptor mediated uptake, both 
processes depend on a functional, interacting cytoskeleton (Peachman et al., 2004).  
Low density lipoprotein (LDL) is the major cholesterol carrier and its uptake is 
mediated by the LDL receptor (Brown et al., 1979b). The uptake of un-modified or native 
LDL is slow when compared to uptake of LDL that is modified by acetylation, or oxidation 
(Goldstein et al., 1979; Henriksen et al., 1981; Nagelkerke et al., 1983). Further to this, 
uptake of modified LDL by in vitro tissue macrophages or murine macrophages is 
preferential over native LDL uptake (Goldstein et al., 1979; Brown et al., 1983; 
Plüddemann et al., 2007). Also, the presence of various, highly efficient ac-LDL receptors 
results in higher levels of ac-LDL being endocytosed. 
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Since the LDL and ac-LDL uptake pathways are well established and it is known that 
both these ligands are endocytosed via receptor mediated pathways (Sparrow et al., 1989), 
we utilized this pathway to test the ability of paclitaxel-treated macrophages to endocytose 
LDL and ac-LDL. We were interested in investigating any impairment in endocytic ability 
after paclitaxel treatment. Since the ligands have multiple receptors, we used both ligands 
for endocytosis experiments to gain a more detailed picture of the effects of paclitaxel. The 
two ligands were conjugated to a fluorescent probe 3,3'-dioctadecylindocarbocyanine (DiI) 
to enable endocytic studies to be carried out (Stephan et al., 1993).  We used RAW264.7 
macrophages for endocytic studies, which have previously been shown to endocytose LDL 
and its modified forms (Yao et al., 2009). We also characterized the macrophages by 
staining with the widely used macrophage markers, CD11b (MAC-1) and F4/80 (Khazen et 
al., 2005; Shen et al., 2008). 
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4.2 Results 
Initially, we characterized the phenotype of the RAW264.7 cells (Fig 4.1.1) by 
staining with fluorescently labelled antibodies F4/80-fitc and CD11b-bio/SA-cyc. Live and 
dead cell gates were set up based on forward and side scatter FACS plots, which 
characterize cells based on size and granularity. IgG-fitc and IgG-cyc antibodies were also 
used as a non-specific IgG control and to set isotype control gates. We also tested the 
uptake of varying concentrations of LDL and ac-LDL in un-treated RAW264.7 cells to 
determine the dose at which sufficient, measurable uptake was achieved (Fig 4.1.2 and Fig 
4.1.3). Analysis of results using two-way ANOVA with Bonferroni correction, showed a 
significant dose dependent increase in levels of uptake. This allowed us to determine 20 
µg/ml of LDL and ac-LDL as the dose at which there was sufficient, measurable rates of 
endocytosis occurring, and any changes to uptake in the presence of MSD would be 
apparent. For both histograms in figure 4.1.2, a shift to the right represents increased uptake 
of LDL or ac-LDL. However, there was no significant difference between the levels of 
LDL and ac-LDL endocytosed at each concentration of the reagent. The background MFI 
of cells alone was low enough to be negligible and was not subtracted from the MFI of cells 
with LDL or ac-LDL.  
Changes to the ability of macrophages to endocytose LDL or ac-LDL when pre-
treated with varying doses of paclitaxel was also investigated (Fig 4.1.4 and Fig 4.1.5). The 
endocytic ability of paclitaxel treated cells was compared to the ability of vehicle treated 
cells as we also wanted to ensure there were negligible effects from vehicle control on the 
endocytic process. Final concentration of vehicle was the same as final concentration of 
vehicle in the drug treated cells, and vehicle concentration was maintained throughout the 
assay. For both histograms in figure 4.1.4, a shift to the right represents increased uptake of 
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LDL or ac-LDL. We did not expect a significant decrease in the ability of paclitaxel treated 
macrophages to carry out receptor mediated endocytosis. Using a two-way ANOVA with 
Bonferroni correction to compare vehicle and paclitaxel treated cells, showed that there was 
no significant enhancement or impairment in the ability of paclitaxel treated cells to 
endocytose LDL or ac-LDL within the assay incubation period of 4 hours. 
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Figure 4.1.1 
   
    
    
Figure 4.1.1 Flow cytometry plots showing F4/80 and CD11b characterized 
RAW264.7 macrophages incubated with DiI labelled LDL particles. (A) RAW264.7 
macrophages showing a live and dead cell gate. (B) RAW264.7 macrophages are F480
+
 
and CD11b
+
 compared to (E, F) IgG isotype controls. (C) RAW264.7 cells endocytose DiI-
LDL and the cell population shifts compared to (D) cell population in the absence of DiI-
LDL.  
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Figure 4.1.2 
   
 
Figure 4.1.2 Dose dependent increases in receptor mediated endocytosis of DiI-LDL 
and DiI-ac-LDL by RAW264.7 macrophages. (A) Dose-dependent increase in 
endocytosis of DiI-LDL by RAW264.7 cells. Events are gated on CD11b
+
//F4/80
+
 
macrophages. Uptake was assessed as an increase in MFI. Optimal uptake is seen with 20 
μg/ml of DiI-LDL. (B) Dose-dependent increase in endocytosis of DiI-ac-LDL by 
RAW264.7 cells. Events are gated on CD11b
+
//F4/80
+
 macrophages. Uptake was assessed 
as an increase in MFI. Optimal uptake is seen with 20 μg/ml of DiI-ac-LDL. Both 
histograms are representative of 2 individual experiments. 
 
  
4.1.2 A. Figure Legend  
 IgG antibody stained cells 
  CD11b+F4/80+ cells with: 
- 0 μg/ml DiI-LDL 
- 5 μg/ml DiI-LDL 
- 10 μg/ml DiI-LDL 
- 20 μg/ml DiI-LDL    
4.1.2.B Figure Legend 
 IgG antibody stained cells 
 CD11b+F4/80+ cells with: 
- 0 μg/ml DiI-ac-LDL 
- 5 μg/ml DiI-ac-LDL 
- 10 μg/ml DiI-ac-LDL 
- 20 μg/ml DiI-ac-LDL 
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Figure 4.1.3 
  
Figure 4.1.3 Uptake of LDL --●-- or ac-LDL --■-- in RAW264.7 macrophages. Cells 
were seeded at 2x10
6
/ml and incubated with 0 μg/ml, 5 μg/ml, 10 μg/ml, or 20 μg/ml of 
LDL --●-- or ac-LDL --■-- for 2 hours. There was no significant difference between the 
levels of LDL or ac-LDL endocytosed at each concentration, however there was a 
significant dose-dependent increase in the level of uptake of both compounds. Graph is 
representative of two experiments. Data points show mean fluorescence intensity ± SEM 
from duplicate wells within one experiment. ***p<0.001 LDL and ac-LDL uptake (MFI) 
vs. concentration of LDL and ac-LDL. Two-way ANOVA with Bonferroni correction,  
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Figure 4.1.4 
 
 
Figure 4.1.4 Uptake of DiI-LDL and DiI-ac-LDL by RAW264.7 macrophages in the 
presence of paclitaxel. (A) Endocytosis of DiI-LDL by RAW264.7 cells treated with 
paclitaxel at varying doses. There is no shift or change in the MFI which represents uptake 
of DiI-LDL at the varying paclitaxel doses. Uptake was assessed as an increase in MFI. (B) 
Endocytosis of DiI-ac-LDL by RAW264.7 cells treated with paclitaxel at varying doses. 
There is no shift or change in the MFI which represents uptake of DiI-ac-LDL at the 
varying paclitaxel doses. Uptake was assessed as an increase in MFI. Both histograms are 
representative of 2 individual experiments. 
 
 
  
4.1.4. A Figure Legend 
 Untreated cells alone  
 Cells with: 
- 0 μM paclitaxel 
- 0.1 μM paclitaxel  
- 1 μM paclitaxel 
- 10 μM paclitaxel 
4.1.2.B Figure Legend 
 Untreated cells alone 
 Cells with: 
- 0 μM paclitaxel 
- 0.1 μM paclitaxel 
- 1 μM paclitaxel 
- 10 μM paclitaxel 
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Figure 4.1.5 
 
   
   
Figure 4.1.5 Uptake of DiI-LDL or DiI-ac-LDL in paclitaxel-treated RAW264.7 
macrophages. Cells were seeded at 2x10
6
/ml and pre-treated for 2 hours with paclitaxel at 
0.1 μM, 1 μM or 10 μM doses, (A, C) or an equal concentration of ethanol as a vehicle 
control (B, D). This was followed by incubation with 20 μg/ml of DiI-LDL (A, B) and (C, 
D) DiI-ac-LDL for two hours. (A) There was no significant difference in the ability of 
paclitaxel-treated macrophages ---- to endocytose LDL as compared to ethanol vehicle-
treated macrophages ----. (B) There was no significant difference in the ability of 
paclitaxel-treated macrophages ---- to endocytose ac-LDL as compared to vehicle treated 
macrophages --∆--. Similar levels of LDL and ac-LDL were endocytosed. There was no 
enhancement or impairment of the endocytic process in the paclitaxel-treated macrophages. 
The ethanol vehicle controls are representative of the percentage of ethanol present in the 
paclitaxel drug treated samples, each data point on the vehicle control graph corresponds to 
the 0, 0.1, 1 or 10 µM dose of paclitaxel used. Graphs are representative of three individual 
experiments. Data points are mean fluorescence intensity from two individual experiments 
± SEM. p>0.05, two-way ANOVA with Bonferroni post test.    
A B 
C D 
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4.3 Discussion 
This section of experiments was carried out to investigate the effects of the MSD, 
paclitaxel on the macrophage endocytic process, in particular receptor mediated 
endocytosis (RME). As the name suggests, RME is uptake of small (<0.5 μm) particles via 
a receptor and involves binding of the ligand to its receptor (Goldstein et al., 1979; Smythe 
et al., 1991). A lot of the initial events of receptor mediated uptake are microtubule 
independent. However paclitaxel stabilizes microtubules, and processes that are a part of 
RME such as trafficking of the vesicle containing ligand-receptor complex, endosomal 
fusion with the ligand, and recycling of the receptor is microtubule dependent (Oda et al., 
1995). Furthermore, unlike processes such as phagocytosis, receptor mediated endocytosis 
does not require cell motility. With these facts in mind, we were interested in investigating 
any inhibition or other effects of paclitaxel on this endocytic process. 
We found that RAW264.7 cells were able to endocytose LDL and ac-LDL. Levels of 
ac-LDL taken up were marginally but not significantly higher, as compared to LDL. We 
expected the difference in uptake of these two ligands to be much more distinct, due to the 
fact that there are more cellular receptors for ac-LDL (Goldstein et al., 1979; Gaffney et al., 
1985). The lack of difference in levels of LDL versus ac-LDL taken up could possibly be 
due to the fact that these assays were run in complete media, which contains 10% fetal calf 
serum (FCS). A recent publication found that RAW264.7 cells can be activated by 
cytokines and growth factors in serum, which leads to their activation and subsequent 
enhancement of native LDL uptake (Yao et al., 2009). The publication also found that 
RAW264.7 cells can take up LDL and its modified forms via macropinocytosis, and not 
just receptor mediated endocytosis (Yao et al., 2009). This could also account for there 
being no difference in the level of LDL and ac-LDL endocytosed by RAW264.7 cells. 
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Treatment with paclitaxel was carried out at 3 doses; 0.1 μM, 1 μM and 10 μM, 
which have been used previously (Jordan et al., 1993; Lewkowicz et al., 2008; Robinson et 
al., 2009). We wanted to ensure that the doses picked would stabilize microtubules but also 
be similar to previously tested doses. There was no change in the level of LDL or ac-LDL 
taken up by RAW264.7 macrophages in the presence of paclitaxel. While we did not expect 
dramatic decreases in the ability of treated macrophages to endocytose LDL or ac-LDL, the 
level of uptake was surprisingly similar to vehicle treated controls for both ligands. This 
suggests that microtubule stabilization or bundling does not affect endocytosis of ligands 
such as LDL via their receptors. This is not surprising however since the initial endocytic 
processes are known to be clathrin- and actin-dependent but microtubule independent 
(Schroer et al., 1991; Aderem et al., 1999).  
 
While initial endocytic events do not seem to be affected by paclitaxel, the processes 
following initial uptake could possibly be affected by paclitaxel or other such MSD. The 
ligand binds receptors that are clustered in clathrin coated pits on the plasma membrane 
(Anderson et al., 1982). Once ligand binds, these coated pits invaginate from the membrane 
to from a vesicle. This vesicle is trafficked along the microtubule pathway to fuse with the 
early endosome, after which fusion with the lysozome occurs, where receptors are recycled 
and LDL is degraded (Anderson et al., 1982; Smythe et al., 1991). Studies have found that 
microtubules are required for endosomal sorting and for segregation of the ligand from the 
receptor to facilitate dissociation (Goltz et al., 1992). Other studies have also shown that 
while microtubules are not required for the uptake of ligands, in the presence of 
microtubule inhibitors, vesicle movements are diminished and the degradation of endocytic 
material is hindered (Schroer et al., 1991). It was also seen that delivery of vesicle cargo 
 Chapter 4: Effect of MSD on receptor mediated endocytosis 
  
75 
from vesicles to late endosomes was absent in the presence of microtubule inhibitors, 
suggesting the requirement of microtubules for this process (Gruenberg et al., 1989). While 
the role of microtubules within cellular function is obvious, what is less clear is the extent 
to which these microtubule-dependent processes are maintained in the absence of dynamic 
microtubules. Our results suggest that stabilization of microtubules via MSD treatment 
does not affect endocytosis of ligands such as LDL or its modified forms. However, once 
uptake has occurred, MSD treated macrophages could possibly be unable to process these 
LDL laden vesicles. An interesting detail that could explain the lack of inhibition seen in 
paclitaxel treated macrophages during endocytosis of LDL, is that microtubule poisons 
frequently leave an intact pool of cytoplasmic microtubules that may be competent to 
support vesicle transport over short distances within the cell (Schroer et al., 1991) Another 
possibility could be that vesicle transport to early endosomes is achieved on paclitaxel 
stabilized microtubules, and only events following this are inhibited. It would be ideal to 
study this pathway in primary macrophages, as they can be incubated over longer time 
periods in the presence of drug. Tracking the movement of endosomes to lysozomes or 
even the golgi body in the presence of MSD, for instance via the use of membrane dyes 
(Schroer et al., 1991), would provide a more in-depth understanding of the effects of 
microtubule stabilization on receptor mediated endocytosis.  
Overall, we found that the microtubule stabilizer paclitaxel does not inhibit 
endocytosis of LDL or ac-LDL over 4 hours, even at higher doses of 10 μM. We also found 
that there was no significant difference in the amounts of LDL or ac-LDL taken up despite 
there being multiple receptors for the endocytosis of ac-LDL. Given that multiple ligands 
such as transferrin, protein hormones, lysosomal enzymes, certain viruses and even 
maternal immunoglobulins are endocytosed into the cell (Anderson et al., 1982), it would 
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be beneficial to investigate the effects of microtubule stabilization on the later events of the 
endocytic process. These studies would be excellent in further developing our 
understanding of cellular transport, the role of microtubules and the effects of MSD 
treatment. 
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CHAPTER 5: BACTERIAL PHAGOCYTOSIS BY MSD TREATED RAW264.7 MACROPHAGES. 
5.1 GFP-labelled E.coli and phagocytosis by RAW264.7 macrophages. 
5.1.1 Introduction  
Apart from RME, another important endocytic pathway in macrophages is 
phagocytosis. Macrophages are specialized for phagocytosis and are central to two main 
immune functions. Firstly, they ingest pathogens and activate the microbial death pathway, 
which includes production of hydrolytic enzymes and inflammatory cytokines (Harrison et 
al., 2002; Underhill et al., 2002). Secondly, they are important in combination with 
dendritic cells (DC), to target antigens to MHC I and II complexes, thus bridging the innate 
and adaptive immune systems (Greenberg et al., 2002; Harrison et al., 2002). The 
phagocytic processes are initially actin-dependent, however upon formation of the 
phagosome, actin is shed and the phagosome matures along the microtubule network, 
resulting in fusion with the lysozome (Desjardins et al., 1994b; Aderem et al., 1999). 
Phagocytosis requires an interaction between functional actin filaments and microtubules, 
and functional dynamic microtubules are also required for antigen processing (Underhill et 
al., 2002; Peachman et al., 2004). 
  Phagocytosis is part of the process by which the immune system initiates defence 
against invading pathogens. Immune cell function can be diminished due to neutropenia or 
immunosuppression, for example during chemotherapy with paclitaxel or docetaxel 
(Rowinsky et al., 1995; Javeed et al., 2009). As mentioned previously, MSD treatment 
causes microtubule stabilization and it is possible that functions depending on microtubules 
would be impaired. For these reasons we were interested in studying the effects that MSD 
treatment had on the phagocytic capabilities of macrophages. Previous studies have looked 
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at the MDD colchicine and its effect on phagocytosis, reporting that colchicine significantly 
depressed phagocytic capability in non-activated, non-elicited resident mouse macrophages 
(Khandani et al., 2007). Studies have also shown that treatment with paclitaxel led to 
decreased efficiency of complement-mediated phagocytosis (Lewkowicz et al., 2008). 
While MDD treatment causes microtubules to disperse and break down, MSD treatment 
causes microtubules to stabilize and we hypothesized that in the presence of stabilized 
microtubules, macrophages would display an impaired phagocytic ability. In addition, we 
wanted to investigate the killing ability of these MSD treated macrophages. We 
hypothesized that if phagocytosis itself was not impaired, it could be possible that MSD 
treated macrophages would be unable to kill the phagocytosed bacteria. Furthermore, it is 
known that paclitaxel has LPS mimicry, and is capable of increasing inflammatory cytokine 
production (Ding et al., 1990b), while peloruside A does not share this property (Crume et 
al., 2007). It is also known that paclitaxel and docetaxel have immunomodulatory effects 
and can regulate cytokine production (Chan et al., 2000). Based on the above information, 
we were also interested in the regulation and production of cytokines, especially TNF-α, 
during phagocytosis in MSD treated macrophages. 
 
There are various methods available for the study of phagocytosis. Originally 
methods included fluorescent labelling of particles, followed by quenching of extracellular 
fluorescence with trypan blue (Wan et al., 1993; Klippel et al., 2007). Other methods 
suggested repeated washing of cells after phagocytosis to detach extracellular particles, 
followed by lysis of the cell to release intracellular particles for quantification (Khandani et 
al., 2007). There are also a variety of methods that use live cell imaging, and flurogenic 
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probes coupled with quantification via a spectrophotometer or flow cytometer (Russell et 
al., 2009). We wanted to study the uptake of live bacteria rather than uptake of particles 
such as IgG-opsonized sheep red blood cells (SRBC) or latex beads as different receptors 
are involved in recognition of differing particles (Takeda et al., 2003). In addition, cellular 
and immune responses can differ depending on the phagocytosed material. The activation 
state of macrophages and the amount of hydrolytic enzymes produced change depending on 
the presence of LPS and IFN-γ stimuli (Yates et al., 2007). The use of live bacteria would 
stimulate macrophages similarly to an in vivo infection, leading to more efficient 
phagocytosis. It was also thought that to evaluate the true effects of MSD on phagocytosis, 
the assays should be as close as possible to real infections and this resulted in us choosing 
viable bacteria. Furthermore, we would be able to look into the immunomodulatory effects 
of MSD on cytokine production during bacterial killing.  
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5.1.2 Results 
Initially, GFP positive (GFP+ve) E.coli was used to infect RAW264.7 cells, 
following the methods described section 2. The GFP signal was not constitutive but was 
IPTG inducible. We also had access to GFP negative (GFP-ve) bacteria that allowed 
calibration of instruments, and confirmation that RAW264.7 cells phagocytosed both 
strains of bacteria similarly (Fig5.1.1). All cells were not stained for macrophage markers 
in the early assays as staining was carried out in FACS buffer containing sodium azide, 
which seemed to cause loss of GFP signal or inhibit survival of bacteria after two to four 
hours (Fig 5.1.2). However, macrophages alone stained for CD11b-PE were included as a 
control to set live cell and bacterial gates. We tested varying concentrations of bacteria to 
determine optimal multiplicity of infection (MOI). At low MOI, it was relatively easy to 
distinguish the two populations; however at higher MOI it was difficult to ascertain the 
macrophage population from the bacterial population (Fig 5.1.3).  
 
We then stained macrophages using an Invitrogen cell tracker probe, cell tracker 
orange (5-(and-6)-(((4-chloromethly)benzoyl)amino)tetramethylrhodamine (CMTMR), as 
this stain did not require FACS buffer, ensuring maintenance of GFP+ve signal (Fig 5.1.4). 
However although we could distinguish bacterial and cell populations, it was not possible 
to determine internal phagocytosed bacteria from external bacteria adhered to the 
macrophages, especially with increasing MOI (Fig 5.1.4 and Fig 5.1.5). 
 
The next method trialled to address the problem of differentiating intracellular vs 
extracellular bacteria was via the use of an antibiotic treatment that kills extracellular 
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bacteria (Al-Mariri, 2008; Subramanian et al., 2008). After infection of macrophages, cells 
are treated with antibiotics such as gentamicin for 2 to 4 hours to kill or incapacitate 
extracellular bacteria. We used this antibiotic method to kill extracellular bacteria; however 
we found that gentamicin-killed bacteria were still fluorescent and expressed GFP similarly 
to live bacteria (Fig 5.1.6). We also trialled quenching of extracellular fluorescence via 
trypan blue, however this too was unsuccessful, as trypan blue is fluorescent itself causing a 
baseline fluorescence. In addition it seemed to mask the intracellular GFP signal.   
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Figure 5.1.1 
 
 
      
       
 
Figure 5.1.1 Histogram and Flow cytometry plots showing GFP+ve and GFP-ve E.coli. 
(A) Positive and negative GFP E.coli are distinct populations (B, C) RAW264.7 
macrophages phagocytose GFP+ve bacteria and show a shift in the lower right quadrant, 
compared to (D, E) RAW264.7 macrophages phagocytose GFP-ve bacteria but remain in 
the lower left  quadrant, and are not GFP+ve.  
5.1.1 Figure Legend 
 GFP negative bacteria 
 GFP positive bacteria 
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Figure 5.1.2 
       
       
       
Figure 5.1.2 Flow cytometry plots showing effect of FACS buffer on GFP+ve E.coli. 
(A) Bacterial population with a live cell and bacterial gate. (B) Bacteria survive in FACS 
buffer for 20 minutes and emit a strong GFP signal, compared to (C, D) bacteria in FACS 
buffer for 2 hours, with a decrease in bacterial count and fluorescence. (E, F) Bacteria are 
most affected after 4 hours in FACS buffer, GFP signal is low and the population has 
decreased.  
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Figure 5.1.3 
  
  
 
Figure 5.1.3 Bacterial population is hard to distinguish from unstained macrophages, 
when bacteria are added at high MOI. (A, B, C) RAW264.7 macrophage population can 
be distinguished from GFP+ve bacteria at low MOI. FACS plot C shows low population of 
bacteria from bacterial gate, compared to (D, E, F) where at high MOI bacteria and 
RAW264.7 macrophages are harder to distinguish. FACS plot F shows high population of 
bacteria from bacterial gate.  
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Figure 5.1.4 
      
     
       
Figure 5.1.4 CMTMR labelled macrophages and GFP+ve bacteria. (A, B) RAW264.7 
macrophages stained with CMTMR. (C, D) Macrophages with low MOI bacteria cause a 
shift in the population making the cells double positive for CMTMR and GFP. (E, F, G) 
With higher MOI, it is harder to distinguish external bacteria from phagocytosed, internal 
bacteria. There is an increase in number of double positive live cells, however bacterial gate 
(G) also shows double positive cells, indicating the presence of mixed cells and bacteria. 
  
Chapter 5: Bacterial phagocytosis by  
MSD treated RAW264.7 macrophages. 
 
86 
Figure 5.1.5 
   
Figure 5.1.5 RAW264.7 cells incubated with increasing MOI of GFP+ve bacteria. 
Compared to MOI 1:1 and 10:1, at MOI of 100:1 there is an evident shift in the histogram. 
However it is not clear if bacteria are internalized or adherent and the increased 
fluorescence can be due to an increase in MOI. (MOI: multiplicity of infection of bacteria: 
macrophage) 
Figure 5.1.6 
         
Figure 5.1.6 GFP+ve bacteria incubated with gentamicin are fluorescent and express a 
GFP+ve signal. Incubation of bacteria with 100 μg/ml of the antibiotic gentamicin, to 
facilitate bacterial killing, has no effect on the expression of the GFP signal. Bacteria are 
dead, however they still fluoresce, indicating that extracellular bacteria treated with 
gentamicin would still express GFP.   
5.1.5 Figure Legend  
 CMTMR stained cells 
 CMTMR stained cells with  
GFP+ve bacteria: 
- MOI 1:1 
- MOI 10:1 
- MOI 100:1    
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5.1.3 Discussion 
The use of GFP labelled bacteria to study phagocytosis was successful if the MOI 
was low. At low MOI, it can be assumed that all bacteria will be internalized and this can 
be confirmed via cytospins. However to study the effect of MSD treatment and microtubule 
stabilization on phagocytosis, it was essential to have the phagocytosis assays working with 
maximum bacteria. If MOI was low, then the effects seen with MSD treatment might be 
negligible as macrophages would still phagocytose bacteria. Also to mirror in vivo 
conditions, a higher MOI was preferred. We found that at higher MOI, it was increasingly 
difficult to distinguish between the macrophage and bacteria populations, especially since 
the macrophage populations were not stained. Staining of macrophages for markers such as 
CD11b and F4/80 was carried out in FACS buffer, and we found that this had a negative 
effect on survival of bacteria. A similar result was seen where sodium azide caused 
inhibition of E.coli phagocytosis in murine peritoneal macrophages (Miliukiene et al., 
2007). Therefore using FACS buffer would skew the phagocytic results. Another problem 
with increasing MOI was the fact that high concentration bacterial cultures can have toxic 
effects on the macrophages (Ralph et al., 1977b).  
The use of the cellular stain cell tracker orange (CMTMR) was helpful in 
differentiating between the two populations, however we once again had the problem of 
identifying intracellular and extracellular bacteria. Our initial aim was to identify inhibition 
or enhancement to phagocytic ability of MSD treated macrophages. To enable us to answer 
this aim, it was necessary to be able to differentiate internalized bacteria from adherent 
bacteria. The next method we trialled was using antibiotic treatments to kill extracellular 
bacteria. The idea behind this method was that once macrophages were infected and 
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phagocytosis had occurred, use of an antibiotic to kill extracellular bacteria would aid in 
distinguishing intracellular and extracellular bacteria. However we found gentamicin-killed 
bacteria to be fluorescent, with the result being that we were still unable to identify 
phagocytosed bacterial populations successfully. It was also interesting to find that the 
trypan blue quenching protocol has reports of letdowns as well as success by different 
research groups (Peiser et al., 2000; Klippel et al., 2007). 
 
Overall, use of GFP labelled bacteria and flow cytometry to study phagocytosis was 
unsuccessful for our experiments due to our requirement of needing to distinguish between 
internal bacteria and external bacteria. These methods are established methods and have 
been used successfully, especially in experiments where adherence and ingestion have 
together been regarded as uptake (Peiser et al., 2002; Areschoug et al., 2008).  
Due to the limitations faced when using the above methods, we decided to explore 
other phagocytic assays that would allow differentiation between extracellular and 
intracellular bacterial populations. A recently developed dye from Invitrogen Molecular 
Probes
®
 proved to be an excellent option for the study of phagocytosis. The dye is a pH-
sensitive rhodamine-based dye, designed to allow specific determination of phagocytic 
events from non-specific binding. These assays are discussed in the following sections. 
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5.2 pHrodo E.coli bioparticles and phagocytosis by RAW264.7 macrophages.  
5.2.1 Introduction 
As discussed in the previous section, one of the problems faced when studying 
phagocytosis is the difficulty in differentiating between internalized bacteria and adherent 
bacteria. In most cases, the previously discussed methods are sufficient; however, they may 
overestimate the actual engulfment of bacteria due to the detection of surface-bound 
bacteria. To determine the true engulfment of bacteria, we employed a novel flurogenic 
approach to distinguish phagocytic events from non-specific bound bacteria. The flurogenic 
pHrodo reagent is a rhodamine based dye that has low or no fluorescence at neutral pH and 
dramatically increases its fluorescence with a drop in pH (Fig 5.2.1) (Invitrogen, Molecular 
Probes). This system measures endocytosis or phagocytosis based upon acidification of 
ingested particles. Extracellular or bound particles do not fluoresce, thereby giving a direct 
measure of phagocytic events. pHrodo E.coli bioparticles have been used to study 
phagocytosis successfully (Lambert et al., 2008), while pHrodo-SE dye has been used to 
label apoptotic thymocytes, which are then used as phagocytic targets (Miksa et al., 2009). 
Thus this novel reagent can be used in various applications to study RME or phagocytosis.  
We used pHrodo-labelled E.coli bioparticles
®
 (hereafter referred to as pHrodo or 
pHrodo particles) to investigate the phagocytic ability of MSD treated macrophages. Once 
particles are phagocytosed, they start to fluorescence, however upon fusion of the 
phagosome with the lysozome, the pH drops further due to hydrolytic enzymes in the 
lysozome (Desjardins et al., 1994a; Luzio et al., 2007). The drop in pH leads to increasing 
intensity of fluorescence, so over time as more bacteria are phagocytosed and phagosomes 
fuse with lysozomes, there is increasing fluorescence seen within macrophages.   
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Figure 5.2.1 
 
 
Figure 5.2.1 Increase in fluorescence of phagocytosed pHrodo E.coli bioparticles. 
E.coli labelled with pHrodo™ dye are added to macrophages. Non-fluorescent bacteria 
display an increase in fluorescence intensity once phagocytosed. Extracellular and adherent 
bacteria are non-fluorescent.  
Adapted from Invitrogen “pHrodo™ indicators - enlightening phagocytosis” distribution poster.  
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5.2.1.2 Effects of MSD treatment on pHrodo phagocytosis in RAW264.7 
macrophages. 
We initially tested pHrodo with un-treated RAW264.7 macrophages to optimize 
culture conditions and concentrations. RAW264.7 macrophages were stained with 
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE or CFSE) and phagocytic 
assays were carried out as described in the methods. Figure 5.2.2 shows live gated plots of 
CFSE stained RAW264.7 macrophages and baseline fluorescence of the pHrodo particles. 
The increase in mean fluorescence intensity (MFI) of pHrodo from baseline fluorescence is 
seen with the macrophages and pHrodo co-incubation plots. Due to the pHrodo being non-
fluorescent when extracellular, distinguishing between the two populations was possible 
and actual phagocytic events were quantified.     
Optimization of pHrodo uptake enabled us to use this system to investigate effects of 
MSD treatment on the phagocytic ability of macrophages. As mentioned earlier, there are 
few studies that investigate the effects of MSD on macrophage functions that also depend 
on microtubules. Our aim was to determine if treatment with MSD caused any inhibition or 
impairment to the macrophage ability to phagocytose bacteria. We hypothesised that MSD 
treatment would cause a reduction in the ability of macrophages to phagocytose bacteria. 
However, it was possible that due to the immunostimulatory properties of some of these 
MSD, macrophage phagocytic ability would be enhanced. We were also interested in the 
cytokine profile expressed by MSD treated macrophages during phagocytosis. LPS and 
paclitaxel cause an increase in TNF-α, while this inflammatory profile is absent with 
peloruside A treatment (Ding et al., 1990b; Crume et al., 2007). With these aims in mind, 
we tested the effects of 3 MSD, namely paclitaxel, docetaxel and peloruside A, on 
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macrophages phagocytosis. Latrunculin A disrupts the actin cytoskeleton and inhibits 
phagocytosis (Coue et al., 1987; Spector et al., 1989; Oliveira et al., 1996). We used this 
drug in our studies as a positive control to ensure inhibition of phagocytosis. While 
paclitaxel, docetaxel and peloruside A are the 3 main MSD studied in this thesis, we also 
had limited access to other novel compounds. Zampanolide, mycothiazole and ixabepilone 
are also studied during various sections of this thesis depending on their availability.  
 
5.2.1.3 Effects of the novel compounds; zampanolide, ixabepilone (Ixempra
®
) 
and mycothiazole on RAW264.7 macrophages during pHrodo phagocytosis. 
Zampanolide is a potent microtubule stabilizer that blocks the cell cycle in the G2/M 
phase and shows cytotoxic activity against several tumour cell lines (Tanaka et al., 1996; 
Field et al., 2009). Ixabepilone is a semi synthetic derivative of epothilone B and it is the 
only epothilone with FDA approval for clinical use (Conlin et al., 2007; Goodin, 2008). 
Epothilones stabilize microtubules similarly to paclitaxel (Altmann, 2003). However, they 
are also competitive inhibitors of paclitaxel binding to microtubules, suggesting that 
paclitaxel and epothilone could share a binding site and have similar affinities for 
microtubules (Bollag et al., 1995; Goodin et al., 2004).  Ixabepilone is used clinically in 
combination or mono-therapies for the treatment of metastatic or locally advanced breast 
cancers that are resistant to taxanes (Donovan et al., 2008; Goodin, 2008; Lechleider et al., 
2008). Mycothiazole is sourced from a Fijian marine sponge, Cacospongia mycofijiensis 
(Sonnenschein et al., 2006). It shows considerable bioactivity and is selective against 
several tumour cell lines, particularly lung cancer. Recent studies have indicated that 
mycothiazole could inhibit activation of hypoxia inducible factor 1 (HIF-1) in tumor cells 
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and at low nM concentrations, it could inhibit hypoxia induced vascular endothelial growth 
factor (VEGF) (Sashidhara et al., 2009). While the main MSD studied in this thesis are 
paclitaxel, peloruside A and docetaxel, we also tested the effects of these novel compounds 
on phagocytosis. 
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5.2.2 Results 
 
Figure 5.2.2 
     
     
     
Figure 5.2.2 pHrodo particles show an increase in fluorescence when phagocytosed by 
macrophages. (A, B) Live gated macrophages are CFSE positive. (C, D) pHrodo particles 
alone have low baseline fluorescence. (E, F) Increase in fluorescence seen with addition of 
pHrodo to macrophages. All samples were incubated for 2 hours at 37°C before being 
collected on the flow cytometer.   
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Effects of MSD treatment on pHrodo phagocytosis in RAW264.7 macrophages. 
Macrophages were stained with CFSE and treated with low (0.1 μM) and high (1 μM) 
doses of MSD as described in methods. Pretreatment with IFN-γ was also carried out as 
noted in figures. Following a 45 minute drug treatment, pHrodo was added to cells. Drug 
concentration was maintained at all times following addition of particles. Ethanol vehicle 
controls and un-treated macrophages infected with pHrodo particles were included as 
controls. A no-cell, pHrodo particle sample was also run to measure base-line fluorescence 
(Fig 5.2.3). Data is expressed as percentage of cells positive for pHrodo phagocytosis (Fig 
5.2.4), or the MFI of the positive cells (Fig 5.2.5). Compared to vehicle controls, treatment 
of macrophages with paclitaxel, peloruside A or docetaxel did not significantly affect the 
phagocytic ability. However as compared to vehicle treated cells, treatment with high dose 
zampanolide and Latrunculin A significantly inhibited phagocytosis (Fig 5.2.4). The MFI 
values from low and high dose zampanolide treatment were significantly lowered compared 
to controls (Fig 5.2.5). 
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Figure 5.2.3 
             
 
Figure 5.2.3 Macrophages (MO) and pHrodo alone show low percent positive cells; 
however intensity of fluorescence is high. (A) Macrophages (MO) and pHrodo together 
have increased fluorescence in comparison to either macrophages or pHrodo alone. Data is 
presented as mean percent positive cells for pHrodo uptake ± SEM. There is no significant 
difference between the levels of fluorescence seen with the three samples. p>0.05, one-way 
ANOVA with Bonferroni post test. (B) MFI of positive cells indicates the fluorescence 
intensity of the positive cells. Macrophages alone and pHrodo alone have high MFI, 
indicating the positive cells are brightly stained, and the baseline fluorescence is high. 
Therefore while macrophages and pHrodo together have higher fluorescence levels, there is 
no significant difference between the levels of fluorescence seen with the three samples. 
p>0.05, one-way ANOVA with Bonferroni post test. 
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Figure 5.2.4 
 
Figure 5.2.4 Phagocytosis of pHrodo by MSD treated macrophages. Cells were pre-
treated with 100 U/ml IFN-γ overnight, followed by an MSD or equal concentration of 
ethanol (vehicle) pre-treatment for 45 minutes and incubation with pHrodo as described in 
methods. pHrodo uptake is expressed as the percent of cells positive for pHrodo uptake. 
Compared to vehicle controls, paclitaxel, docetaxel and peloruside A do not significantly 
inhibit phagocytosis. There was a non-significant decrease in the level of phagocytosis of 
low dose zampanolide treated cells and a significant decrease in the level of phagocytosis 
of high dose zampanolide treated cells. Bars represent mean ± SEM from two independent 
experiments, except zampanolide which is mean ± SEM from one experiment. Gray bars 
 represent 0.1 μM (low dose) MSD treatment/vehicle control; black bars  represent 
1 μM (high dose) MSD treatment/vehicle control. Lat A: latrunculin A. **p<0.01 
zampanolide vs vehicle control, ***p<0.0001 Latrunculin A vs vehicle control, one-way 
ANOVA with Bonferroni correction. 
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Figure 5.2.5 
 
Figure 5.2.5 Changes in fluorescence intensity of cells positive for pHrodo uptake in 
the presence of MSD treatment. There was no change in the fluorescence intensity of 
paclitaxel, docetaxel or peloruside A treated macrophages. However compared to vehicle 
controls, zampanolide and Latrunculin A treated cells exhibited a significant decrease in 
fluorescence intensity. pHrodo uptake is expressed as mean fluorescence intensity ± SEM 
of the cells positive for pHrodo uptake. Gray bars  represent 0.1 μM (low dose) MSD 
treatment/vehicle control; black bars  represent 1 μM (high dose) MSD 
treatment/vehicle control. Data is representative of 2 experiments, except for zampanolide 
which is representative of 1 experiment. Zamp: zampanolide, Lat A: latrunculin A. *p<0.05 
low dose zampanolide vs low dose vehicle control, ***p<0.001 high dose zampanolide vs 
high dose vehicle control, ***p<0.001 Latrunculin A vs high dose vehicle control, one-way 
ANOVA with Bonferroni correction. 
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Effects of ixabepilone and mycothiazole treatment on pHrodo phagocytosis in 
RAW264.7 macrophages. 
Macrophages were stained with CFSE and treated with low (0.1 μM) or high (1 μM) 
doses of either ixabepilone or mycothiazole as described in methods. Pretreatment with 
IFN-γ was also carried out as noted in figures. Following a 45 minute drug treatment, 
pHrodo was added to cells. Drug concentration was maintained at all times following 
addition of particles. Vehicle (ethanol and DMSO) treated samples were included. The 
experiments with ixabepilone, mycothiazole and latrunculin were carried out together; 
however data is presented in 2 figures as the vehicle control for mycothiazole is DMSO, 
while the vehicle control for ixabepilone is ethanol. Data is expressed as percentage of cells 
positive for pHrodo phagocytosis (Fig 5.2.6), or the MFI of the positive cells (Fig 5.2.7). 
Compared to vehicle controls, treatment of macrophages with ixabepilone or mycothiazole 
at either dose, did not significantly affect the phagocytic ability. While with mycothiazole 
treatment a low dose DMSO control was not included, the high dose DMSO treatment had 
no effect on phagocytic ability and so we assume that the low dose vehicle would not affect 
phagocytosis and the results would be similar to phagocytic levels seen in high dose DMSO 
treated cells (Fig 5.2.6 and 5.2.7). Treatment with the positive control Latrunculin A 
significantly inhibited phagocytosis. 
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Figure 5.2.6 
            
Figure 5.2.6 Phagocytosis of pHrodo in the presence of (A) ixabepilone and (B) 
mycothiazole. Cells were pre-treated with 100 U/ml IFN-γ overnight, followed by an MSD 
or equal concentration of ethanol or DMSO (vehicle) pre-treatment for 45 minutes and 
incubation with pHrodo as described in methods. pHrodo uptake is expressed as the percent 
of cells positive for pHrodo uptake. Compared to vehicle controls, except for Latrunculin 
A, there is no significant inhibition of phagocytosis in (A) ixabepilone or (B) mycothiazole 
treated macrophages. Bars represent mean ± SEM from one experiment. (A) Gray bars  
represent 0.1 μM (low dose) ixabepilone/ethanol control; black bars  represent 1 μM 
(high dose) ixabepilone/ethanol control. (B) Bars represent 0.1 μM (low dose)  and 1 
μM (high dose)  mycothiazole treatment and its DMSO vehicle control  . Lat A: 
latrunculin A. ***p<0.001 Latrunculin A vs vehicle control, one-way ANOVA with 
Bonferroni correction. 
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Figure 5.2.7 
               
Figure 5.2.7 Changes in fluorescence intensity of cells positive for pHrodo uptake in 
the presence of (A) ixabepilone and (B) mycothiazole. Compared to vehicle controls, 
there is no significant change in the fluorescence intensity of any of the treated 
macrophages. pHrodo uptake is expressed as mean fluorescence intensity ± SEM of the 
cells positive for pHrodo uptake. (A) Gray bars  represent 0.1 μM (low dose) 
ixabepilone/ethanol control; black bars  represent 1 μM (high dose) ixabepilone/ethanol 
control. (B) Bars represent 0.1 μM (low dose)  and 1 μM (high dose)  mycothiazole 
treatment and its DMSO vehicle control  . Lat A: latrunculin A. Data is representative 
of 1 experiment. p>0.05, one-way ANOVA with Bonferroni correction. 
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5.2.3 Discussion 
This set of experiments was aimed at investigating the effects of MSD treatment on 
macrophage phagocytic ability. We hypothesized that treatment with MSD would lead to 
an inhibition of macrophage phagocytic ability. In comparison to vehicle treated cells, we 
found that treating macrophages with paclitaxel, docetaxel or peloruside A did not 
significantly affect the phagocytic ability. There was no enhancement or impairment to 
phagocytosis of pHrodo. With low dose zampanolide treated cells however, there was a 
non-significant decrease in phagocytosis of pHrodo. High dose zampanolide treated cells 
showed a significant impairment to phagocytosis via a decrease in pHrodo uptake. 
Latrunculin A is an actin destabilizer and a known phagocytic inhibitor (Oliveira et al., 
1996) and as expected, we saw significant impairment to phagocytic processes in 
Latrunculin A treated cells. 
It was interesting to find that zampanolide treated cells had impaired phagocytosis. 
Zampanolide is a potent MSD (Field et al., 2009; Miller et al., 2010), however the other 
MSDs used in this study did not show any decrease in phagocytic ability. A possible 
explanation for this could be related to the fact that zampanolide is active in cells resistant 
to paclitaxel (Field et al., 2009). The IC50 data presented in chapter 3, illustrates that 
RAW264.7 cells are relatively resistant to paclitaxel. It is possible that RAW264.7 cells are 
extremely susceptible to zampanolide. Additionally, in context of MSD dosage, doses of 
0.1 μM and 1 μM are relatively high. The combination of drug susceptibility and high doses 
could have potentially caused the significant decrease in phagocytosis. It would be 
interesting to look at the potency of zampanolide in RAW264.7 cells and understand its 
cytotoxic effects in this cell line. 
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While it is known that zampanolide binds to tubulin, the binding site is unknown 
(Miller et al., 2010) and zampanolide could potentially also have additional activity on 
actin. Zampanolide has been isolated by two separate groups, from a collection of sponges 
that had previously generated a number of bioactive compounds, including laulimalide and 
Latrunculin A (Tanaka et al., 1996; Miller et al., 2010). Zampanolide treated macrophages 
showed a decrease in phagocytic ability similar to that seen with Latrunculin A treated 
macrophages, suggesting that there may be effects on microtubules as well as on the actin 
cytoskeleton. The fact that phagocytosis is initially dependent on actin (Aderem et al., 
1999; Underhill et al., 2002) also adds to the possibility that zampanolide has some actin 
related effects.  
We found no impairment to phagocytic activity in macrophages treated with 
ixabepilone or mycothiazole as compared to the vehicle controls. Ixabepilone is a MSD 
with activity similar to that of paclitaxel (Bollag et al., 1995) and so it is not surprising that 
treatment with ixabepilone did not inhibit macrophage phagocytosis. Mycothiazole’s 
activity is still unknown and this compound has not been classified as yet (Miller et al., 
2010). However, the pattern of un-altered phagocytosis in mycothiazole treated 
macrophages suggests that mycothiazole may have a microtubule stabilizing activity 
similar to that of the other MSDs tested.  
When looking at pHrodo phagocytosis, we measured the percent of cells positive for 
pHrodo uptake, but we also measured the mean fluorescence intensity (MFI) for these 
percent positive cells. At this point, if the CFSE cells alone were autofluorescent or had 
high levels of fluorescence, this was subtracted from MFI of pHrodo and macrophages 
together to remove the effect of baseline fluorescence. The MFI value usually relates 
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intensity of fluorescence to the amount of ligand or fluorescent particles taken up. 
Therefore a high MFI indicates high amount phagocytosis for those cells. However with the 
use of pHrodo care needs to be taken when interpreting the MFI data. Since pHrodo is pH 
sensitive, as pH drops the intensity of fluorescence increases dramatically. Phagosomes 
have a lower pH compared to the cell cytoplasm resulting in fluorescence of pHrodo. 
However, when phagosomes fuse with the lysozomes, there is a further drop in pH due to 
presence of hydrolytic enzymes (Luzio et al., 2007) and this can cause an increase in 
fluorescence intensity. Thus with pHrodo phagocytosis an increase in fluorescence intensity 
does not necessarily relate to an increase in uptake, but could indicate a greater number of 
phagosomes fusing with lysozomes. 
The MFI values of macrophages treated with paclitaxel, docetaxel, peloruside A and 
vehicle control were all similar, indicating that pHrodo uptake and fluorescence was 
similar. In contrast, the MFI of zampanolide treated macrophages was significantly lower, 
which supports the result of less pHrodo uptake due to impaired phagocytosis. The MFI 
results of Latrunculin A treated cells showed that even though percent of cells positive for 
pHrodo uptake was extremely low, the MFI was still high, in relation the the amount of 
pHrodo phagocytosed. This indicates that there was probably a degree of pHrodo uptake 
and those particles fluoresced especially brightly. The MFI results of mycothiazole treated 
cells are similar to the vehicle control and along with the percent positive cells indicate that 
uptake was not impaired. The high dose ixabepilone treated macrophages had high percent 
positive cells, but low MFI indicating that per each cell, fluorescence of pHrodo was lower. 
This could possibly indicate an inability to fuse with lysozomes or inhibition in lysosomal 
trafficking, however a similar result was seen with the high dose ethanol vehicle control, 
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where positive cells were high, but MFI level was low. Taken together, it is unlikely that 
ixabepilone treated macrophages have impaired lysozomal fusion or trafficking. Tracking 
of the pHrodo particles once phagocytosed would be worth studying to understand if 
trafficking to the lysozome is affected. Studies found that phagolysosome formation in 
colchicine treated macrophages was not impaired (Pesanti et al., 1975), which is interesting 
since colchicine is an MDD that disrupts microtubule stability. This suggests that 
microtubules are not required for trafficking of lysozomes during phagolysosomal fusion 
and that this process occurs in a microtubule independent fashion. It would be interesting to 
look at phagolysosome formation in presence of MSD treatment, which would help to 
understand if later events such as stimulation of the adaptive immune response, are affected 
by MSD treatment. 
 
Overall we found that treating macrophages with paclitaxel, docetaxel and peloruside 
A did not impair phagocytosis. We did not find any enhancement to phagocytic ability in 
these MSD treated macrophages either, indicating that the LPS mimicry and 
immunostimulatory effects of paclitaxel does not lead to an increase in phagocytic 
efficiency. With the novel MSD zampanolide, we saw a significant decrease in phagocytic 
ability at high doses, while there was a trend of impaired phagocytosis at the lower dose of 
zampanolide. Mycothiazole did not impair phagocytosis, suggesting that mycothiazole 
could possibly bind and stabilize microtubules similar to paclitaxel and the other MSD. 
Ixabepilone results were similar to results from the other MSDs and indicated that MSD 
treatment does not affect phagocytosis of bacteria. While this indicates that the uptake of 
bacteria is not impaired in the presence of MSD therapy, the processing of bacterial 
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components and antigen presentation to activate the adaptive immune system, both of 
which require functional microtubules (Peachman et al., 2004), could potentially be 
impaired resulting in an inability to respond to infections.  
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5.3 Interactions between MSD and INF-γ during pHrodo phagocytosis. 
5.3.1 Introduction 
IFN-γ is an important cytokine that stimulates macrophages to produce antimicrobial 
and antitumor mechanisms as well as causing an up-regulation of antigen presentation and 
processing pathways via induction of MHC pathways (Young et al., 1995; Schroder et al., 
2006). IFN-γ stimulus also results in the up-regulation of FcRγ, complement proteins that 
aid in opsonization of pathogens, and complement receptors such as Mac-1 that enable 
responses to microbial and intracellular pathogens (Schroder et al., 2004). IFN-γ is also 
known to synergize with LPS and promote production of nitric oxide (NO) (Young et al., 
1995). LPS stimulation in macrophages induces secretion of IL-12 and chemokines which 
attract natural killer cells (NKC) to the site of inflammation, where IL-12 induces 
production of IFN-γ in the NKCs. Further to this, IFN-γ and IL-12 coordinate the link 
between pathogen recognition by the innate immune system, and induction of specific 
adaptive immune responses by promoting Th1 responses (Schroder et al., 2004). Based on 
the above details, when setting up phagocytosis assays, we primed macrophages overnight 
with 100 U/ml IFN-γ to enhance phagocytic responses. 
However, a recent study has found that priming macrophages with IFN-γ led to 
protection from colchicine inhibition of phagocytosis (Khandani et al., 2007). The 
researchers found that resistance to microtubule de-stabilizers was related to IFN-γ 
activation of macrophages, which increased microtubule stability and caused activated 
macrophages to exhibit a high proportion of drug resistant microtubules. Another study also 
reported microtubule stabilization due to activation of macrophages with IFN-γ and LPS 
stimulation (Binker et al., 2007). Based on this, we decided to investigate the phagocytic 
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efficiency of macrophages treated with MSD in the absence of IFN-γ priming. It was 
possible that the lack of inhibition to phagocytosis seen initially was due to overnight 
priming with IFN-γ, and removal of this activation might result in inhibition of 
phagocytosis by macrophages in the presence of MSD. We did not expect a significant 
decrease in phagocytosis in MSD treated macrophages in the absence of IFN-γ. We 
expected that colchicine treatment would inhibit phagocytosis due to colchicine being a 
microtubule destabilizer.  We studied the effect of IFN-γ activation on MSD treated 
macrophages by carrying out pHrodo phagocytosis in parallel, with macrophages that were 
primed overnight with IFN-γ, as well as macrophages that were left in media alone for the 
same duration, followed by MSD treatment and incubation with pHrodo particles. 
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5.3.2 Results 
Figure 5.3.1 
 
 
Figure 5.3.1 pHrodo phagocytosis by MSD treated macrophages is not affected, by (A) 
presence or (B) absence of IFN-γ pre-treatment. For both graphs, phagocytosis of 
pHrodo by MSD treated macrophages is not inhibited as compared to vehicle controls 
irrespective of IFN-γ treatment. There is a significant inhibition to phagocytosis in 
colchicine treated and latrunculin A treated macrophages as compared to vehicle control, 
however this inhibition is similar in both the absence and presence of IFN-γ. For both 
graphs, gray bars  represent 0.1 μM (low dose) MSD/vehicle control, while black bars 
 represent 1 μM (high dose) MSD/vehicle control. Colchicine was used at 10 μM, 
corresponding to high dose vehicle control. Bars represent mean ± SEM from duplicate 
wells of 1 experiment. ***p<0.001 colchicine vs vehicle control, ***p<0.001 Latrunculin 
A vs vehicle control, one-way ANOVA with Bonferroni post test.  
A 
B 
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5.3.3 Discussion 
Macrophages pre-treated with IFN-γ are activated to respond optimally to bacterial 
and LPS challenge (Bach et al., 1997; Boehm et al., 1997). However, it was thought that 
this optimal response due to IFN-γ pre-treatment might be masking possible phagocytic 
inhibition due to MSD treatment. Based on this, we were interested in comparing the 
effects of MSD on macrophage phagocytosis in the presence and absence of IFN-γ. Since 
we were also interested in studying NO and TNF-α production in MSD treated 
macrophages during phagocytosis, it was important to understand the possible effects of 
IFN-γ pre-treatment as IFN-γ has important roles in stimulating production of pro-
inflammatory cytokines IL-12 and TNF-α, as well production of NO (Boehm et al., 1997). 
We found no difference in the phagocytic abilities of MSD treated macrophages 
irrespective of IFN-γ pre-treatment. Macrophages that were not activated were able to 
respond to bacterial challenge similarly to activated macrophages. In contrast to the study 
carried out by Khandani, A. et al. 2007., we found no difference to the ability of colchicine 
treated macrophages to phagocytose bacteria in the absence or presence of IFN-γ pre-
treatment. The researchers found that IFN-γ pre-treatment caused colchicine treated 
macrophages to phagocytose bacteria similarly to un-treated macrophages, whereas non-
activated macrophages, in the presence of colchicine displayed impaired phagocytosis. 
Reasons that could explain why our results did not show a difference with colchicine 
and IFN-γ as compared to colchicine alone could be related to differences in experimental 
set up. We used 100 U/ml of IFN-γ as compared to 500 U/ml used in the paper, also the 
incubation time for phagocytosis was longer in our studies (60 minutes) as opposed to 30 
minutes. The higher dose of IFN-γ could have increased stability of microtubules and 
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created a greater population of drug-resistant microtubules, while the 100 U/ml dose used 
by us might not have been sufficient to cause the same degree of stability. The stable 
microtubules and increased uptake could have led to colchicine treatment having no 
inhibitory effect in the presence of IFN-γ. Another consideration is the particle used for 
testing phagocytic uptake. The presence of live bacteria as compared to polystyrene beads 
or IgG opsonised sheep red blood cells (SRBC) used in the Khandani, A. et al., study 
would also have caused different immune responses and activation of different signalling 
pathways due to differences in size of particles, and receptors involved in uptake (Koval et 
al., 1998). This could have also caused differences in the ability of macrophages to 
phagocytose targets. However, both our study and the Khandani, A. et al., 2007 study were 
carried out for different purposes and the methods were selected to suit different aims, 
therefore direct comparisons of our differing results is not advisable.    
Early electron micrographs have shown the presence of microtubules in regions of 
actin accumulation around large beads (Reaven et al., 1973), however, there was no 
specific role for microtubules noted. A later study comparing C3bi mediated and FcR 
mediated phagocytosis, showed the requirement of microtubules for complement mediated 
phagocytosis only (Allen et al., 1996), while a contrasting study showed the need for 
microtubules in FcR mediated phagocytosis (Khandani et al., 2007). Paclitaxel treatment 
was also seen to affect the efficiency of complement mediated phagocytosis while FcR 
mediated phagocytosis was less affected (Lewkowicz et al., 2008) Our study looked at 
bacterial phagocytosis which can occur via FcR if bacteria are coated with antibodies or via 
complement receptors if bacteria are opsonized with serum protein (Allen et al., 1996). The 
lack of phagocytic inhibition we saw in our studies in the presence of MSD, both with and 
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without IFN-γ could be due to the two phagocytic pathways, the complement and the FcR 
pathway, working together to compensate for any inhibition. It is possible that MSD 
treatment affected complement pathways to a greater degree; however this may have been 
masked by the efficiency of the FcR pathway or vice versa. Since paclitaxel and peloruside 
A have immunomodulatory and immunostimulatory properties (Chan et al., 2000; Crume et 
al., 2007) it could also have been possible that in the absence of IFN-γ these drugs may 
have acted as immune stimulators causing phagocytic activity to be maintained. Paclitaxel 
mimics LPS, which would have increased the stimulation presented to macrophages to 
respond to the bacterial challenge. Using cells that constitutively express GFP-labelled 
tubulin and with the help of confocal techniques, investigating the uptake of pHrodo 
labelled bacteria in the presence of MSD treatment would be an interesting study. This 
would allow simultaneous study of the effects of MSD on microtubules and the role of 
stabilized microtubules in phagocytosis. 
 
Overall we found that absence of IFN-γ pre-treatment did not affect phagocytic 
ability in the presence of MSD treatment. We also found that colchicine treated 
macrophages exhibited an inhibition in phagocytosis, irrespective of absence or presence of 
IFN-γ pre-treatment. It would be worth investigating the amount of acetylated α-tubulin in 
microtubules during bacterial phagocytosis in MSD and colchicine treated RAW264.7 cells 
in the presence and absence of IFN-γ at differing doses. Levels of acetylated α-tubulin 
indicate level of stabilized microtubules (Schulze et al., 1987), which would allow 
understanding if the different components such as LPS and IFN-γ have roles in stabilizing 
microtubules and if this stability is maintained in the presence of colchicine.   
Chapter 5: Bacterial phagocytosis by  
MSD treated RAW264.7 macrophages. 
 
113 
5.4 Use of confocal microscopy to visualize pHrodo phagocytosis 
5.4.1 Introduction 
While flow cytometry allows multiparametric analysis of thousands of cells per 
minute, resulting in extremely quantitative data, these events cannot be visualized at the 
cellular level. Confocal microscopy allows live cell imaging to enable visualization of 
phagocytosis over time. We were able to use the confocal microscope to visualize 
phagocytosis of pHrodo in RAW264.7 cells, thus complementing our flow cytometry data. 
Phagocytosis was visualized in untreated RAW264.7 cells as well as with paclitaxel, 
Latrunculin A and Colchicine treated RAW264.7 cells. Experiments were set up as 
described in section 2. Briefly, cells were not stained or IFN-γ stimulated. Pre-treatment of 
cells with the respective drug or vehicle was carried out for 45 minutes following addition 
of pHrodo. Images were taken 30 minutes after addition of pHrodo and thereafter data was 
collected every 30 minutes over 4 to 5 hours. We used differential interference contrast 
(DIC) and red fluorescent channels to collect data, as phase contrast enabled clear 
visualization of the cell outlines. Additionally, untreated macrophages were stained with 
blue fluorescent Hoechst 33342 and CFSE or Hoechst alone and incubated with pHrodo to 
visualize phagocytosis.  
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5.4.2 Results 
Figure 5.4.1 
      
      
 
   
Figure 5.4.1 pHrodo particles fluoresce only when phagocytosed. Untreated RAW264.7 
cells incubated with pHrodo particles. Each image is one plane from an XYZ-axis image 
through a field of view. Internalized pHrodo displays bright red fluorescence while 
particles outside the cells are non fluorescent ( ). Representative DIC images with 
fluorescence overlay. Images collected 8.5 (A, B, C) and 5 hours (D) after addition of 
pHrodo to the cells. Scale bars represent 10 μm, (A, B); 20 µm (C); and 30 µm (D).  
  
A B 
C D 
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Figure 5.4.2 A 
 
 
 
Figure 5.4.2 B 
     
Figure 5.4.2 Phagocytosed pHrodo has a higher intensity of fluorescence as compared 
to external pHrodo. (A) A series of XYZ-axis images through a field of view, show 
untreated cells with internalized pHrodo fluorescing brightly, while extra cellular pHrodo is 
non-fluorescent ( ) The images show consecutive planes through one field of view, 
moving up through the cell. Representative DIC images with fluorescence overlay. Scale 
bars, 5 µm. (B) A macrophage DIC image with fluorescence intensity overlay. The red 
fluorescent channel is altered to show intensity. Regions of high intensity are bright blue to 
red and regions of low intensity are dark blue (white arrows) as seen with the intensity scale 
bar. Scale bars, 10 µm. All images collected 8.5 hours after addition of pHrodo to the cells.   
A B C 
D E F 
Chapter 5: Bacterial phagocytosis by  
MSD treated RAW264.7 macrophages. 
 
116 
Figure 5.4.3 
   
   
 
   
 
Figure 5.4.3 Series of images showing pHrodo phagocytosis in CFSE and Hoechst 
stained RAW264.7 cells. (a-f) CFSE and Hoechst stained cells phagocytose pHrodo. (b) 
Arrows indicate extracellular pHrodo that has adhered to cells, but is non-fluorescent. (e, f) 
arrows indicate Hoechst stained nuclear material of extracellular pHrodo. (g-h) Hoechst 
stained cells with phagocytosed pHrodo, extracellular pHrodo is non-fluorescent. Images 
are one plane from an XYZ-axis image or stacked image of all planes through a field of 
view. All images were taken 8.5 hours after addition of pHrodo. (a-f) Representative CFSE 
images with pHrodo and Hoechst overlay (g, h) Representative DIC images with pHrodo 
and Hoechst overlay. Scale bars represent 10 μm (a – g), and 20 µm (h). 
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Figure 5.4.4 
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Figure 5.4.4 Unstained cells (A, B) phagocytose more pHrodo as compared to Hoechst 
(C, D) and CFSE (E, F) stained cells. All images are taken 105 minutes after addition of 
pHrodo, and unstained cells (A, B) have phagocytosed higher amounts of pHrodo as 
compared to CFSE (E, F) or Hoechst (C, D) stained cells. Additionally, unstained cells 
have greater levels of pHrodo per cell as compared to CFSE and Hoechst stained cells. 
Each image is one plane from an XYZ-axis image through a field of view. Representative 
DIC images with fluorescence overlay, (A, B). Representative DIC images with pHrodo 
and Hoechst overlay, (C, D). Representative DIC images with pHrodo and CFSE overlay, 
(E, F). Scale bars represent 30 μm (A, B, C, F), and 20 µm (D, E). All images were 
analyzed as described in the confocal microscopy analysis: Section 2.12.3 
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Figure 5.4.5 
 
 
 
 
Figure 5.4.5 Time-lapse images showing internalization and acidification of pHrodo 
during phagocytosis by RAW264.7 cells. Images show increasing pHrodo fluorescence 
over time as internalization increases. All images are one plane from an XYZ-axis image 
through a randomly selected field of view. Images were taken every 30 minutes for 4.5 
hours after addition of pHrodo particles to untreated RAW264.7 cells. Representative DIC 
images with fluorescence overlay. Scale bars represent 20 μm. 
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 Figure 5.4.6  
 
Figure 5.4.6 Phagocytosis of 
pHrodo accompanied with 
increase in fluorescence over 
time in (a) untreated and (b) 
paclitaxel treated cells, while (c) 
colchicine and (d) latrunculin A 
treated cells show reduced or no 
phagocytosis respectively. Each 
image is one plane through a field 
of view, representative of all 
images at that time point. Time 
lapse images taken over 4 hours 
and show level of phagocytosis at 
30 minutes and 240 minutes. (Not 
all images are shown; see 
appendix C for all images). 
Representative DIC images with 
fluorescence overlay. Scale bars 
for each image represent 30 μm.  
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Figure 5.4.7 
 
Figure 5.4.7 Vehicle treated macrophages phagocytose pHrodo similarly to untreated 
macrophages. RAW264.7 cells were left untreated or treated with ethanol as a vehicle 
control. pHrodo phagocytosis was measured at 75, 195 and 285 minutes after vehicle 
treatment. Phagocytosis levels between untreated and ethanol treated macrophages are 
highly comparable. p>0.05, two-way ANOVA with Bonferroni post test.  
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Figure 5.4.8 
 
Figure 5.4.8 Colchicine and Latrunculin A treated cells show a significant decrease in 
phagocytic ability, while paclitaxel treated cells show altered phagocytosis patterns. 
RAW264.7 cells were left untreated or pre-treated for 45 minutes with 1 µM paclitaxel, 1 
µM latrunculin A or 10 µM colchicine. Phagocytosis was measured at 30 minute intervals 
after pHrodo addition. As compared to untreated macrophages, latrunculin A and 
colchicine treated macrophages show a highly significant decrease in phagocytic ability. 
While paclitaxel treated macrophages phagocytose pHrodo to similar levels as untreated 
macrophages, there are significant differences in how fast the phagocytosis occurs. The 
time taken for phagocytosis to peak before decreasing also differs for untreated and 
paclitaxel treated macrophages. ***p>0.001 latrunculin A treated vs untreated, ***p<0.001 
colchicine treated vs untreated, **p<0.01 paclitaxel vs untreated, two-way ANOVA with 
Bonferroni post test.  
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Figure 5.4.9 
 
Figure 5.4.9 Colchicine and Latrunculin A treated cells show a significant decrease in 
phagocytic ability, while paclitaxel treated cells show alterations in initial phagocytic 
patterns. RAW264.7 cells were left untreated or pre-treated for 45 minutes with 1 µM 
paclitaxel, 1 µM latrunculin A, 10 µM colchicine or equivalent concentration of ethanol as 
vehicle control. Phagocytosis was measured at 30 minute intervals after pHrodo addition. 
As compared to vehicle treated macrophages, latrunculin A and colchicine treated 
macrophages show a significant decrease in phagocytic ability. While paclitaxel treated 
macrophages phagocytose pHrodo to similar levels as untreated and vehicle treated 
macrophages, there is a significant difference in how fast the phagocytosis occurs. 
***p>0.001 latrunculin A treated vs vehicle control, ***p<0.001 colchicine treated vs 
vehicle control, **p<0.01 paclitaxel vs vehicle control, two-way ANOVA with Bonferroni 
post test.  
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5.4.3 Discussion 
Using the confocal microscope to visualize cells was extremely beneficial. Firstly, it 
enabled us to ensure that the pHrodo dye was working according to manufacturer’s 
specifications, and that we were observing phagocytic events accurately. It allowed 
excellent visual confirmation that fluorescence was only with internalized pHrodo particles. 
The use of confocal imaging provided us with a different approach via which we could 
confirm results from flow cytometry, thus validating both our techniques as the results 
obtained from these techniques were comparable. 
When initially optimizing imaging procedures, similarly as with flow cytometry 
assays, we stained cells with CFSE before addition of pHrodo. However, we found that 
cells labelled with CFSE alone, Hoechst alone or Hoechst and CFSE together took longer 
to phagocytose pHrodo as compared to unstained cells. In addition, these stained cells also 
took up lower concentrations of pHrodo as compared to unstained cells. It is known that 
CFSE at high concentrations is toxic to cells (Parish et al., 2001). The staining protocol 
used for confocal microscopy experiments was consistent with flow cytometry staining 
protocols as described in section 2. However, one factor that could have contributed 
towards the CFSE toxicity seen in confocal experiments was the day on which the cells 
were stained. With confocal assays, the cells were seeded at low concentrations and 
allowed to proliferate, and CFSE staining was carried out on adherent cells on the day of 
the experiment. This meant that dye quenching and washing steps were carried out to 
prevent cells from detaching. In contrast, with the flow cytometry assays, the cells were 
stained while in suspension and washed at least 3 times before being allowed to adhere 
overnight. This was followed by replacing old media with new media on the day of the 
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experiment. The insufficient washing of adherent cells and the fact that staining was carried 
out on the experimental day could have increased dye concentrations and caused toxicity to 
the cells, with the result that pHrodo phagocytosis was slower. However staining cells 
before seeding was not suitable as CFSE dye is used to measure proliferation and gets 
divided in daughter cells, which means that our staining would have not been uniform 
across the cell monolayers. We did however notice that CFSE stained cells, if incubated 
with pHrodo overnight, were able to phagocytose pHrodo similarly to overnight incubated 
unstained cells. This indicated that phagocytosis was not impaired but took longer due to 
the presence of dye. An improvement to the protocol used, would be to seed cells and allow 
monolayer proliferation at least 3 days in advance, followed by cell staining on the day 
previous to the experimental day to allow sufficient dye efflux.    
Nevertheless, the use of unstained cells was sufficient for our aims. Analysis of the 
confocal assay data indicates that phagocytosis increases until 175 to 200 minutes. With 
flow cytometry assays we collected data after a 120 minute incubation, and found no 
inhibition to phagocytosis in the presence of paclitaxel. However, with increasing time, 
paclitaxel treated macrophages have phagocytic levels comparable to those of untreated or 
vehicle treated macrophages. This suggests that our flow cytometry data is reliable and the 
time frames chosen were sufficient.  
 
Since phagocytosis in vehicle treated and untreated macrophages are extremely 
comparable, it was possible to compare phagocytosis in drug treated macrophages to 
untreated and vehicle treated macrophages separately (Fig 5.4.5 and Fig 5.4.6). It was 
necessary to collect data from all treatments on the same day to be able to compare results, 
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therefore data was collected every 30 minutes for 4 hours in untreated and drug treated 
macrophages, however with the vehicle treated cells, data was collected at 75, 195 and 285 
minutes after vehicle treatment. Due to this, when analyzing data, comparisons made to 
vehicle treated cells are made at the 75, 195 and 285 minute time point, but when 
comparing data to untreated cells, all time points over the collection period are analyzed. 
Comparison of phagocytosis over short time frames for paclitaxel and untreated 
macrophages shows interesting results. The data suggest that overall phagocytosis is not 
impaired in paclitaxel treated macrophages, however, the kinetics of uptake may be 
different. From figure 5.4.5, we see that initial rate of phagocytosis is faster in paclitaxel 
treated macrophages. It is also interesting that as compared to paclitaxel treated 
macrophages, untreated macrophages reach their peak phagocytic capacity earlier and then 
decline phagocytosis to maintain a steady rate of uptake. In contrast, in the paclitaxel 
treated macrophages the phagocytic peak occurs later but amounts of pHrodo phagocytosed 
are comparable to untreated macrophages. This difference in kinetics could be due to the 
stabilizing effect of paclitaxel on microtubules, as well as its LPS-mimicry which could be 
providing additional stimulation to macrophages. The trafficking of vesicles via motor 
proteins on stabilized microtubules is still possible (Mizuno et al., 1994; Apodaca, 2001), 
indicating that phagocytosis might be unaffected if populations of microtubules are 
stabilized. 
Another explanation could be related to paclitaxel’s LPS mimicry. In the presence of 
paclitaxel, there would be additional stimulation of macrophages to respond to LPS and this 
could explain the initial increase in rate of phagocytosis. Furthermore, LPS interacts with 
microtubules causing their stabilization (Ding et al., 1992; Allen et al., 1997b). LPS 
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stimulation also causes changes in microtubule composition (Allen et al., 1997a). 
Phagosome maturation occurs along the endocytic pathway (Harrison et al., 2002) and 
movement of the phagosome is microtubule dependent. It has been suggested that 
attachment of phagosomes to microtubules occurs via MAPs (Blocker et al., 1996). The 
fact that LPS can alter microtubule stability and composition could lead to increased 
phagosome binding and these factors combined with paclitaxel stimulation could explain 
lack of inhibition to phagocytosis in the presence of paclitaxel as well as the initial increase 
in phagocytic rate in paclitaxel treated macrophages. 
When compared to vehicle treated cells, the difference in rate of phagocytosis in 
paclitaxel treated cells is not as evident due to the longer time intervals during imaging. 
However, the data shows an initial increase in phagocytosis in paclitaxel treated 
macrophages, similar to the increase seen when comparing paclitaxel treated macrophages 
to untreated macrophages. Imaging with longer intervals leads to masking of the phagocytic 
saturation time points, suggesting that overall, phagocytosis is not affected with  paclitaxel, 
or vehicle treatment, but the efficiency and kinetics differ in paclitaxel treated 
macrophages. 
Colchicine treated macrophages displayed impaired phagocytosis. While these cells 
did phagocytose pHrodo, the rate of phagocytosis was significantly slower and significantly 
lower amounts of pHrodo were phagocytosed. This was similar to results seen with flow 
cytometry. The data suggest that phagocytosis is significantly impaired in the presence of 
microtubule destabilizers, such as colchicine, as compared to little or no inhibition in the 
presence of microtubule stabilizers. This once more endorses the fact that the presence of 
stable microtubules is not as detrimental to macrophage function as the presence of 
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destabilized microtubules. Latrunculin A treatement completely blocked phagocytosis as 
expected (Oliveira et al., 1996) and affirms the greater need for actin during initial 
phagocytosis.  
Data from these assays support the use of pHrodo labelled E.coli in allowing study of 
phagocytic mechanisms where intracellular and extracellular events needed to be defined. 
We found that the results from confocal studies backed up the results from the flow 
cytometry studies and in addition allowed visualization of phagocytosis. It would be 
interesting to study the kinetics of phagocytosis as MSD could affect the rate at which 
phagocytosis occurs. Furthermore, visualizing phagocytosis in peloruside treated 
macrophages similarly as with colchicine and paclitaxel treated macrophages would also be 
extremely beneficial to understanding any differences in phagocytic efficiency. These 
experiments also support the fact that studying phagocytosis for longer time points is more 
informative. Phagocytosis occurs within two hours, as seen from flow cytometry data, 
however studying the rate of phagocytosis and time course over which MSD treated 
macrophages maintain the rate of phagocytosis would also be useful.   
 
Our results taken together suggest that at the tested doses, treatment with paclitaxel, 
docetaxel and peloruside A does not inhibit bacterial phagocytosis. However, zampanolide 
treatment significantly affects phagocytosis at the doses tested. We also found that 
mycothiazole and ixabepilone do not significantly inhibit bacteria phagocytosis. It is 
possible that if drug treatments were carried out for longer time periods that we would see 
an inhibition of phagocytosis, with the other tested MSD, however the methods we used 
were comparable to previous studies. This allows us to draw reasonable conclusions 
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regarding phagocytosis ability and the effects of MSD treatment. We also found that IFN-γ 
activation had no effect on enhancing or inhibiting phagocytosis in the presence of MSD or 
colchicine treatment.  
Chapter 6: Bacterial killing by  
MSD treated RAW264.7 macrophages. 
 
130 
CHAPTER 6: BACTERIAL KILLING BY MSD TREATED RAW264.7 MACROPHAGES 
6.1 Introduction 
Macrophage phagocytosis involves binding, ingestion and killing of the pathogen. As 
discussed in previous sections, while the initial phagocytic events are actin dependent, 
(Aderem et al., 1999; Al-Haddad et al., 2001; Underhill et al., 2002) evidence suggests that 
the latter phagocytic events, such as transport from the cell periphery towards the nuclear 
region, are microtubule dependent (Toyohara et al., 1989; Desjardins et al., 1994b; Blocker 
et al., 1996) Studies have also shown that newly formed phagosomes require dynamic 
microtubules for slow movements and that bi-directional movement of phagosomes along 
the microtubules requires the microtubule molecular motors kinesin and dynein (Blocker et 
al., 1997; Blocker et al., 1998). 
We had studied the effect of MSD on initial phagocytic events, but since later 
phagocytic events are more microtubule dependent, we decided to investigate the effect of 
MSD on macrophage killing ability. In particular, we looked at the ability of MSD treated 
macrophages to exert bactericidal effects. Since it is known that paclitaxel exhibits LPS 
mimicry (Ding et al., 1990b; Bogdan et al., 1992) it was thought that paclitaxel treated 
macrophages may exhibit increases in bacterial killing by increasing macrophage 
stimulation. Additionally, to date there are no studies that have looked at the effects of 
docetaxel or peloruside A on macrophage killing, making this study interesting in terms of 
development of these drugs for clinical use. Treatment with MSD could also alter 
phagosome trafficking and thus alter cytokine secretion since phagosomes play a role in 
secretion of cytokines (Murray et al., 2005). 
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Macrophage bactericidal activity in the presence of MSD was studied using a 
gentamicin survival assay as described in the methods. In brief, this assay works on the 
principle of antibiotic susceptibility of extracellular bacteria, while intracellular bacteria are 
protected from the antibiotic (Fig 6.1.1) (Vaudaux et al., 1979; Elsinghorst, 1994; Laroux 
et al., 2005). To carry out these assays macrophages were incubated with bacteria for 
phagocytosis to occur; following which 100 µg/ml gentamicin was used to kill extracellular 
bacteria. Cells were then washed in PBS and lysed with Triton X-100 to recover 
intracellular bacteria. We also included control wells, where cells were incubated with 
bacteria, but not treated with gentamicin. Instead, after the incubation for phagocytosis 
these cells were immediately lysed with Triton X-100 to recover intracellular and 
extracellular bacteria. All the samples were then diluted onto Luria Bertoni (LB) agar plates 
to allow overnight colony growth, after which colony forming units (CFU) were counted.  
The control wells enabled us to have an idea of the total bacterial counts as compared with 
gentamicin treated samples that showed only internalized bacteria. The CFU counted were 
bacteria that were phagocytosed and survived inside the macrophages. In addition, there 
were cells without MSD treatment that were incubated with bacteria. These macrophages 
were gentamicin treated and lysed similarly to other samples to give CFU counts. Thus 
comparing the non drug treated CFU counts to MSD treated CFU counts enabled us to 
assess macrophage bactericidal ability as high CFU counts equate to impaired killing, while 
low CFU counts equate to enhanced killing. 
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Figure 6.1.1  
 
 
Figure 6.1.1 Plating of bacteria after gentamicin treatment enables determination of 
macrophage bactericidal activity. 1 hour infection of macrophages allows phagocytosis 
to occur. Treatment with 100 µg/ml gentamicin kills extracellular bacteria, but intracellular 
bacteria are protected. Lysed macrophages are plated on LB agar before internal killing 
occurs. Comparison of bacterial CFU in MSD treated or untreated macrophages enables 
determination of enhanced or impaired bactericidal activity. 
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6.2 Results 
6.2.1 Phagocytosis of E.coli in RAW264.7 macrophages. 
Initially we tested the uptake of differing concentrations of E.coli with untreated 
RAW264.7 macrophages to ensure assays were carried out at the optimal time-frame and 
bacterial concentration required for phagocytosis to occur. Bacterial infections are normally 
set up using bacteria: macrophage infection ratio called the multiplicity of infection (MOI) 
(O'Riordan et al., 2002; Sukumaran et al., 2003). Since these studies have reported using 
MOI values from 0.1:1 up to 150:1, we optimized bacterial MOI for phagocytosis (Fig 
6.2.1). We tested bacterial phagocytosis in RAW264.7 macrophages as well as in J774.2 
murine macrophages to compare internalization efficiency in both these cell lines (Fig 
6.2.2). Internalization of bacteria was confirmed using cytospins (Fig 6.2.3), which were 
stained for visualization via giemsa staining as described in the method section 2.8. We also 
tested if opsonisation of bacteria or IFN-γ pre-treatment of macrophages was required for 
optimal phagocytic efficiency (Fig 6.2.4). 
  
Chapter 6: Bacterial killing by  
MSD treated RAW264.7 macrophages. 
 
134 
Figure 6.2.1 
    
Figure 6.2.1 Phagocytosis of bacteria in RAW264.7 macrophages at varying MOI. 
Cells were seeded at 2x10
6
/ml and infected with bacteria at an MOI of (A) 10:1 bacteria: 
macrophage or (B) 25:1 bacteria: macrophage. There was no significant difference between 
the amount of bacteria internalized at either MOI 10 or MOI 25, when compared to each 
other. There was a significant reduction in bacterial colony forming units/ml (CFU/ml) 
after gentamicin treatment. Bars represent mean survival of bacteria as CFU/ml ± SEM. 
Bacteria alone and macrophage (MO) + bacteria represent total live bacteria, while bacteria 
with macrophages and gentamicin shows internal live bacteria only. Graph is representative 
of at least 3 experiments. *p<0.05, one-way ANOVA with Bonferroni post test. 
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Figure 6.2.2 
     
Figure 6.2.2 Effect of opsonisation on phagocytosis of bacteria at MOI 25:1 in (A) 
J774.2 and (B) RAW264.7 macrophages. Cells were seeded at 2x10
6
/ml and infected 
with bacteria at an MOI of 25:1. There was no significant difference between the levels of 
bacteria internalized either with or without opsonisation in either cell line. There was a 
significant difference in survival of bacteria after gentamicin treatment in both cell lines. 
For both graphs, bars represent mean survival of bacteria as colony forming units/ml 
(CFU/ml) ± SEM. Open bars  represent samples with non-opsonized bacteria, while 
dark bars  represent samples with opsonized bacteria. Bact: bacteria, MO: macrophage, 
Gmycin: gentamicin, Opz: opsonized, N-Opz: non-opsonized. Graph is representative of at 
least 3 experiments. For both graphs: ***p<0.001 MO + non-opsonized bacteria and 
gentamicin vs MO + non-opsonized bacteria, ***p<0.001 MO + opsonized bacteria and 
gentamicin vs MO + opsonized bacteria, ***p<0.001 bacteria + gentamicin vs MO + non-
opsonized bacteria, ***p<0.001 bacteria + gentamicin vs MO opsonized bacteria, one-way 
ANOVA with Bonferroni post test. 
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Figure 6.2.3 
      
       
Figure 6.2.3 Confirmation of E.coli internalization by RAW264.7 and J774.2 
macrophages. Cells were seeded at 2x10
6
/ml and incubated with MOI 25 bacteria for 1 
hour, followed by 2 hours incubation with 100 μg/ml gentamicin. (a, b) RAW264.7 cells 
with internalized bacteria (dark blue rods), shown with arrows.  arrows indicate 
macrophage pseudopodia in the process of internalization of bacteria. (c, d) J774.2 cells 
with internalized bacteria (dark blue rods), shown with arrows. arrows indicate 
macrophage pseudopodia in the process of internalization of bacteria. Cytospin images 
taken under bright field 100X magnification. 
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Figure 6.2.4 
 
Figure 6.2.4 RAW264.7 macrophages phagocytose similar levels of bacteria 
irrespective of IFN-γ pre-treatment or bacterial opsonisation. Cells were pre-treated 
with 100U/ml IFN-γ, seeded and incubated with bacteria as described in methods. There 
was no significant difference in the survival of bacteria either with or without opsonisation 
of bacteria. Macrophage pre-treatment with IFN-γ did not significantly alter survival of 
bacterial. Bars represent mean survival of bacteria as CFU/ml ± SEM. MO: macrophage, 
Gmycin: gentamicin, Opz: opsonized, N-Opz: non-opsonized. Graph is representative of at 
least 3 experiments. p>0.05, one-way ANOVA with Bonferroni post test. 
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6.2.2 Bacterial phagocytosis and killing in MSD treated RAW264.7 macrophages 
Macrophages were seeded and stimulated overnight with 100 U/ml of IFN-γ, as 
described in the methods. Following this, a 45 minute drug treatment was carried out with 
low (0.1 μM) or high (1 μM) doses of MSD or the equivalent vehicle control. Bacteria were 
then added to the cells at MOI of 25:1. Drug concentration was maintained at all times 
following addition of bacteria. Un-treated macrophages infected with bacteria and bacteria 
alone were also included as controls. We treated macrophages with paclitaxel, docetaxel 
and peloruside A (Fig 6.2.5). Additionally we also investigated the effects of zampanolide, 
ixabepilone and mycothiazole (Fig 6.2.6). As with pHrodo studies, we included Latrunculin 
A as a positive control for these experiments. We expected inhibition of phagocytosis in 
macrophages treated with Latrunculin A and therefore no survival of colonies after 
gentamicin treatment. 
Results are expressed as mean survival of bacteria as colony forming units per 
millilitre (CFU/ml). Data from these studies fell into a high CFU/ml (control CFU > 1000 
CFU/ml) or low CFU/ml (control CFU < 1000 CFU/ml) categories, which is noted in figure 
legends. Compared to vehicle controls, treatment of macrophages with paclitaxel, 
peloruside A or docetaxel at high or low doses, did not significantly affect the macrophage 
killing ability when bacterial colony counts were high. However when bacterial counts 
were low, there was a significant difference in the killing ability of low dose paclitaxel 
treated macrophages. Compared to vehicle treated cells, treatment with zampanolide, 
mycothiazole, or ixabepilone did not significantly alter bactericidal activity of 
macrophages.   
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Figure 6.2.5 
 
   
Figure 6.2.5 Bacterial survival in RAW264.7 macrophages treated with high and low 
dose MSD. (A) Bacterial survival was in the high CFU/ml range. Compared to vehicle 
controls, neither paclitaxel, peloruside A nor docetaxel significantly alters the killing ability 
of macrophages. (B) Bacterial survival was in the low CFU/ml range. Compared to vehicle 
controls, only low dose paclitaxel significantly impaired killing ability of macrophages. In 
both experiments, all samples are gentamicin treated. Bars represent mean survival as 
CFU/ml ± SEM. Pale bars  represent 0.1μM (low dose) MSD treatment/vehicle control, 
while black bars  represent 1μM (high dose) MSD treatment/vehicle control. Lat A: 
latrunculin A. Graphs are representative of 1 experiment, each with duplicate wells and 2 
CFU plates per well. *p<0.05 Lat A vs high dose ethanol vehicle control, one-way 
ANOVA with Newman-Keuls post test, ***p<0.001 0.1 µM paclitaxel vs low dose ethanol 
vehicle control, one-way ANOVA with Newman-Keuls post test. 
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Figure 6.2.6 
       
 
Figure 6.2.6 Bacterial survival in RAW264.7 macrophages treated with low and high 
dose MSD.  (A) Bacterial survival was in the low CFU/ml range. Compared to vehicle 
controls, high dose ixabepilone significantly increases bacterial killing, while high dose 
mycothiazole significantly impairs bacterial killing. Latrunculin A (assay positive control) 
inhibits phagocytosis and bacterial survival is significantly impaired. (B) Bacterial survival 
was in the high CFU/ml range. Compared to vehicle control, low dose zampanolide treated 
macrophages significantly impair bacterial killing, while high dose zampanolide treatment 
does not alter killing ability. Latrunculin A significantly impairs bacterial survival as 
phagocytosis is impaired. In both experiments, all samples are gentamicin treated. For both 
graphs, bars represent mean survival as CFU/ml ± SEM. Pale bars  represent 0.1 μM 
(low dose) MSD/vehicle treatment, black bars  represent 1 μM (high dose) 
MSD/vehicle treatment, while crossed bars  represent high dose mycothiazole and 0.1% 
DMSO vehicle control. Lat A: latrunculin A, Zamp: zampanolide, ixabep: ixabepilone, 
mycz: mycathiazole. Graphs are representative of 1 experiment, each with duplicate wells 
and 2 CFU plates per well. (A) **p<0.01 Lat A vs high dose vehicle control, **p<0.01 high 
dose ixabepilone vs high dose vehicle control, one-way ANOVA with Newman-Keuls post 
test. (B) ***p<0.001 low dose zampanolide vs low dose vehicle control, **p<0.01 Lat A vs 
high dose vehicle control, one-way ANOVA with Newman-Keuls post test  
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6.2.3 Effects of IFN-γ pre-treatment on MSD treated RAW264.7 macrophages 
during bacterial killing 
As discussed in section 5.3, IFN-γ plays an important role in activating macrophages 
during bacterial infections. In the presence of IFN-γ macrophages are optimally activated. 
However we were interested in bactericidal ability of MSD treated macrophages and it 
seemed practical to study these effects when activation of macrophages was not optimal 
and the macrophage response to bacteria was solely due to the LPS stimuli. It was thought 
that removal of the optimal conditions might expose effects of MSD on macrophages, and 
that this lack of optimal conditions would also mimic in vivo situations where immune 
systems may be compromised and treatment with MSD was required.  
As a result, we tested the effects of MSD on macrophages killing efficiency in the 
absence of IFN-γ as compared to in the presence of IFN-γ (Fig 6.2.7). It was possible that 
there would be inhibition to killing during MSD treatment due to lack of added stimuli 
from IFN-γ. However it was equally possible that with MSD such as paclitaxel or 
docetaxel, in the absence of IFN-γ, these drugs would compensate for the lack of stimuli 
and maintain bactericidal activity due to their immunomodulatory properties (Chan et al., 
2000; Si et al., 2003). In addition, based on previous studies where treatment with IFN-γ 
has led to resistance towards colchicine effects (Khandani et al., 2007), we tested the 
effects of colchicine treatment on bacterial killing in the presence and absence of IFN-γ.  
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Figure 6.2.7 
           
           
Figure 6.2.7 Effects of IFN-γ pre-treatment on bacterial killing by MSD treated 
RAW264.7 macrophages. Macrophages were either pre-treated overnight with 100 U/ml 
of IFN-γ or the same volume of media alone. The absence or presence of IFN-γ did not 
cause a significant alteration to macrophage killing ability in the presence of (a) paclitaxel, 
(c) docetaxel, or (d) colchicine. In contrast, at high doses of peloruside A and Latrunculin 
A there was a significant increase in bacterial killing as compared to vehicle control 
irrespective of IFN-γ presence. Bars represent mean survival as CFU/ml ± SEM. White 
bars  represent 0.1μM (low dose) MSD/vehicle treatment, while black bars  
represent 1μM (high dose) MSD/vehicle treatment. Lat A: latrunculin A, colch: colchicine. 
Graphs are representative of 1 experiment, each with duplicate wells and 1 CFU plate per 
well. *p<0.05 1 µM peloruside A, IFN-γ vs high dose ethanol vehicle control, **p<0.01 1 
µM peloruside A, no IFN-γ vs high dose ethanol vehicle control, **p<0.01 10 µM 
latrunculin A vs high dose vehicle control with and without IFN-γ, one-way ANOVA with 
Newman-Keuls post test.  
A  B 
C D 
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6.3 Discussion 
Bacterial killing is an important aspect of phagocytosis. Binding, ingestion and 
killing of pathogens are all aspects of macrophage bactericidal activity, however while an 
MSD treated macrophage may be able to ingest bacteria, it might be impaired while killing 
it. Additionally, while it has been well established that microtubules are important in 
phagocytosis (Kaplan, 1977; Toyohara et al., 1989; Blocker et al., 1997; Blocker et al., 
1998; Khandani et al., 2007), there are few studies that address the effects of MSD induced 
microtubule stabilization on macrophage bactericidal abilities. Based on this, the main aim 
of these experiments was to distinguish killing ability from phagogcytic ability and 
understand the effects of MSD treatment on the macrophage ability of bacterial killing. We 
were interested in assessing if treatment with MSD would increase or decrease bactericidal 
ability in macrophages, especially since phagocytosis was not impaired.  
 Initially we tested two concentrations of bacteria for suitable infection rates in 
RAW264.7 macrophages. Bacterial phagocytosis occurred at MOI values of 10:1 and 25:1 
however, an MOI of 25 resulted in slightly higher amounts of internalized, live bacteria. 
While this value was not significantly greater than the levels of internalization at MOI 10, 
we decided to use the higher MOI for infections. This was to ensure that upon treatment 
with MSD there was sufficient bacterial challenge to the immune system. If bacterial levels 
were low, it could be possible that in the presence of MSD there would be no effect on 
killing ability; therefore we chose to use a higher MOI.   
It is known that macrophage phagocytosis of bacterial and other pathogens occurs via 
complement or FcR mediated pathways (Aderem et al., 1999; Underhill et al., 2002). We 
investigated the requirement of opsonisation for phagocytosis, by opsonising bacteria with 
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BALB/c mouse serum which contained opsonins and IgG antibodies. However we found 
that E.coli phagocytosis was not affected by presence or absence of serum opsonins. This 
was also seen in another study (Sukumaran et al., 2003) and suggests that E.coli 
phagocytosis does not need complement or antibody and that TLR-LPS stimulation is 
sufficient to trigger phagocytosis. IFN-γ pre-treatment to activate RAW264.7 macrophages 
for optimal phagocytosis was also investigated, but the rates of phagocytosis and killing 
were not significantly affected irrespective of IFN-γ pre-treatment.  
We found that the gentamicin antibiotic treatment in the infection assay was 
successful in killing extracellular bacteria as expected. This was confirmed by the lack of 
colony growth when bacteria alone were treated with gentamicin, as well as the reduction 
in CFU numbers when comparing macrophages and bacteria alone with macrophages and 
bacteria with gentamicin treatment. The gentamicin survival assay enabled us to study 
macrophage killing ability, because bacteria that are phagocytosed are protected from 
antibiotic killing. However, bacterial killing occurs inside the macrophage as well, 
therefore measuring bacteria after a short period of time (between 90 to 120 minutes) 
lessens the chance of bacterial replication or excessive bacterial killing within the 
macrophage (Campbell et al., 1994; Laroux et al., 2005). When comparing CFU counts 
from macrophages that are non-drug treated to MSD treated macrophages, there are two 
possible results; i)CFU counts are similar in MSD treated and non treated macrophages 
indicating that there was no increase in killing ability or ii)CFU counts are lower in MSD 
treated macrophages indicating that there was an increase in killing ability. Thus this assay 
gives us an idea of the enhancement or impairment to killing capacity. Relating this back to 
the presence of MSD allows understanding the effects of MSD on bacterial killing. 
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The results of MSD treatment on bacterial killing were remarkable and suggested 
different levels of inhibition in bacterial killing. The inhibitory effects of MSD on bacterial 
killing were also only seen when bacterial CFU were low. This was interesting because the 
MOI of all assays were 25:1 and macrophages were seeded at the same concentrations and 
in the same experimental media. Results from the MSD killing assays were presented as 
relating to high and low CFU to avoid masking the effects of MSD seen in the presence of 
low CFU values. The difference in CFU numbers is hard to explain as assay results seemed 
to fall into these two categories without a corresponding change in assay conditions. It may 
be possible that at some stage of cell line passage macrophages were more competent and 
able to kill bacteria efficiently resulting in low CFU values irrespective of MSD presence. 
It could also be possible that MSDs stimulated killing to a greater extent and caused low 
CFU numbers, however the low CFU was also seen in non MSD treated macrophages. 
Therefore, it seems more likely that the variation in CFU results was due to an unknown 
interaction between macrophages and bacteria. As cells were used only between 2 and 10 
passages, it is unlikely that some experiments had mature, activated cells, which were 
competent in bacterial killing and other experiments had younger cells at low passage that 
were not as efficient at bacterial killing. We do not have any explanations as to why killing 
assays sometimes had low and other times had high CFU numbers. However, it still stands 
that we saw greater effects of MSD treatment when CFU counts were low. 
When treated with paclitaxel, peloruside A or docetaxel at low or high doses, there 
was no significant change in bacterial killing when bacterial survival was in the high CFU 
category. There was a significant change, with increased killing in latrunculin treated 
macrophages, but this was due to latrunculin blocking phagocytosis. This resulted in all the 
Chapter 6: Bacterial killing by  
MSD treated RAW264.7 macrophages. 
 
146 
bacteria being extracellular and gentamicin treatment resulted in bacterial killing and lack 
of CFU.  
In contrast, with high CFU counts and treatment with low dose zampanolide, there 
was a significant inhibition of killing, while high dose zampanolide restored the killing 
ability of macrophage to levels similar to those of vehicle treated macrophages. This 
suggests that zampanolide may have some stimulatory effect on macrophages similar to 
paclitaxel. However from pHrodo phagocytosis assays, it can be seen that there is a 
significant dose dependent inhibition of phagocytosis in the presence of zampanolide. 
Taken together these results suggest that zampanolide treatment not only impairs 
phagocytosis, but also impairs killing. At high CFU levels, and low doses of zampanolide, 
there is limited phagocytosis, and bacteria that are taken up cannot be killed.  Additionally, 
with high dose zampanolide and high CFU, bacterial uptake is significantly inhibited and 
bacteria that might be taken up are not killed efficiently. A possible explanation for this 
could be the binding site of zampanolide, which is unknown (Miller et al., 2010) interfering 
with LPS binding of microtubules, leading to loss of sufficient stimulation and impaired 
phagocytosis. As mentioned previously, zampanolide could also affect actin, and this 
combined with microtubule effects would additionally impair endocytic trafficking and 
affecting killing (Apodaca, 2001).    
When CFU counts were low and cells were treated with paclitaxel, peloruside A or 
docetaxel, there was significant alteration to killing in the presence of low dose paclitaxel 
treated macrophages. The CFU counts were significantly higher; indicating that these 
paclitaxel treated cells had impaired bactericidal activity. The data from pHrodo 
phagocytosis demonstrates that there is no increase in phagocytosis, which indicates that 
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the high CFU counts are not due to increased phagocytosis, but rather due to decreased 
killing ability. Taken together, the low and high CFU data suggest that if cells phagocytose 
high numbers of bacteria, irrespective of MSD treatment, killing is impaired. This is 
because the high CFU counts are seen with vehicle treated macrophages as well as MSD 
treated macrophages. However if for some unknown reason, cells phagocytose less 
bacteria, then paclitaxel treatment affects how well these bacteria are killed. With low dose 
paclitaxel, there was an inhibition to killing, and this was alleviated in the presence of high 
dose paclitaxel, possibly due to LPS mimicry exhibited by paclitaxel. These results are 
extremely interesting, especially when considering the LPS mimicry of paclitaxel. Similarly 
to LPS, paclitaxel can cause activation of TLR-4 by binding to TLR-4 in combination with 
the accessory protein MD-2 (Kawasaki et al., 2000; Kawasaki et al., 2001a). This 
interaction is MD-2 dependent and species specific and thus paclitaxel displays LPS 
mimicry only in murine macrophages and monocytes (Shimazu et al., 1999; Kawasaki et 
al., 2001a; Zimmer et al., 2008).  It would be prudent to study bactericidal effects in 
paclitaxel treated human macrophage cell line such as 2MAC (Dialynas et al., 1997) as 
there would be a lack of LPS mimicry in these cells. It is likely that due to paclitaxel’s lack 
of LPS mimicry in human cells, there will be inhibition to bacterial killing. Furthermore, 
these studies are in vitro and a more detailed understanding would be gained from doing 
these studies on human macrophage cell lines. Testing these MSD in vivo in mice, would 
also provide a more in depth picture of the effects of the MSD on macrophage phagocytosis 
and killing. 
When studying the effects of the novel compounds ixabepilone, and mycothiazole, 
we found that in the presence of high doses of ixabepilone, bacterial killing was enhanced, 
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but at low doses the killing efficiency was similar to vehicle treated macrophages. 
Ixabepilone competes for the same binding site as paclitaxel, however it is active in 
paclitaxel resistant cells (Bollag et al., 1995; Goodin et al., 2004), suggesting that in 
RAW264.7 cells which are comparatively resistant to paclitaxel, the effects of ixabepilone 
would be more pronounced. This is seen when high dose ixabepilone significantly increases 
macrophage killing ability. It is unknown if ixabepilone exhibits LPS mimicry and it would 
be worthwhile to determine this as paclitaxel’s semi-synthetic analogue, docetaxel does not 
exhibit LPS mimicry. We carried out this assay once, and the CFU obtained were in the low 
category, it is possible that if CFU were to be higher, there would be no effect of 
ixabepilone treatment. The effects of mycothiazole are also interesting. There was a 
significant inhibition to bacterial killing in the presence of high dose mycothiazole. While 
the intracellular targets for mycothiazole are unknown (Miller et al., 2010), these results 
combined with pHrodo results suggest that mycothiazole may possibly affect microtubule 
stability similar to MSDs. A recent study has found that mycothiazole treatment led to 
reduced ROS production (unpublished data; Meyer, K. et al. 2010). If initial inflammatory 
mediators are suppressed, this may explain the lack of efficient killing in macrophages. In 
the same study, it was also proposed that mycothiazole may have multiple targets 
(unpublished data; Meyer, K. et al. 2010), however the researchers found that mycothiazole 
did not affect cell cycle progression, suggesting that microtubules were not targeted by this 
compound. In this case, there could be an alternate mechanism by which mycothiazole 
affects bacterial killing and given the variety of responses and activity of mycothiazole in 
differing cell lines (unpublished data; Meyer, K. et al. 2010). this is not unlikely. 
Additionally, due to limited supply of both ixabepilone and mycothiazole, they were 
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assayed once in our studies and it would be beneficial to replicate these assays to confirm 
our results. 
Similarly to the pHrodo assays, we tested the effects of IFN-γ treatment on efficiency 
of bacterial killing in the presence of MSD. There was no significant alteration to bacterial 
killing ability in the presence or absence of IFN-γ in macrophages treated with paclitaxel or 
docetaxel. Levels of survival were comparable in MSD and vehicle treated cells, 
irrespective of IFN-γ treatment. Overall there was a trend of increased bacterial survival, 
indicating decreased killing ability, in the absence of IFN-γ, irrespective of drug treatments. 
This is expected as IFN-γ activates macrophages to respond to bacterial stimulus (Young et 
al., 1995; Schroder et al., 2004). In the presence of peloruside A, latrunculin A and 
colchicine however, there was significant alterations to bacterial killing. When 
macrophages were treated with low doses of peloruside A, irrespective of IFN-γ treatment, 
there was no significant inhibition to bacterial killing ability. However, in the presence of 
high dose peloruside A, there was a significant increase in bacterial killing. The presence of 
IFN-γ significantly increased killing ability at high doses of peloruside A, however in the 
absence of INF-γ, the increase in killing ability was much more significant. This suggests 
that in the absence of IFN-γ, peloruside A stimulates cells to maintain killing ability. The 
increased significance in the peloruside A, non IFN-γ treated cells, could be due to the non 
IFN-γ, vehicle control treated cells exhibiting high bacterial survival. However this still 
supports the theory that in the absence of IFN-γ, bacterial killing is sub-optimal and 
treatment with peloruside A leads to rescue of the killing efficiency. In latrunculin A 
treated macrophages, as expected, there was a significant decrease in bacterial survival, 
irrespective of IFN-γ treatment. In colchicine treated macrophages, while there was no 
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significant alteration to killing ability, in the presence of IFN-γ bacterial survival was lower 
than in the absence of IFN-γ. This is similar to results seen with pHrodo assays, where 
colchicine treatment had significantly decreased uptake of bacteria irrespective of IFN-γ 
treatment. We did not find colchicine treatment to inhibit bacterial killing and survival 
levels were comparable to the level of survival seen with the MSD treated samples. 
Colchicine is a microtubule destabilizer, and we would expect alterations to bacterial 
killing as transport pathways would be affected.  However the lack of inhibition seen in 
bacterial killing could be due to the presence of a stable pool of cytoplasmic microtubules 
that are able to maintain cellular function (Schroer et al., 1991). 
 
Overall, we found that bacterial killing was not significantly affected in the clinically 
used MSD paclitaxel and docetaxel. However, we found peloruside A could significantly 
increase bacterial killing if optimal stimulation was absent. We also found that zampanolide 
treatment affects the ability of macrophages to phagocytose and kill bacteria efficiently and 
this suggests that if used clinically there is likely to be altered immune responses in the 
presence of bacteria. Similarly, we found that ixabepilone treatment enhances microbial 
killing, while mycothiazole impaired microbial killing. With all of these assays, the results 
are preliminary due to limited compound availability and repeating these assays is required.  
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CHAPTER 7: EFFECTS OF MSD TREATMENT ON CYTOKINE PRODUCTION DURING 
BACTERIAL KILLING IN RAW264.7 MACROPHAGES. 
 
Macrophage stimulation with LPS results in production of the inflammatory 
cytokines TNF-α, IL-12 and NO (Tracey et al., 1994; Ma et al., 1996; Sosroseno et al., 
2002). These cytokines play an important role in bactericidal activities and aid in clearance 
of bacteria. MSD can alter cytokine profiles and treatment with these drugs can also result 
in immunostimulatory effects (Mullins et al., 1999; Tsavaris et al., 2002; Crume et al., 
2007). The stabilization of microtubules due to MSD treatment can also lead to inhibition 
in vesicle trafficking and thus affect release of cytokines (Murray et al., 2005). We were 
interested in studying the effects of MSD treatment on macrophage ability of phagocytosis 
and bacterial killing. The ability of macrophages to respond to pathogens and resolve 
infections is linked to cytokine signalling and optimal macrophage responses involve 
cytokines (Zhang et al., 2008). 
For this reason, we decided to investigate the effects of MSD treatment on cytokine 
production during phagocytosis and bacterial killing. We were interested in changes to the 
cytokine profile that would help explain any enhancement or inhibitions in macrophage 
phagocytic and bactericidal ability during MSD treatment. We looked at changes to TNF-α 
production as this cytokine is produced earliest in response to bacterial and LPS stimulation 
(Tracey et al., 1993). We also looked at nitric oxide production which is produced in 
response to bacterial LPS (Stuehr et al., 1985). The maximum incubation time for most of 
our bacterial phagocytic assays were 3 hours or less. TNF-α was the only cytokine with 
optimal production levels that was measurable within this time frame. There was limited 
nitric oxide production at this early time point and IL-12 production was negligible.  
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7.1 Interactions between TNF-α and paclitaxel in LPS stimulated RAW264.7 
macrophages. 
7.1.1 Introduction  
Paclitaxel stimulates an inflammatory profile in macrophages, leading to a release of 
TNF-α, IL-12 and NO (Fitzpatrick et al., 2003). Previous studies in our lab using BMDM, 
have demonstrated that in the presence of limiting doses of LPS, paclitaxel can lower the 
amount of TNF-α produced, leading to an anti-inflammatory profile (Crume et al., 2007). 
Paclitaxel has also been seen to increase metabolism levels in LPS-stimulated BMDM 
(Crume et al., 2007). Additionally, as mentioned before, paclitaxel can mimic the effects of 
LPS in murine macrophages (Ding et al., 1990b). We therefore decided to investigate the 
ability of LPS to stimulate TNF-α production in RAW264.7 and J774.2 murine 
macrophages over a 2 hour and 8 hour incubation (Fig 7.1.1). We were interested in 
determining optimal times for TNF-α measurement as well as concentrations of LPS that 
could be considered as low or high doses depending on their ability to induce TNF-α 
production. We also looked at the rate of metabolism of these cells in the presence of LPS 
(Fig 7.1.2). We then studied the effect of paclitaxel treatment on TNF-α production (Fig 
7.1.3) to see if limiting LPS doses caused paclitaxel to exhibit an anti-inflammatory profile 
as previously seen. We also studied the corresponding 2 and 8 hour cell metabolic levels 
(Fig 7.1.4) when the cells were stimulated with LPS and paclitaxel.  
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7.1.2 Results 
Figure 7.1.1 
 
 
Figure 7.1.1 TNF-α production in (A) 2 hour LPS-stimulated RAW264.7 and J774.2 
macrophages and (B) 8 hour LPS-stimulated RAW264.7 and J774.2 macrophages. 
Cells with a concentration of 2x 10
5
/ml were seeded at 50 µL/well, with a range of 
concentrations of LPS, starting at 100 ng/ml serial diluted down. (A) At 2 hours, 
RAW264.7 and J774.2 cells produce significantly more TNF-α when compared to controls. 
RAW264.7 cells are significantly more responsive to LPS as compared to J774.2 cells. (B) 
At 8 hours, RAW264.7 and J774.2 cells produce significantly higher levels of TNF-α in 
comparison to controls. Levels of TNF-α production in J774.2 cells at 8 hours are similar to 
the levels of TNF-α seen in RAW264.7 cells at 2 hours. For both graphs, data points are 
representative of mean ± SEM of triplicate wells from two experiments. **p<0.01, 
***p<0.001, RAW264.7 or J774.2 + LPS vs cells alone, two-way ANOVA with Bonferroni 
post test.  
  
A 
Figure 7.2.1A Figure Legend 
Figure 7.2.1B Figure Legend 
B 
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Figure 7.1.2  
        
 
        
 
Figure 7.1.2 RAW264.7 and J774.2 cells exhibit a constant rate of metabolism in the 
presence of (A) 2 hours or (B) 8 hours LPS-stimulation. RAW264.7 and J774.2 cells do 
not significantly alter their metabolic rates in response to a range of LPS concentrations 
over (A) 2 hours or (B) 8 hours. Data points represent rate of metabolism as a percentage of 
control from untreated cells. Each point is mean ± SEM of three replicates each from two 
experiments. p>0.05, two-way ANOVA with Bonferroni post test.  
Figure 7.2.2A: Figure Legend 
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Figure 7.2.2B: Figure Legend 
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Figure 7.1.3  
 
 
Figure 7.1.3 Effect of paclitaxel on TNF-α production from (A) 2 hours and (B) 8 
hours LPS stimulated RAW264.7 macrophages. Cells were cultured with 0.3 ng/ml LPS 
(low dose) or 5 ng/ml LPS (high dose) and a range of paclitaxel concentrations. (A) There 
were no significant changes to TNF-α production at 2 hours as compared to LPS stimulated 
vehicle control. (B) 8 hours paclitaxel treatment did not alter TNF-α production, however at 
both doses of LPS alone, there was a significant increase in TNF-α production as compared 
to LPS stimulated vehicle control. For both graphs, data points are representative of mean ± 
SEM of triplicate wells from two experiments. *p<0.05, ***p<0.001, cells with LPS vs 
cells with LPS and vehicle, two-way ANOVA with Bonferroni post test.  
Figure 7.2.3A, B:  
Figure Legend 
A 
B 
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Figure 7.1.4 
       
 
         
 
Figure 7.1.4 Rate of metabolism in paclitaxel treated, LPS stimulated RAW264.7 cells 
at (A) 2 hours and (B) 8 hours. (A) RAW264.7 macrophages exhibit extremely 
comparable rates of metabolism at 2 hours, irrespective of treatment with paclitaxel alone 
or paclitaxel and low or high dose LPS (B) There is no significant change in the metabolic 
rate of RAW264.7 cells at 8hours when stimulated with paclitaxel alone or paclitaxel and 
low or high dose LPS. However, at 8 hours there is a variation in metabolic rates at each 
treatment, which is not seen at the 2 hours treatment. RAW264.7 macrophages treated with 
5 ng/ml LPS have the highest rate of metabolism at 8 hours, followed by 0.3 ng/ml LPS 
treatment and paclitaxel treatment. For both graphs, rate of metabolism is measured as a 
percentage of control from untreated cells. Each point is mean ± SEM of three replicates 
each from two experiments. p>0.05, two-way ANOVA with Bonferroni post test.   
Figure 7.2.4 A, B: Figure Legend 
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7.1.3 Discussion 
This set of assays was done to study the effects of paclitaxel on TNF-α production in 
the presence of LPS stimulation. Initially we tested the responsiveness of both the 
macrophage cell lines RAW264.7 and J774.2 to LPS stimulation. We found that 
RAW264.7 macrophages are much more sensitive to LPS stimulation, seen by the high 
levels of TNF-α produced in RAW264.7 cells. At 2 hours RAW264.7 cells produce 
approximately 9 times more TNF-α as compared to J774.2 cells. However by 8 hours, the 
J774.2 cells produce similar levels of TNF-α as seen with the RAW264.7 cells in 2 hours. 
Both the RAW264.7 and J774.2 cells showed increasing levels of TNF-α production before 
levelling out, indicating that increasing LPS only caused increases in TNF-α up to certain 
concentrations, after which increasing LPS did not correspond to increasing TNF- α levels. 
While the J774.2 cells took longer to produce TNF-α, reaching maximum production levels 
at 8 hours, the RAW264.7 cells exhibited decreased TNF-α level at 8 hours. This could be 
due to reabsorption of the high amounts of TNF-α produced or it could be a combination of 
reabsorption and declining TNF-α production due to cellular energy being used up for the 
initial burst of TNF-α production. There was however, no corresponding increase in 
metabolic rate of RAW264.7 cells at 2 or 8 hours.  
From the graphs, the ED50 values (LPS concentration at which half-maximal TNF- α 
is produced) for RAW264.7 cells and J774.2 cells at 2 hours were approximately 1 ng/ml 
and 2 ng/ml LPS respectively, while at 8 hours, the ED50 values were 1.5 ng/ml in 
RAW264.7 and 0.5 ng/ml in J774.2 cells. This is comparable to previous studies from our 
lab, where the approximate ED50 value of 1 ng/ml LPS, was seen in primary BMDM when 
measuring TNF- α production (Robinson, 2009). This is interesting as it indicates that the 
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same concentration of LPS is required for peak TNF-α production in all the three cell types, 
irrespective of LPS stimulation times, which was 2 and 8 hours in our assays and 8 hours in 
the work by Robinson, 2009.  
Based on the initial assays, we chose RAW264.7 cells for the remainder of the studies 
as they were more sensitive to LPS stimulation. However titrating LPS doses low enough to 
get a good distinction between high and low doses was challenging. The low dose chosen 
was 0.3 ng/ml which still led to comparably high TNF-α production. Additionally there was 
not a huge distinction between levels of TNF-α produced with 0.3 ng/ml or 5 ng/ml LPS. 
While retrospectively it seems as though it may have been better to pick the J774.2 cell line 
as these cells were not as LPS sensitive, the LPS dosage was equally hard to titrate in these 
cells with not much distinction between low and high doses of LPS in terms of TNF-α 
production. We found that the metabolic rate of RAW264.7 cells at 2 hours was unaffected 
by the presence of paclitaxel, with high or low dose LPS. Previous studies (Crume et al., 
2007), have shown that paclitaxel causes a metabolic increase in BMMO however this 
increase was measured after a 72 hour incubation and it is likely that at the early time point 
measured there would be no increase in metabolic activity despite there being increased 
TNF-α production.  
In contrast, at 8 hours, the metabolic rate of cells treated with high dose LPS was 
higher in comparison with metabolic rates for cells treated with low dose LPS and 
paclitaxel or paclitaxel alone. Cells treated with low dose LPS for 8 hours, had metabolic 
rates similar to that of cells treated with high or low dose LPS for 2 hours. Additionally, 
cells treated with paclitaxel showed a marginal decrease in metabolic rate at 8 hours as 
compared to treatment at 2 hours or compared to treatment with high dose LPS for 8 hours. 
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However, none of these observed changes in metabolic rates were significant. We also 
confirmed in chapter 3 that an 8 hour treatment with paclitaxel alone caused a significant 
change in cell metabolism compared to 2 hours. This data together indicates that increasing 
LPS stimulus or paclitaxel exposure does not increase cell metabolism or affect cell 
viability over short incubation times. However at 8 hours, while LPS stimulus increases cell 
metabolism due to activation of inflammatory responses (Crume et al., 2007), treatment 
with paclitaxel alone seems to affect cell viability as determined by decreases in cell 
metabolism. One possible reason for this could be that the cells start to show susceptibility 
to paclitaxel, also they lack the extra LPS stimulation and this could possibly affect 
metabolism as well.  There may be increases in metabolism if cells were treated with LPS 
and paclitaxel for longer, however as noted in chapter 3, the time course of this incubation 
would be limited due to the cytotoxic effects of paclitaxel on proliferating cells. 
Compared to vehicle controls, paclitaxel did not cause any inhibition to TNF-α 
production when cells were treated with low dose LPS and paclitaxel or high dose LPS and 
paclitaxel at 2 or 8 hours. An interesting observation made was that cells treated with low 
or high dose LPS alone for 8 hours produced significantly more TNF-α as compared to 
cells treated with the same dose of LPS and in the presence of ethanol as a vehicle control. 
The data suggests that TNF-α production is inhibited in the presence of ethanol, an effect 
that has been seen previously (Xie et al., 1995; Stoltz et al., 2000; Feng et al., 2002). The 
lack of inhibition to TNF-α production in the presence of limiting LPS and paclitaxel could 
be due to the high sensitivity of RAW264.7 cells to LPS stimulation. In previous studies 
paclitaxel treatment in the presence of LPS doses of 20 ng/ml or less caused a decrease in 
TNF-α production (Crume et al., 2007), however with LPS doses as low as 0.3 ng/ml we 
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did not see a decrease in TNF-α production, once again indicating that RAW264.7 cells 
were extremely sensitive to LPS. As seen previously, we found that cells treated with 
paclitaxel alone were able to produce TNF-α, indicating that paclitaxel displays LPS 
mimicry in murine macrophages. 
 
Overall, the data from these assays suggested that compared to BMDM or J774.2 
cells, RAW264.7 cells were extremely sensitive to LPS stimuli. We also found that 
paclitaxel or LPS stimulation alone or in combination did not increase cell metabolism in 2 
hours. However an 8 hour treatment of paclitaxel alone seemed to decrease cell 
metabolism, which was an indicator of cell viability. The decrease in cell viability at 8 
hours in the presence of paclitaxel seemed to be rescued by additional stimulation of high 
dose LPS for the same incubation period. We also found that in contrast to previous work 
in BMDM, paclitaxel treatment at limiting LPS doses did not decrease TNF-α production. 
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7.2 Changes in TNF-α and NO production during pHrodo phagocytosis in MSD 
treated macrophages. 
7.2.1 Introduction  
This set of assays was carried out to study the effects of MSD treatment on cytokine 
production during bacterial phagocytosis. As mentioned earlier, macrophages produce 
TNF-α and NO in response to LPS stimuli or paclitaxel treatment (Stuehr et al., 1985; Ding 
et al., 1990b; Nakano et al., 1999; Bingle et al., 2002). Studies have also shown paclitaxel 
and docetaxel capable of modifying cytokine profiles (Tsavaris et al., 2002). Additionally, 
while peloruside A stabilizes microtubules similarly to paclitaxel; it does not share 
paclitaxel’s ability to induce an inflammatory profile (Hood et al., 2001; Crume et al., 
2007).  There are few studies investigating the effects of peloruside A on cytokine 
production during bacterial phagocytosis. Furthermore, given the LPS mimicry displayed 
by paclitaxel, and the immunomodulatory effects of paclitaxel and docetaxel we were 
interested in investigating the interactions of MSD treatment and LPS stimuli on cytokine 
production during bacterial phagocytosis. Similarly to peloruside A, docetaxel does not 
exhibit LPS mimicry, and we were interested in the possible anti-inflammatory effects of 
these actives. 
As described in the methods, supernatants were collected during infection assays with 
pHrodo, and stored at -20°C for cytokine analysis at a later stage. TNF-α, and NO 
production was tested at a 2 hour time-point. TNF-α ELISAs and Greiss reactions were run 
as described in the methods. Treating macrophages with the MSD paclitaxel, peloruside A, 
or docetaxel did not cause any significant alteration in TNF-α production (Fig 7.2.1A and 
7.2.1B). Zampanolide treated macrophages exhibited a trend of decreasing TNF-α 
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production with increasing zampanolide dosage (Fig 7.2.1A). Latrunculin A treated 
macrophages were able to produce TNF-α at levels comparable to those of vehicle control. 
Additionally treatment with ixabepilone did not alter TNF-α production, while 
mycothiazole treatment showed a trend of increased TNF-α levels with increasing dose of 
drug (Fig 7.2.2A and 7.2.2B).   
The effect of MSD treatment on NO production was interesting. At high doses of 
paclitaxel, peloruside A, docetaxel, zampanolide and latrunculin we found inhibition to NO 
production (Fig 7.2.3). Additionally, while ixabepilone and mycothiazole did not 
significantly affect NO production (Fig 7.2.3B and 7.2.3C), there was a trend suggesting 
that high doses of these compounds could affect NO production.  
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7.2.2 Results  
Figure 7.2.1 
  
  
Figure 7.2.1 Drug treatment during pHrodo phagocytosis does not alter TNF-α 
production in RAW264.7 macrophages. (A, B) Treatment with paclitaxel, peloruside A, 
docetaxel or zampanolide does not significantly alter TNF-α production during pHrodo 
phagocytosis. In both graphs, latrunculin A treatment does not inhibit TNF-α production. 
TNF-α production from A and B corresponds to 1 individual pHrodo infection assay each. 
Graphs are representative of 2 ELISAs each with duplicate wells. p>0.05, one-way 
ANOVA with Bonferroni post test. White bars indicate 0.1 µM (low dose) treatment / 
vehicle control , while black bars indicate 1 µM (high dose) treatment / vehicle control 
. Vehicle controls contain the same final concentration of ethanol as the drug treated 
samples. Lat A: latrunculin A, zamp: zampanolide.  
  
A 
B 
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Figure 7.2.2 
         
Figure 7.2.2 Drug treatment during pHrodo phagocytosis does not alter TNF-α 
production in RAW264.7 macrophages. (A) As compared to vehicle control, treatment 
with ixabepilone does not significantly alter TNF-α production during pHrodo 
phagocytosis. p>0.05, one-way ANOVA with Bonferroni post test. (B) Treatment with 
mycothiazole does not alter TNF-α production as compared to DMSO vehicle control. 
p>0.05, one-way ANOVA with Bonferroni post test. White bars indicate 0.1 µM (low 
dose) treatment / vehicle control , while black bars indicate 1 µM (high dose)  treatment 
/ vehicle control . Vehicle control samples contain the same final concentration of 
ethanol or DMSO as the drug treated samples. Lat A: latrunculin A, ixabepilone: ixabep, 
mycz: mycothiazole. Graphs are representative of 2 experiments, each with duplicate wells. 
 
  
A B 
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Figure 7.2.3 
 
                
 
Figure 7.2.3 Treatment with high dose MSD affects nitric oxide production during 
phagocytosis of bacteria. (A) High doses of paclitaxel, peloruside A, docetaxel 
zampanolide and latrunculin A significantly inhibit NO production. Additionally, 
zampanolide treatment eliminates NO production, to a higher degree as compared to other 
MSD used. ***p<0.001 paclitaxel vs vehicle control, peloruside A vs vehicle control, 
docetaxel vs vehicle control, zampanolide vs vehicle control, latrunculin A vs vehicle 
control, one-way ANOVA with Newman-Keuls post test. (B) ixabepilone or (C) 
mycothiazole treatment does not significantly affect NO production, there is a trend of high 
doses of both these compounds affecting NO production to a greater degree than low doses 
of the same compound. p>0.05 one-way ANOVA with Newman-Keuls post test. White 
bars indicate low dose treatment/vehicle control , while black bars indicate high dose 
treatment/vehicle control . Vehicle control samples contain the same final concentration 
of ethanol or DMSO as the drug treated samples. Lat A: latrunculin A, zamp: zampanolide, 
ixabepilone: ixabep, mycz: mycothiazole. Graphs are representative of 2 experiments, each 
with duplicate wells.  
  
A 
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7.2.3 Discussion 
This set of assays focussed on the effects of MSD treatment on TNF-α and NO 
production during pHrodo phagocytosis. Cytokines such as TNF-α and NO stimulate 
macrophages to increase responses to bacterial invasion (Zhang et al., 2008). Additionally, 
the presence of TNF-α also helps increase bacterial resistance (Havell, 1989). Researchers 
have proposed that the pharmacological and toxicological properties of the taxanes could be 
related in part to the cytokines and pro-inflammatory proteins induced by these actives 
(Chan et al., 2000; Fitzpatrick et al., 2003). Based on this combined information, we tested 
infection assay supernatants for the presence inflammatory cytokines TNF-α and NO to 
investigate the effects that MSD treatment could have on production of these cytokines 
during phagocytic processes. 
We found that MSD treatment did not inhibit TNF-α production during phagocytosis 
of pHrodo. The levels of TNF-α produced were similar in the presence of paclitaxel, 
peloruside and docetaxel. We also found that treatment of macrophages with latrunculin A 
did not inhibit TNF-α production, which indicates that although phagocytosis is impaired 
due to actin stabilization (Oliveira et al., 1996), LPS and TLR-4 are functional and interact 
to stimulate an immune response. However, macrophages treated with zampanolide 
exhibited a trend of decreasing TNF-α production with increasing dose of MSD. This is not 
surprising, because as seen in chapter 5 and 6, macrophages treated with zampanolide were 
unable to phagocytose and/or kill bacteria efficiently. This data taken together suggests that 
zampanolide treatment could impair immune responses and macrophage function, 
especially in terms of resistance to bacterial infections.  
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Interestingly, as seen with the high and low CFU counts in chapter 6, we observed 
that when TNF-α production was lower, the trends seen in the presence of MSD treatment 
were altered to a greater degree than when TNF-α production was higher. We found that 
paclitaxel treatment consistently exhibited a trend of dose-dependent increase in TNF-α 
production, irrespective of baseline levels of TNF-α. This is most likely due to the LPS 
mimicry causing higher paclitaxel doses to induce correspondingly higher levels of TNF-α 
(Ding et al., 1990b). However, we saw contrasting effects with peloruside A treatment. 
When the baseline levels of TNF-α was high, peloruside A treated macrophages exhibited a 
trend of dose dependent increase in TNF-α production, but when the baseline level of TNF-
α was low, peloruside A treatment led to a dose dependent decrease in TNF-α production. 
This is surprising as peloruside A lacks LPS mimicry and displays an anti-inflammatory 
profile in LPS-stimulated BMMO (Crume et al., 2007). A possible reason for this could be 
that with high levels of TNF-α present, peloruside A was unable to exert its anti-
inflammatory profile. This is beneficial in terms of clinical use, as if bacterial load is high, 
macrophages are stimulated to increase inflammatory cytokines and ameliorate infection, 
and peloruside A treatment would not inhibit macrophage response to bacteria. 
We saw a similar effect with docetaxel treated macrophages. Docetaxel does not have 
LPS mimicry or display an inflammatory profile (Manthey et al., 1993; Fitzpatrick et al., 
2003). When TNF-α levels were low, docetaxel caused an inhibition in TNF-α production, 
but this was not significant as compared to vehicle treated macrophages. However when 
TNF-α levels were higher, docetaxel did not inhibit TNF-α production. We also looked at 
the effects of ixabepilone and mycothiazole treatment on TNF-α production, and found no 
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significant changes to TNF-α production in the presence of high or low doses of these two 
compounds. 
Results from NO production were most interesting in terms of alterations to cytokine 
production. We measured NO2¯ production as an indicator of NO production as described 
in the methods. Our study measures NO production as at the 2 hour time point, however 
optimal production of NO occurs at later time points and production is normally measured 
at 8 hours (Robinson, 2009), 20 hours (Nakano et al., 1999), 24 hours (Stuehr et al., 1985; 
Sosroseno et al., 2002), 48 hours (Kirikae et al., 1996) or even as late as 72 hours (Crume 
et al., 2007). While these studies measured optimal peak levels of NO production, there are 
studies that have shown low levels of NO being produced in the presence of LPS, at earlier 
time points of 2 or 4 hours (Chamulitrat et al., 1995; Xie et al., 1995), which is similar to 
our results, where NO was detected at 2 and 3 hour time points. 
We found that high doses of paclitaxel, peloruside A, docetaxel, zampanolide and 
latrunculin A caused significant inhibition to NO production during pHrodo phagocytosis. 
While the data is significant, it is preliminary and it would be worthwhile to repeat these 
assays for a greater understanding of the inhibition seen with high doses of MSD on NO 
production. Interestingly, paclitaxel, peloruside A, docetaxel and latrunculin A inhibited 
NO; however, high dose zampanolide treatment completely blocked NO production. This 
suggests that zampanolide could possibly be used as an anti-inflammatory therapeutic 
similarly to peloruside A, as we found zampanolide inhibited TNF-α production as well as 
NO production. Since the data suggests that MSD inhibits NO production, it would be 
valuable to study the effects of not only zampanolide, but also the other MSD on NO 
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production at later time points. This would enable understanding MSD effects when 
optimal NO is produced during phagocytosis.  
While ixabepilone and mycothiazole did not significantly alter NO production, there 
was a trend suggesting high dose mycothiazole reduced NO production similarly to 
zampanolide. Results from ixabepilone are variable and it is hard to conclude or predict the 
possible effects of this drug on NO production. Overall these results are preliminary and it 
would be worthwhile to repeat these assays for a better understanding of the significance of 
the data. 
 
Overall, we found that MSD treatment can considerably alter TNF-α and NO 
production. Interesting effects were seen with peloruside A in terms of reduction of TNF-α 
production, which would be useful when developing this compound for clinical use. We 
also found zampanolide treatment significantly inhibited cytokine production. Taken 
together, these results suggest that MSD treatment significantly alters the levels of cytokine 
production during bacterial infections. Furthermore, the effects of MSD on phagocytic 
efficiency may be unrelated to the microtubule stabilizing capabilities of MSD and could 
likely be due to MSD altering cytokine production, which in turn affects phagocytosis, as 
suggested previously (Chan et al., 2000; Fitzpatrick et al., 2003).  
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7.3 Changes in cytokine production during bacterial killing in MSD treated 
macrophages. 
7.3.1 Introduction 
This set of assays focussed on the effects of MSD on cytokine production during 
bacterial killing. As described in section 7.2, MSD treatment can affect cytokine 
production, which directly affects macrophage ability to function. TNF-α, and NO are 
important in maintanence of bacterial resistance (Havell, 1989; Bogdan et al., 2000). 
Additionally, IL-12 is also produced by bacterial or LPS stimulated macrophages and this 
cytokine regulates activation of the adaptive immune response (Trinchieri, 2003; Hamza et 
al., 2010). Similarly to cytokine detection during bacterial phagocytosis, we investigated 
the effects of MSD treatment on the production of TNF-α, NO and Il-12 during bacterial 
killing. We expected to find high levels of TNF-α, as peak levels of this cytokine are 
produced early on. However, we expected low or limited production of NO and IL-12 as 
these cytokines are typically produced later in the immune response, once TNF- peaks and 
begins to decline. This is evidenced by production of NO and IL-12 being typically 
measured at later time points (Stuehr et al., 1987; Mullins et al., 1999; Nakano et al., 
1999).  
As described in the methods, supernatants were collected during bacterial killing 
assays with E.coli, and stored at -20°C for cytokine analysis at a later stage. TNF-α, NO 
and IL-12 production was tested as at a 3 hour hour time-point. As described with high and 
low CFU results in chapter 6, TNF-α production is presented corresponding to high or low 
CFU values, which is noted in figure legends. TNF-α and IL-12 ELISAs and Greiss 
reactions were run as described in the methods. Compared to vehicle controls, peloruside A 
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and docetaxel did not significantly increase or decrease TNF-α production, irrespective of 
the presence of high or low CFU counts. (Fig 7.3.1A and B) With paclitaxel, at the low 
CFU counts (Fig 7.3.1B), we found an increase in TNF-α production, but there was no 
corresponding increase in TNF-α at the high dose of paclitaxel. Interestingly, with low dose 
zampanolide (Fig 7.3.2A and B) TNF-α production was significantly reduced when CFU 
counts were higher as compared to when CFU counts were low. TNF-α production was not 
altered in macrophages treated with ixabepilone or mycothiazole (Fig 7.3.2C) 
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7.3.2 Results 
Figure 7.3.1 
 
 
Figure 7.3.1 Changes in TNF-α production by MSD treated macrophages during 
bacterial killing. (A) TNF-α production corresponds to high CFU counts. There is no 
significant alteration in TNF-α production when treated with MSD. (B) TNF-α production 
corresponds to low CFU counts. Compared to vehicle controls, low dose paclitaxel 
significantly increases TNF-α production. *p<0.05 low dose paclitaxel vs vehicle control, 
one-way ANOVA with Newman-Keuls post test. TNF-α production from A and B 
corresponds to 1 individual infection assay each. Graphs are representative of 1 ELISAs 
each with duplicate wells. Latrunculin A does not inhibit TNF-α production. White bars 
indicate low dose treatment/vehicle control , while black bars indicate high dose 
treatment/vehicle control . Vehicle controls contain the same final concentration of 
ethanol as the drug treated samples. Lat A: latrunculin A.  
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Figure 7.3.2 
          
 
 
 
 
 
 
 
 
 
Figure 7.3.2 Effect of zampanolide, ixabepilone and mycothiazole on TNF-α 
production during bacterial killing. (A) TNF-α production corresponds to low CFU 
counts. There is no significant alteration in TNF-α production when treated with 
zampanolide. p>0.05, one-way ANOVA with Newman-Keuls post test. (B) TNF-α 
production corresponds to high CFU counts. Compared to vehicle controls, low dose 
zampanolide significantly decreases TNF-α production. *p<0.05 low dose zampanolide vs 
vehicle control, one-way ANOVA with Newman-Keuls post test. (C) TNF-α production 
corresponds to low CFU counts. There is no significant alteration in TNF-α production 
when treated with ixabepilone or mycothiazole. p>0.05, one-way ANOVA with Newman-
Keuls post test. Graphs are representative of 1 ELISA each with duplicate wells. White bars 
indicate low dose treatment/vehicle control , while black bars indicate high dose 
treatment/vehicle control , chequered bars indicate 1 µM mycothiazole and its DMSO 
vehicle control . Vehicle controls contain the same final concentration of ethanol or 
DMSO as the drug treated samples. Lat A: latrunculin A, zamp: zampanolide, ixabep: 
ixabepilone, mycz: mycothiazole.  
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Figure 7.3.3 
 
 
Figure 7.3.3 NO production is not significantly affected by MSD treatment at (A) 1 
hour or (B) 3 hours during bacterial killing. (A) There was no significant alteration to 
NO production during bacterial killing in the presence of paclitaxel, peloruside A, 
docetaxel or latrunculin A at 1 hour of drug treatment. p>0.05, one-way ANOVA with 
Newman-Keuls post test (B) There was no significant alteration to NO production during 
bacterial killing in the presence of paclitaxel, peloruside A, docetaxel or latrunculin A at 3 
hours of drug treatment. p>0.05, one-way ANOVA with Newman-Keuls post test For both 
graphs, NO production corresponds to low CFU counts. White bars indicate 0.1 µM (low 
dose) treatment / vehicle control , while black bars indicate 1 µM (high dose)  treatment 
/ vehicle control . Vehicle controls contain the same final concentration of ethanol as 
the drug treated samples. Lat A: latrunculin A 
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Figure 7.3.4 
   
Figure 7.3.4 NO production is not significantly affected by MSD or mycothiazole 
treatment at (A) 1 hour or (B) 3 hours during bacterial killing. (A) There was no 
significant alteration to NO production during bacterial killing in the presence of 
zampanolide, ixabepilone or mycothiazole at 1 hour of drug treatment. p>0.05, one-way 
ANOVA with Newman-Keuls post test (B) There was no significant alteration to NO 
production during bacterial killing in the presence of zampanolide, ixabepilone or 
mycothiazole at 3 hours of drug treatment. p>0.05, one-way ANOVA with Newman-Keuls 
post test For both graphs, NO production corresponds to low CFU counts. White bars 
indicate low dose MSD treatment , while black bars indicate high dose 
treatment/vehicle control , chequered bars indicate 1 µM mycothiazole and its DMSO 
vehicle control . Vehicle controls contain the same final concentration of ethanol or 
DMSO as the drug treated samples. Lat A: latrunculin A, zamp: zampanolide, ixabep: 
ixabepilone, mycz: mycothiazole.  
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Figure 7.3.5 
 
Figure 7.3.5 At 3 hours, Il-12 production is variable during bacterial killing in MSD 
treated macrophages. IL-12 production corresponds to high CFU counts. There is no 
significant change in level of IL-12 produced when treated with paclitaxel, peloruside A, or 
latrunculin A at 3 hours. p>0.05 one-way ANOVA with Bonferroni post test. White bars 
indicate 0.1 µM (low dose) MSD treatment , while black bars indicate 1 µM (high 
dose) treatment / vehicle control , lined bars  indicate macrophages with bacteria, 
used instead of vehicle controls, which did not produce measureable IL-12. Vehicle 
controls contain the same final concentration of ethanol as the drug treated samples. Lat A: 
latrunculin A. 
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7.3.3 Discussion 
The main aim of these assays was studying the role of cytokines in bacterial killing 
and the changes that occurred following MSD treatment. As described previously, the 
immunomodulation seen in the presence of MSD such as paclitaxel and docetaxel or 
peloruside A could be well be due to the effects of these compounds on cytokine 
production (Chan et al., 2000), rather than a direct effect of MSD on processes such as 
bacterial killing. To better understand the results we saw during bacterial killing by MSD 
treated macrophages, we studied the cytokines produced during these events. TNF-α was an 
obvious cytokine to study due to its role in bacterial defense (Havell, 1989), and its 
signaling via TLR-4 to activate macrophages (Tracey et al., 1994). TNF-α is also one of the 
earlier cytokines produced during bacterial infections (Fong et al., 1989; Tracey et al., 
1993). Besides TNF-α, we studied changes to levels of NO and IL-12 as these cytokines are 
also produced during bacterial infections (Holan et al., 2001; Hamza et al., 2010). While 
TNF-α is produced within 90 minutes of bacterial stimulus (Fong et al., 1989), NO and IL-
12 are typically produced later on in the infection process and generally peak in production 
once TNF-α production begins to decline (Stuehr et al., 1987; Mullins et al., 1999). 
However we hypothesized that with the excess LPS and bacterial stimulation there may be 
low levels of NO and IL-12 produced at the earlier time points. 
We found that levels of TNF-α produced fell into two categories of high and low 
cytokine production. Not surprisingly, the high and low cytokine levels corresponded to the 
high and low CFU counts in the bacterial killing assays in chapter 6. We found that when 
CFU counts were higher, levels of TNF-α increased, and the various MSD treatments had 
no significant effect on modifying TNF-α production. Interestingly when TNF-α levels and 
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CFU counts were low, paclitaxel treatment at low doses caused a significant increase in 
levels of TNF-α produced. This increase corresponded to a significant increase in bacterial 
survival, as seen in chapter 6 (Fig 6.2.1), where macrophage bactericidal ability was 
impaired. While TNF-α levels are high, it is possible that the higher levels of LPS in 
combination with paclitaxel stimulation caused internalization of TNFR (Ding et al., 1989; 
Ding et al., 1990b). Thus although TNF-α is produced, it maybe unable to exert bactericidal 
effects due to lack of cellular receptors and this could have caused the increased CFU seen. 
We did not find any significant alteration to TNF-α production in peloruside A or docetaxel 
treated macrophages. This corresponds to CFU data where there was no significant 
alteration to bacterial survival in the presence of these two MSDs.  
 Treatment with zampanolide, ixabepilone and mycothiazole did not alter TNF-α 
production when there was high cytokine production. This is interesting as the high 
cytokine data corresponds to the low CFU data in chapter 6 (Fig 6.2.2). When CFU counts 
were low, ixabepilone treated macrophages showed significantly increased bactericidal 
activity. Ixabepilone stabilizes microtubules similarly to paclitaxel and it is a competitive 
inhibitor for the binding site of paclitaxel (Bollag et al., 1995; Goodin, 2008). Additionally 
as noted in previous sections, ixabepilone is effective in paclitaxel resistant cell lines 
(Bollag et al., 1995; Conlin et al., 2007). This suggests that the two MSD are similar, 
however, ixabepilone LPS mimicry status is unknown. It would be worth investigating this, 
as having LPS mimicry would cause internalization of TNFR (Ding et al., 1989), but lack 
of LPS mimicry would mean that any TNF-α  produced would be utilized for bacterial 
killing. We found that mycothiazole treated cells had impaired bacterial killing, while still 
producing relatively high levels of TNF-α. pHrodo phagocytosis data suggests that 
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mycothiazole treatment does not impair phagocytic capability. The data suggests that while 
mycothiazole treatment does not alter initial TLR stimulation via LPS or cytokine 
production, signaling pathways and trafficking or transport processes involved in killing 
may be impaired. However, more in-depth studies are needed before we can speculate on 
the mechanism by which mycothiazole affects bacterial killing. 
The effects of zampanolide on TNF-α production was also remarkable. In chapter 6, 
our data suggested that in the presence of zampanolide, there is limited phagocytosis, and 
bacteria that are taken up cannot be killed. The TFN-α data in figure 7.3.2A and B 
corresponds to low and high CFU counts, respectively. When CFU counts are high, there is 
no alteration to TNF-α production and the cytokine is produced in amounts similar to that 
of vehicle treated cells. In contrast, in the presence of low CFU counts, cytokine production 
is significantly decreased. Together the data suggests that in the presence of sufficient LPS 
stimuli, cytokine production is maintained, but the drug treatment blocks the bactericidal 
effect of the cytokine. However, in the presence of low LPS stimulation, zampanolide is 
able to alter cytokine production and thus inhibit bacterial phagocytosis. It was recently 
found that release of TNF-α in macrophages occurs via recycling endosomes and that the 
phagosome plays a role in delivery of this endosome to the cellular surface (Murray et al., 
2005; Manderson et al., 2007). It is possible that zampanolide treatment affects membrane 
trafficking and thus inhibits phagocytosis and cytokine release via affecting function of the 
recycling endosomes. Microtubules could also be affected thus further inhibiting antigen 
processing (Peachman et al., 2004). 
We looked at NO production at 1 and 3 hours during bacterial killing. While there 
were low levels of NO produced from all samples, there were no significant effects of MSD 
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treatment on NO production. Part of this could be related to the fact that these timepoints 
are early and less NO is produced within this time frame, with the result that we do not see 
any alteration in NO levels. However, despite this being preliminary data with low levels of 
NO production, there are interesting trends in the presence of peloruside A treated 
macrophages. Compared to the 1 hour time point, NO production increases by 3 hours. In 
paclitaxel treated samples, there is no significant reduction in NO production between 1 and 
3 hours. However at 3 hours, in the presence of low dose peloruside A treated samples, NO 
production increases, but at the higher dose, peloruside A seems to lower NO production to 
levels similar to those seen at 1 hour. This is similar to results seen previously where 
peloruside A decreases inflammatory cytokines (Crume et al., 2007). It would be extremely 
interesting to study IFN-γ and IL-12 along with NO cytokine production in macrophages 
treated with MSD for longer periods. Considering that LPS stimulus is high due to presence 
of bacteria, the NO levels measured were comparatively low; once again suggesting that it 
would be advisable to measure this cytokine at later time points. We also studied IL-12 
production; however this cytokine is also normally measured at later time points. The data 
is extremely variable and it is hard to speculate on any MSD related effects or trends 
exhibited. It is difficult to comment on IL-12 production as vehicle treated cells did not 
produce IL-12. While it is possible that ethanol vehicle control played a role in decreasing 
levels of IL-12, it would be advisable and more accurate to measure IL-12 production at 
later time points during bacterial phagocytosis and killing. There are studies that report NO 
and IL-12 production is linked, where IL-12 increases NO production in the presence of 
LPS (Sosroseno et al., 2002) and IL-12 gene expression is regulated by NO (Rothe et al., 
1996). In view of these studies, it would be advisable to study IL-12 and NO in conjunction 
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and at later time points. Additionally, when studying NO production in the presence of 
MSD, it would be interesting to study phagocytosis and killing in primary macrophages, as 
these cells do not proliferate and drug treatments can be studied over longer periods of 
time. 
 
Overall, we found that MSD treatment affects cytokine production although these 
effects might not translate into inhibition or enhancement during bacterial killing. We also 
found that TNF-α production was altered with zampanolide treatment when bacterial killing 
was un-affected, thus suggesting that zampanolide can affect cytokine production 
distinctively to macrophage function. The data suggests that paclitaxel, peloruside A and 
docetaxel treatment do not affect TNF-α production. We also found that in limiting LPS 
conditions paclitaxel does not decrease TNF-α production but via its LPS mimicry, TNF-α  
production is increased or maintained at normal levels. We found that increasing 
inflammatory stimuli in RAW264.7 macrophages did not cause an increase in cell 
metabolism due to the high sensitivity of this cell line to LPS. Finally, it would be worth 
repeating TNF-α and NO tests as these results are from one or two experiments and more 
valuable conclusions can be drawn with a bigger sample size.  
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7.4 Effect of IFN-γ pretreatment on TNF-α production in MSD treated 
macrophages during phagocytosis and killing. 
7.4.1 Introduction 
This set of assays examined the effect of IFN-γ pre-treatment on TNF-α production 
during bacterial phagocytosis and killing in MSD treated macrophages. We were interested 
in studying any enhancement or inhibition to levels of TNF-α and linking this to the 
absence or presence of IFN-γ pre-treatment. IFN-γ stimulates macrophages and induces 
antimicrobial mechanisms, along with up-regulating antigen processing and presentation 
pathways (Schroder et al., 2004). INF-γ also has a role in regulation of immunomodulatory 
cytokines TNF-α and IL-12 (Bach et al., 1997). Due to this, pre-treating macrophages with 
IFN-γ caused optimal activation and enabled macrophages to efficiently phagocytose and 
kill bacteria. However we were interested in the effects of MSD, particularly when optimal 
states of activation were absent. We wanted to understand if MSD treatment during sub-
optimal activation states would enhance or further impair macrophage bactericidal activity. 
This was interesting since paclitaxel has LPS mimicry (Ding et al., 1990b), while paclitaxel 
and docetaxel are immunomodulatory (Chan et al., 2000).  
Figure 7.4.1 shows effects of IFN-γ pre-treatment on TNF-α production during 
bacterial killing in the presence of MSD treatment. Overall, comparing the effects of IFN-γ 
treatment, higher levels of TNF-α were produced in the presence of IFN-γ, irrespective of 
MSD treatment, which was as expected (Fig 7.4.1A). In the absence of IFN-γ pre-
treatment, MSD treatment seems to stimulate TNF-α production (Fig 7.4.1B). However 
MSD treatment did not increase TNF-α production to levels seen with IFN-γ pre-treatment. 
We found that in the presence of IFN-γ, treatment with high dose docetaxel, latrunculin A 
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or colchicine caused a significant decrease in TNF-α production. In the absence of IFN-γ, 
low dose paclitaxel treatment significantly increased TNF-α production, while colchicine 
significantly decreased TNF-α production. Figure 7.4.2 shows effects of IFN-γ pre-
treatment on TNF-α production during pHrodo phagocytosis in the presence of MSD 
treatment. There was an increase in TNF-α production in the presence of low dose 
paclitaxel and colchicine treated macrophages once again showed a significant decrease in 
TNF-α production. 
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Figure 7.4.1 
 
 
Figure 7.4.1 Absence or presence of IFN-γ pre-treatment alters TNF-α production 
during bacterial killing in drug treated RAW264.7 macrophages. (A) RAW264.7 
macrophages are pre-treated with IFN-γ. TNF-α production is significantly reduced in the 
presence of high dose docetaxel, latrunculin A and colchicine when macrophages are pre-
treated with IFN-γ. ***p<0.001 docetaxel vs vehicle control, latrunculin A vs vehicle 
control, colchicine vs vehicle control, one-way ANOVA with Newman-Keuls post test. (B) 
RAW264.7 macrophages lack IFN-γ pre-treatment. TNF-α production is significantly 
increased in the presence of low dose paclitaxel and reduced in the presence of colchicine 
when IFN-γ pre-treatment is absent. *p<0.05 paclitaxel vs vehicle control, colchicine vs 
vehicle control, one-way ANOVA with Newman-Keuls post test. Both graphs are 
representative of 1 experiment, each with duplicate wells. White bars indicate low dose 
MSD treatment , while black bars indicate high dose treatment/vehicle control . 
Vehicle controls contain the same final concentration of ethanol or DMSO as the drug 
treated samples. Lat A: latrunculin A, colch: colchicine   
A 
B 
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Figure 7.4.2 
 
 
Figure 7.4.2 Absence or presence of IFN-γ pre-treatment alters TNF-α production 
during phagocytosis in drug treated RAW264.7 macrophages. (A) RAW264.7 
macrophages are pre-treated with IFN-γ. TNF-α production is significantly increased in the 
presence of low dose paclitaxel and reduced in the presence of colchicine when 
macrophages are pre-treated with IFN-γ. *p<0.05 paclitaxel vs vehicle control, ***p<0.001 
colchicine vs vehicle control, one-way ANOVA with Newman-Keuls post test. (B) 
RAW264.7 macrophages lack IFN-γ pre-treatment. TNF-α production is not altered when 
IFN-γ pre-treatment is absent. p>0.05, one-way ANOVA with Newman-Keuls post test. 
Both graphs are representative of 1 experiment, each with duplicate wells. White bars 
indicate low dose MSD treatment/vehicle control , while black bars indicate high dose 
treatment/vehicle control . Vehicle controls contain the same final concentration of 
ethanol or DMSO as the drug treated samples. Lat A: latrunculin A, colch: colchicine  
A 
B 
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7.4.3 Discussion 
These assays were carried out to study the effects of MSD treatments on bacterial 
phagocytosis and killing, when optimal stimulation was absent. To test this, we carried out 
these assays in the absence and presence of IFN-γ. As described earlier, IFN-γ activates 
macrophages to display microbicidal functions, and secrete pro-inflammatory cytokines 
(Young et al., 1995; Schroder et al., 2004). However, in previous assays we pre-treated 
macrophages with IFN-γ to activate efficient responses to bacterial challenge and this could 
have masked MSD related effects. It has also been proposed that MSD treatment may affect 
cytokines which in turn affect macrophage function (Chan et al., 2000).  
We investigated the effects of IFN-γ on TNF-α production during bacterial killing. 
Presence of IFN-γ led to increased TNF-α production as macrophages were activated and 
bactericidal responses were optimal (Schroder et al., 2004). However in the absence of 
IFN-γ, lower levels of TNF-α were produced due to the lack of stimulatory signals, despite 
the presence of LPS. As compared to levels of TNF-α during bacterial killing, levels of 
TNF-α were lower during bacterial phagocytosis (Fig 7.4.2), irrespective of the presence of 
IFN-γ. This indicated that the role of IFN-γ was primarily to activate macrophages during 
bacterial killing, while phagocytosis occurred via FcR, CRs and TLR-4 signalling. This 
data also suggests that TNF-α production is associated with bactericidal effects to a greater 
extent as compared to phagocytic events (Havell, 1989).  
When studying bacterial killing, in the presence of IFN-γ, we found no change to 
TNF-α production when macrophages were treated with paclitaxel or peloruside A. This 
was surprising in the case of paclitaxel treatment, as paclitaxel mimics LPS and we 
expected increases in production of inflammatory cytokines such as TNF-α. However, it is 
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possible that the presence of IFN-γ and LPS led to maximal TNF-α production and 
additional stimulation with paclitaxel did not result in excess TNF-α being produced. In 
contrast during bacterial phagocytosis, levels of TNF-α were lower irrespective of the 
presence of IFN-γ. In these conditions, low dose paclitaxel caused a small but significant 
increase in TNF-α production. However with increasing dose of paclitaxel, there was no 
increase in TNF-α production, possibly due to the higher dose MSD treatment impairing 
delivery of TNF-α via recycling endosomes (Murray et al., 2005; Manderson et al., 2007). 
Treatment of macrophages with peloruside A did not cause any alterations to TNF-α 
production during bacterial phagocytosis or killing, irrespective of the absence or presence 
of IFN-γ. This was surprising as peloruside A is known to decrease pro-inflammatory 
mediators (Crume et al., 2007). However we did not see this decrease even when levels of 
TNF-α were high as in the presence of IFN-γ. In contrast, treatment with docetaxel at high 
dose caused a significant decrease in TNF-α production during bacterial killing. It is known 
that docetaxel has immunomodulatory properties (Chan et al., 2000; Si et al., 2003; Prell et 
al., 2006), and does not mimic LPS or induce TNF-α (Manthey et al., 1993; Fitzpatrick et 
al., 2003). However, we found that docetaxel can reduce TNF-α production, which suggests 
it may have considerable use as an anti-inflammatory agent as well as a chemotherapeutic 
agent.  The reduction in TNF-α could also be due to drug treatment affecting cytokine 
secretion and vesicle trafficking (Murray et al., 2005; Manderson et al., 2007). 
Additionally, we found latrunculin A decreased TNF-α production, which could be related 
to the fact that bacterial phagocytosis was impaired in the presence of latrunculin A. The 
levels of TNF-α produced in the presence of IFN-γ and latrunculin A are similar to the 
levels produced during bacterial phagocytosis. This suggests that the presence of bacteria 
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and LPS triggers TNF-α production, however, absence of phagocytosis leads to decreased 
TNF-α as killing mechanisms are not activated within the macrophage.  
We found a significant decrease in TNF-α during bacterial killing in the presence of 
IFN-γ and colchicine treatment. Colchicine is an anti-inflammatory microtubule 
depolymerizer and is known to decrease production of LPS-induced TNF-α (Rao et al., 
1997; Isowa et al., 1999). Colchicine treatment also causes a downregulation of TNF-αR 
(Ding et al., 1990a), further contributing to its anti-inflammatory effects. Additionally, we 
found colchicine treatment caused a significant decrease in TNF-α production during 
bacterial killing in the absence of IFN-γ. This suggests that irrespective of macrophage 
activation, colchicine still exerts anti-inflammatory effects. Interestingly, in the presence of 
IFN-γ during bacterial phagocytosis (Fig 7.4.2), colchicine significantly decreased TNF-α 
production. In contrast, in the absence of IFN-γ stimulation during phagocytosis when 
TNF-α levels are low, there is no inhibition in the presence of colchicine. Overall this data 
suggests that colchicine is an effective anti-inflammatory drug and its effects on TNF-α and 
pro-inflammatory mediators are independent of the presence of LPS or macrophage 
activation status. It also demonstrates that the anti-inflammatory properties are dependent 
only on the levels of inflammatory cytokine irrespective of the processes such as 
phagocytosis or bacterial killing. 
 
Overall during bacterial phagocytosis, there were no significant effects seen with 
activating macrophages as compared to lack of activation. However during bacterial killing, 
activation of macrophages led to significant increases in TNF-α production. The increase in 
TNF-α was modulated in the presence of high dose docetaxel, latrunculin A and colchicine, 
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however, treatment with paclitaxel or peloruside A did not have any affect on the high 
levels of TNF-α, which was surprising in the case of peloruside A. We also found 
colchicine treatment reduced TNF-α independent of macrophage activation status and 
phagocytic or bactericidal activities. Taken together the data suggests that inflammatory 
cytokine production during bacterial phagocytosis and killing by MSD treated macrophages 
is not altered.   
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CHAPTER 8: GENERAL DISCUSSION 
 
8.1 Review of overall findings 
This thesis focused on the effects exerted by MSD on macrophage function. In 
particular, it investigated the effects of MSD on endocytic and killing processes within the 
macrophage. We used the RAW264.7 and J774.2 murine macrophage cell lines to study 
these processes. While MSD are cytotoxic to dividing cells (Zhou et al., 2005; Schmidt et 
al., 2007), over the period of our experiments, the cells were not dividing and we could 
examine effects distinct from mitosis related cytotoxic effects.   
 
This study focused on two main endocytic pathways; receptor mediated endocytosis 
and phagocytosis. The rationale of this study was based on the fact that there are few 
studies that investigate the effects of MSD on non-proliferating cells. However, immune 
cells such as the macrophage depend on functional microtubules for vesicle trafficking, 
phagoslysosomal fusion, antigen processing, and cytokine delivery (Ostlund et al., 1979; 
Peachman et al., 2004; Murray et al., 2005; Manderson et al., 2007). We were interested in 
studying the effects that MSD dependent microtubule stabilization would have on receptor 
mediated endocytosis, as well as bacterial phagocytosis and killing. Additionally, some of 
the MSD have immunomodulatory effects or exhibit LPS mimicry (Ding et al., 1990b; 
Herbst et al., 2003; Si et al., 2003; Crume et al., 2007). MSD can also affect cytokine 
production independently to causing microtubule stabilization (Tsavaris et al., 2002; Crume 
et al., 2007). This can directly alter processes dependent on cytokine production such as 
bacterial killing (Havell, 1989) We also studied the effects of MSD during optimal 
macrophage activation in the presence of IFN-γ and the effect of MSD when this activation 
was lacking. 
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Our investigations also expanded upon previous work in our lab by showing that 
MSD did not inhibit production of TNF-α by RAW264.7 murine macrophages in the 
presence of limiting LPS. This was in contrast to findings that paclitaxel reduced levels of 
TNF-α in the presence of LPS below 20 ng/ml (Crume et al., 2007; Robinson, 2009). The 
RAW264.7 cells also did not exhibit increased metabolic rates in the presence of paclitaxel, 
in contrast to BMDM which did increase their metabolic rates when treated with paclitaxel 
(Crume et al., 2007; Robinson, 2009). RAW264.7 cells were extremely sensitive to LPS 
stimulation and treatment of cells with LPS alone at doses as low as 0.3 ng/ml resulted in 
high levels of TNF-α being produced.  
 
Our work involving LDL and ac-LDL endocytosis demonstrated that paclitaxel 
treatment did not impair receptor mediated endocytic processes, even at high doses over 4 
hours of treatment. However during these assays we looked at early uptake and endocytic 
processes and found no impairment. This is supported by studies where colchicine, which is 
a microtubule destabilizer, did not affect binding of LDL to cell receptors and endocytic 
rates were lowered, but LDL still accumulated in the cells (Ostlund et al., 1979). However, 
studies have shown that colchicine treatment inhibited degradation of these particles, as 
transport from the early endosome to the late endosome or lysozome was inhibited (Ostlund 
et al., 1979; Gruenberg et al., 1989). These findings support a role for microtubules in 
transport of vesicles and the studies suggest that while initial uptake is not impaired, 
processes such as lysozomal degradation are impaired. It is possible that treatment with 
paclitaxel or other MSDs would impair degradation of endocytosed particles while 
maintaining the initial uptake of these particles. Our studies also suggest that receptor 
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function is not affected by paclitaxel, and the endocytic rate is maintained, which suggests 
receptor recycling is unaffected. 
 
Our work showed for the first time that phagocytosis and killing of live bacteria in 
the presence of paclitaxel, peloruside A or docetaxel was not impaired. Understanding 
effects of MSD on microtubule-dependent cellular processes other than cell division is 
important as investigations into compounds that function as chemotherapeutics and 
immunomodulators increase (Chan et al., 2000; Garnett et al., 2008; Zitvogel et al., 2008; 
Miller et al., 2010). We found that in the absence of optimal activation with IFN-γ, MSD 
maintained phagocytic activity and the data suggests that these compounds stimulated 
macrophages to respond to bacterial stimulus. Additionally we investigated the effects of 
these compounds on inflammatory cytokine production. We found that there were no 
alterations to TNF-α production during phagocytosis or killing, however NO production 
was significantly lowered in the presence of high doses of MSD during bacterial 
phagocytosis, suggesting that although macrophages maintain response to bacterial 
presence, the initial cytokine response to the presence of LPS may be altered due to 
microtubule stabilization. 
 
Additionally to investigating paclitaxel, docetaxel and peloruside A, we also studied 
the effects of 3 novel compounds zampanolide, ixabepilone and mycothiazole. Our study is 
the first to investigate the effects of these 3 compounds on macrophage response to live 
bacteria. Perhaps the most interesting effects regarding macrophage responses to bacteria 
were seen in the presence of zampanolide. Our data provides evidence that treatment with 
the MSD zampanolide significantly impairs bacterial phagocytosis and killing. We also 
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found that treatment with zampanolide significantly affects TNF-α and NO production. It 
remains to be seen if the effects on macrophage function are a result of impaired cytokine 
production or an unknown intracellular target of zampanolide, since data from other MSD 
tested suggests that microtubule stabilization does not impair bacterial phagocytosis or 
killing.  
We also found that ixabepilone, which is currently used clinically as a 
chemotherapeutic, enhances bacterial killing. However this MSD does not alter phagocytic 
efficiency or cytokine production. In contrast, mycothiazole impairs bacterial killing, 
however it does not alter cytokine production or phagocytic ability. The mode of action of 
mycothiazole is as yet unknown (Miller et al., 2010) and it will be extremely interesting to 
investigate this in light of current findings. 
 
Overall our findings suggest that initial endocytic processes within the macrophage, 
although dependent on microtubules, are not immediately affected by the presence of MSD. 
It is possible that treatment with MSD will alter or inhibit later aspects of endocytosis, such 
as vesicle and antigen trafficking. When interpreting these results we should remember that 
these results are based in an in vitro situation and in vivo there are multiple factors that 
could alter the interaction of MSD with macrophages, thus resulting in different effects or 
outcomes.  
 
Improved understanding of how MSD can affect immune responses is vital with the 
current expansion of this field. We have seen how these cytotoxic anticancer drugs have 
additional effects on the immune system, and it is only by understanding these interactions 
that the true potential of these compounds can be harnessed for their use as effective 
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therapeutics. While nature has provided excellent potential chemotherapeutics in the form 
of MTA, an in-depth understanding of their side effects on immune cells are needed before 
these compounds are used, not only as chemotherapeutics but also as immune modifiers.  
We have seen the potential of MSD to be used as immune modifiers in autoimmune 
diseases (Cao et al., 2000; Crume et al., 2009). We hope that with in-depth understanding 
of the immunopharmacology and toxic effects of of these compounds at high doses 
(Rowinsky et al., 1995; Panchagnula, 1998), we will be better equipped to use these 
compounds with improved efficiency, lower toxicity and as chemoimmunotherapeutics.   
 
8.2 Future Directions 
This study demonstrates that MSD treatment can affect immune cell function and 
cytokine production. It opens new avenues for extending the findings reported in this study, 
particularly in regards to studying effects of MSD treatment on BMDM during bacterial 
phagocytosis and killing. Future studies would likely involve studying the effects of MSD 
on antigen trafficking and presentation, as this would help elucidate the effects of MSD on 
the role of the ER and golgi in trafficking and antigen presentation on MHC complexes. It 
is possible that activation of the adaptive immune system would be impaired in the 
presence of MSD and this would be a beneficial study. 
Further pathways open for investigation are understanding the effects of MSD 
treatment, particularly paclitaxel, on the kinetics of bacterial phagocytosis. The confocal 
microscope techniques used in this research offer a good starting point to investigate the 
uptake kinetics of pHrodo. Additionally the role of the lysosome and lysosomal fusion 
during bacterial killing would also be interesting to investigate, as MSD treatment could 
alter the efficiency with which this process occurs. 
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Numerous questions still remain unanswered, in particular regarding the effects of 
zampanolide on macrophage endocytic processes and cytokine production. Zampanolide 
has recently been shown to be an MSD; however its effects in this study are dramatically in 
contrast with all other MSD studied. It would be extremely interesting to investigate 
possible reasons for the effects seen with zampanolide, as the data from this study suggests 
that zampanolide could have alternative cellular targets than just microtubules. The 
cytotoxic effects of zampanolide on RAW264.7 cells would also be a good point to 
investigate in light of the effects of this compound on the RAW264.7 cell line.  
Another interesting avenue to investigate would be the effects seen with peloruside A 
in RAW264.7 macrophages, which were in contrast to effects seen with BMDM. While we 
found that RAW264.7 cells are extremely sensitive to LPS stimulation, even at low doses, 
this does not completely explain the lack of downregulation to TNF-α and NO production 
in peloruside A treated macrophages. It would also be of great interest to study bacterial 
phagocytosis and killing in peloruside treated BMDM.  
Lastly, a valuable avenue to follow would be investigating macrophage bactericidal 
activity in vivo in the presence of MSD treatment. This would allow studying MSD effects 
on macrophages as well as other immune cells, in the presence of MSD treatment, when 
multiple pathways are able to interact with each other. This would provide a good 
understanding of the dosing regime required and the possible toxic side effects, while also 
providing a picture of the efficiency of immune responses to bacterial stimulation in vivo in 
the presence of MSD.  
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8.3 Final conclusions 
This study set out to investigate the immune-mediated effects of MSDs on 
macrophages. In particular we studied the ability of MSD treated macrophages to 
phagocytose and kill bacteria. We also investigated the endocytosis of ligands via cell 
surface receptors in these MSD treated macrophages. Another aspect studied in this project 
was the effects of MSD on cytokine production. Firstly, we found that treatment with 
certain MSDs did not inhibit bacterial phagocytosis or killing. However other MSDs did 
inhibit macrophage function suggesting that different MSDs can alter immune function. 
Furthermore, cytokine production was also inhibited to varying degrees. Taken together, 
the data suggests that overall, MSD directly affect cytokine production causing indirect 
effects to macrophage function. Secondly, we found that zampanolide is far more potent 
and inhibits macrophage function significantly, suggesting that for clinical development the 
side effects of this compound need to be studied extensively. This project is the first to 
explore the effects of MSD on macrophage phagocytosis of live E.coli bacteria. The results 
suggest that during clinical use of MSD, the ability of patients to fight off bacterial 
infections maybe altered due to impaired cytokine production and altered kinetics during 
macrophage responses to the presence of bacteria.   
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Appendices 
Appendix A: Recipes 
Phosphate Buffered Saline (PBS) (2 Litres)  
Na2HPO4  8.7 mM  
NaH2PO4  1.3 mM  
NaCl   145 mM 
2 litres sterile double distilled water  
 
FACS Buffer: 
2%  FCS 
0.1%  Sodium Azide 
97.9%  PBS 
 
Complete T cell media (CTCM) – media for cell line culture 
85.9%  Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) 
1%  Non-essential Amino Acids (10mM; 100x, Invitrogen) 
1%  Penicillin/Streptomycin (Penstrep; 100000 U/mL, Invitrogen) 
1%  L-Glutamine (200mM, Invitrogen) 
1%  HEPES (1M, Sigma) 
0.1%  β-Mercaptoethanol (1000 x 55mM, Invitrogen) 
10%  sterile-filtered heat-inactivated FCS 
  
  Appendices
   
218 
Wash Buffer 
96%  Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) 
3%  HEPES (1M, Sigma) 
1%  Penicillin/Streptomycin (Penstrep; 100000 U/mL, Invitrogen) 
 
Experimental Media – for phagocytosis assays 
95%  DMEM 
5%  sterile filtered heat-inactivated FCS 
 
Freezing Media – for Liquid Nitrogen cell storage 
90%  sterile filtered heat-inactivated FCS 
10%  DMSO (Sigma) 
 
MTT solution 
5 mg.mL
-1
 MTT in 1x dPBS, sterile filtered 
Kept Sterile, MTT - toxic and light sensitive, handled using protective clothing, and stored 
for 4 weeks or longer at 4°C, protected from light. Discarded appropriately. 
 
MTT Solubiliser 
10%  w/v SDS in 0.01N HCl 
(10 g SDS, 1 mL 1 M HCl, 99 mL ddH2O) 
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Greiss Reaction reagents 
Solution A: 1% w.v sulphanilamide in 2.5% phosphoric acid 
Solution B: 0.1% w.v N-(1-naphthyl) ethylenediamine in 2.5% phosphoric acid 
 
Luria- Bertani Broth (LB broth) (500ml) 
5 g NaCl 
5 g Tryptone 
2.5 g Yeast extract 
500 ml sterile ddH2O, autoclaved and cooled to touch 
34 μg/ml chloramphenicol added and flame sealed to store at room temperature.  
 
Luria-Bertani Agar (LB agar) (500ml) 
5 g NaCl 
5 g Tryptone 
5 g BactoAgar 
2.5 g Yeast extract 
500 ml sterile ddH2O, autoclaved and cooled to touch. 
34 μg/ml chloramphenicol added, agar poured into 20 mm petri dishes, allowed to solidify 
and plates stored upside down at 4°C. 
 
Krebs Buffer 
130 mM NaCl 
1.3 mM KCl 
2.2 mM MgSO4.6H2O 
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1.2 mM KH2PO4 
10 mM HEPES 
10 mM D-glucose 
500 ml sterile double distilled water, pH 7.4 
Staining protocol for cytospins 
Fixation: 10 dips in methanol 
Allow excess methanol to drip off 
Staining: 10 dips in 100% Geimsa 
Allow excess Geimsa to drip off 
Wash: 10 – 20 dips in sterile distilled water, followed by rinsing gently in sterile distilled 
water to remove excess Geimsa stain. 
Air dry with sample facing upwards. 
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Appendix B: Antibody List 
CD11b-bio Serotec 
F4/80-Fitc Serotec 
Streptavidin-Cyc BD Bioscience 
IgG2-α-Fitc BD Bioscience 
IgG2-α-bio BD Bioscience 
 Anti-mouse-CD16/32 (24G2) (FcR block) BD Bioscience 
 
 
 
